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Turning the tide against TB:  Remaking ineffective host defenses into 
mechanisms for tuberculosis control 
 
Abstract 
 
Most antibiotics, including the drugs currently used for treating tuberculosis (TB), 
were first discovered as molecules that inhibit bacterial growth in laboratory 
culture conditions and later translated to infection models and clinical use. 
Mycobacterium tuberculosis (Mtb) has evolved specifically to survive in its human 
host, and it is in this infectious context that new drugs need to work. The host 
environment is characterized by a multitude of antimicrobial defenses induced by 
the immune system, and we can leverage these defenses to kill Mtb in vivo. Mtb 
employs a diverse set of responses to survive host defenses. By blocking these 
responses, we can make Mtb more susceptible to host immunity, turning these 
previously impotent defenses into effective strategies of immune control.  
In this dissertation, I characterize tryptophan biosynthesis as a bacterial pathway 
required to combat the specific CD4 T cell-mediated defense mechanism of 
tryptophan starvation. Armed with this understanding, I searched for and found 
small molecule inhibitors of Mtb tryptophan biosynthesis with potency in the 
micromolar range in media lacking tryptophan. The molecules worked even 
better in a macrophage model of Mtb infection, and had remarkable synergy with 
interferon-γ. In macrophages, interferon-γ and the tryptophan biosynthesis 
inhibitor blocked worked in conjunction to kill Mtb, the former catabolizing 
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exogenous sources of tryptophan and the latter blocking endogenous tryptophan 
synthesis.  
The findings in this dissertation show that understanding how Mtb genes work in 
the infectious context can help identify good in vivo drug targets. Furthermore, 
we begin to scratch the surface of failing host defenses that can be revived to 
effectiveness with the inhibition of the right host-adaptation pathways in Mtb. 
Essential genes will continue to serve as a good repository of potential drug 
targets—and to that end, Chapter 2 describes a renewed assessment of Mtb 
essential genes—but by expanding our understanding the genetic requirements 
of bacterial survival against immune system components (Chapter 3), we can 
identify new therapies that help our immune system kill Mtb (Chapter 4).  
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Chapter 1. 
Overview and Introduction 
 
 
 
 
 
 
 
 
 
 
This chapter contains one manuscript that is in press as a review: 
  
Zhang YJ, Rubin EJ. Feast or Famine: The Host-Pathogen Battle over Amino Acids. Cellular 
Microbiology. In press. 
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Section 1. 1: Thesis Overview and Attributions 
Overview 
For most of the 20th century, Tuberculosis (TB) was a disease on the decline. 
Improved sanitation and living conditions had helped put TB on a downward 
trajectory, and the advent of semi-effective vaccine and nearly fully-effective 
antibiotics made eradication of the disease seem possible, if not imminent. 
However, two major factors crept in around the 1980s that changed reversed the 
course of the global Mtb epidemic. First, drug resistance became an issue, and it 
soon became appreciated that there was resistance against all available drugs, 
and that certain strains harbored multiple drug resistance alleles. Second, the 
HIV epidemic created huge populations of people who had an increased risk of 
getting TB. Today, TB is once again one of the preeminent threats to global 
health, infecting about 2 billion people, causing disease in about 10 million each 
year, and killing about 2 million this past year.  
 
Discovering new drugs for TB, then, is one of the main global health priorities. 
Current drug regimens are able to both treat active disease and prevent future 
disease by drastically decreasing the risk of reactivation. However, even the 
shortest treatments require daily dosing of 2-4 drugs for 6 months, and many 
drug resistant strains necessitate up to 30 months of treatment. Accelerating the 
treatment process would be a tremendous aid to global anti-TB efforts. 
Furthermore, while multiple drug resistant (MDR) cases are still treatable by a 
combination of available drugs, extensively drug resistant (XDR) and totally drug 
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resistant (TDR) strains are becoming alarmingly prevalent, and treatment of 
these bacteria desperately is in desperate need of new drugs and new drug 
targets. 
 
Discovering new drugs could be aided by the identification of mycobacterial 
processes to target. Traditionally, drugs have been discovered by screening 
small molecule libraries in laboratory culture conditions to identify small molecule 
inhibitors of essential growth processes. Identifying these essential processes, 
then, is a crucial task in determining targets that would be good for drug design. 
To that end, Chapter 2 of this thesis describes a process by which we determine 
the requirement for growth of just about every gene in the genome.  We 
introduced a transposon into a pool of bacteria, such that all bacteria in the pool 
have a single transposon disrupting a single genomic site. We then employed 
deep sequencing technology to map the insertion sites of each transposon in the 
library. Making the assumption that genomic regions lacking insertions represent 
genes required for optimal growth in vitro, we searched the genome for these 
regions with an underrepresented number of reads, and were able to identify 
genes, individual protein-domain-encoding regions, small RNAs, and other 
intergenic regions that were required for growth.  
 
Proteins required for in vitro growth are not the only proteins worth targeting for 
drug treatment. Mtb, after all, lives primarily in the host, and the host is a very 
different environment than laboratory cultures. To that end, Chapter 3 describes 
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the studies that helped us determine the genes required for growth in a mouse. 
We used the same transposon library, comparing the surviving pool of bacteria 
retrieved from the mouse to the library with which we infected the mice. We were 
also interested specifically in the mycobacterial determinants of surviving 
elements of the immune system. CD4 T cells are one of the most important 
groups of adaptive immune cells. They are important for limiting bacterial growth 
one month after infection, but even at their fullest induced activity in mice, Mtb is 
able to survive the effects of CD4 T cells We infected our library into both 
wildtype mice and mice lacking CD4 T cells to find the mycobacterial 
determinants for surviving CD4-mediated stress.  
 
Amongst many other things, we found that CD4 T cells induce the requirement 
for Mtb to make its own tryptophan. This suggested the CD4 T cells have a 
strategy to decrease the amount of exogenously available tryptophan to Mtb, and 
the first half of Chapter 4 is dedicated to the elucidation of this CD4-mediated 
starvation strategy. Using a cell culture model of Mtb infection and CD4 T cell 
help, we determined that CD4 T cells, through the secretion of interferon-γ, 
induces an intracellular enzyme, indoleamine-2,3-dioxygenase, that depletes 
intracellular tryptophan, making it necessary for Mtb to produce its own 
tryptophan during infection. 
 
This was an interesting pathway, but a futile one in Mtb. We described a 
starvation pathway that would have killed certain tryptophan-auxotrophic 
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pathogens, but could not kill Mtb because of its ability to synthesize tryptophan. 
On the other hand, it also represented a potential point of therapeutic intervention. 
If we could inhibit tryptophan biosynthesis, we would be able to negate Mtb’s 
adaptation to tryptophan starvation, and in the process turn an ineffective host 
response into an effective mechanism of TB control. The second half of Chapter 
4 is devoted the discovery of such an in inhibitory compound. We show that this 
small molecule is able to kill TB in media lacking tryptophan. We show also that 
this small molecule is able to kill Mtb in macrophages. Because we showed that 
tryptophan biosynthesis was demanded by CD4-mediated mechanisms, we 
predicted that a small molecule inhibitor targeting tryptophan biosynthesis would 
make Mtb more susceptible to CD4 T cells. Indeed, when treated with both CD4 
T cells in co-culture or with interferon-γ, the small molecule does kill Mtb at a 
much higher rate, demonstrating its synergy with these mechanisms of immune 
activation.  
 
In summary, this dissertation identifies genes required for growth in vitro, genes 
required for growth in vivo, and the subset of the latter that are required for 
surviving the CD4 T cell response. By identifying tryptophan biosynthesis as part 
of the indispensible response to CD4 T cells, we note that this biosynthetic 
pathway is ripe for chemical inhibition to kill Mtb in conjunction with the immune 
system. Finally, we identify a small molecule inhibitor of tryptophan biosynthesis 
and show its synergy with the immune system in a macrophage culture. As this 
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dissertation is being presented, the small molecule is being tested for efficacy in 
mice, in hopes that it will be able to kill Mtb in an established mouse infection.  
 
Attributions 
In addition to the general introductory statements in Sections 1.1, this Chapter is 
also composed of two manuscripts, both written by Eric Rubin and myself. The 
first manuscript is currently in press at Cellular Microbiology as a microreview. I 
wrote this review while in Babak Javid’s lab in Tsinghua University in Beijing, and 
am grateful for his input and his motivation during that time. Cara Boutte, Hesper 
Rego and Kristi Guinn, members of the Rubin Lab also helped me revise this 
manuscript. The second manuscript is a draft of a review that we intend on 
submitting as a review article.  
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Section 1.2: The Host-Pathogen Battle over Amino Acids 
Overview 
Intracellular bacterial pathogens often rely on their hosts for essential nutrients. 
Host cells, in turn, attempt to limit nutrient availability, using starvation as a 
mechanism of innate immunity. Here we discuss both host mechanisms of amino 
acid starvation and the diverse adaptations of pathogens to their nutrient-
deprived environments. These processes provide both key insights into immune 
subversion and new targets for drug development. 
 
Attributions 
The following section is in press as a review article at Cellular Microbiology. 
Thanks to Cara Boutte, Hesper Rego and Kristi Guinn for help in reviewing and 
revising this manuscript. 
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Introduction 
Successful bacterial pathogens exploit their hosts to support their own 
survival. Pathogens rely on their hosts for nutrients necessary for survival, 
injuring the hosts in the process. For their part, the hosts are hardly gracious. In 
fact, the ability to keep would-be pathogens away from the nutrients turns out to 
be a key part of host defense. This interplay exists for all essential nutrients, 
including carbon, nitrogen, and transitional metals(Eisenreich et al., 2010, 
Rohmer et al., 2011, Hood et al., 2012, Skaar, 2010).  
For many potential pathogens, amino acids are critical nutrients. While 
many organisms can synthesize their own amino acids, others must scavenge 
them in order to make proteins. Additionally, many bacterial pathogens are able 
to use amino acids as a carbon source, some even as their principle carbon 
source(Venugopal et al., 2011, Eylert et al., 2010, Molofsky et al., 2004, Wieland 
et al., 2005). Accordingly, mammalian hosts have evolved mechanisms to starve 
bacteria of amino acids. And, to counter this, bacteria have a diversity of means 
to respond to this stress.  
Here we will review the evidence for and mechanisms of host-mediated 
amino acid starvation and the bacterial response to amino acid depletion. We 
have chosen three intracellular pathogens to illustrate the diversity of bacterial 
responses. The first, Chlamydia trachomatis, is a natural auxotroph for many 
amino acids and responds to amino acid starvation primarily by differentiating to 
a viable but non-replicating form. The second, Mycobacterium tuberculosis, has 
evolved to become independent of host amino acid availability and constitutively 
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synthesizes its own amino acids. The third, Legionella pneumophila, is able to 
extract amino acids from an otherwise stingy host by exploiting host machinery—
including amino acid transporters and the host proteasome—to make amino 
acids available in the pathogen’s intracellular niche.  
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Host cells are able to starve intracellular pathogens of amino acids 
The Evidence 
The exact intracellular niches of bacterial pathogens are difficult to isolate; 
thus their metabolite contents are difficult to measure directly. Pathogen 
adaptation to the intracellular environment, however, suggests that host cells are 
able to limit amino acid availability.  The most compelling fact is that amino acid 
auxotroph strains of many bacterial pathogens are often attenuated for 
intracellular growth and during host infection. For example, Mycobacterium 
tuberculosis requires the biosynthesis pathways for at least four amino acids to 
survive during a model infection of mice and within isolated mouse and human 
macrophages. Leucine, proline and lysine auxotrophs are attenuated in vivo, the 
latter by so much that they have been tested as live-attenuated vaccine 
candidates(Hondalus et al., 2000, Smith et al., 2001, Pavelka et al., 2003b). 
Additionally, multiple groups have shown the requirement of several tryptophan 
biosynthesis enzymes for survival in mice and macrophages(Smith et al., 2001, 
Parish, 2003). Salmonella auxotrophs for aromatic amino acids, histidine and 
methionine have also been shown to be attenuated in vivo (Hoiseth et al., 1981, 
Fields et al., 1986, O&apos;Callaghan et al., 1988). 
Measuring the pathogen’s transcriptional response to the intracellular 
niche paints the same picture of amino acid starvation. Since pathogens often 
regulate gene expression in response to environmental signals, expression 
profiles can serve as bioprobes of the conditions they encounter. Many 
intracellular pathogens upregulate amino acid biosynthesis genes during 
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infection(Chatterji et al., 2001).  This is true for bacterial pathogens as well as 
fungal pathogens like Candida albicans(Rubin-Bejerano et al., 2003). Many 
fungal species encode a kinase, Gcn4, that senses exogenous amino acid 
availability. Upon infection, Gcn4 is activated and coordinates Candida amino 
acid biosynthesis(Tripathi et al., 2002). Additionally, the stringent response, a 
conserved bacterial signaling pathway that senses amino acid starvation, among 
other stresses, is often required for intracellular growth(Magnusson et al., 2005, 
Potrykus et al., 2008). RelA senses amino acid starvation and synthesizes 
ppGpp, which induces necessary adaptive changes, including transcriptional 
upregulation of amino acid biosynthesis genes(Traxler et al., 2008). In many 
intracellular pathogens, including M. tuberculosis and Salmonella, RelA is 
upregulated and specifically required for intracellular growth(Pizarro-Cerdá et al., 
2004, Song et al., 2004, Primm et al., 2000, Thompson et al., 2006).  
The Mechanisms 
While there is much evidence that the host can create an amino acid 
depleted niche, the mechanisms for producing this starved niche are not well 
characterized. One major clue, however, comes from the autophagic response to 
intracellular pathogens. Autophagy is an important cellular process through which 
eukaryotic cells respond to a variety of stresses, including metabolite starvation 
and damaged organelles(Deretic, 2009, Deretic et al., 2009, Levine, 2005). 
Bacterial invasion also induces an autophagic response, called xenophagy, 
wherein invading pathogens are delivered to autophagosomes to be broken 
down(Deretic, 2009, Deretic et al., 2009, Levine, 2005). This process of 
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xenophagy is required for optimal suppression of the growth of multiple 
intracellular pathogens, including Listeria, Shigella, and Mycobacterium 
species(Suzuki et al., 2007, Zhao et al., 2008, Gutierrez et al., 2004, Singh et al., 
2006, Singh et al., 2010, Yuk et al., 2009).  
Nutritional signals play a key regulatory role in autophagy. In particular, 
autophagy is inhibited when the cytosol contains high concentrations of amino 
acids. Tattoli and colleagues found that intracellular amino acid levels must be 
low in order for xenophagy to be fully induced(Sancak et al., 2010, Sancak et al., 
2008). They found that the activity of mTOR, a checkpoint kinase that links 
nutrient sensing to metabolic activity, decreased upon infection with the 
intracellular pathogens Salmonella and Shigella (Tattoli et al., 2012b). This 
indicated a possible amino acid starvation, as mTOR activity decreases when 
amino acid levels are low. Moreover, cytosolic levels of isoleucine and leucine fell 
within an hour after infection(Tattoli et al., 2012b). Interestingly, Shigella-induced 
amino acid starvation lasted at least four hours, while Salmonella induced a more 
transient one-hour starvation. The authors hypothesized that membrane damage 
might be responsible for amino acid starvation as the temporal pattern of such 
damage (transient for Salmonella; lasting for Shigella) matched the loss of amino 
acids. In fact, even aseptic membrane damage, induced by digitonin, could 
induce amino acid starvation. While this does not rule out alternative 
mechanisms, this study strongly supports the possibility that bacteria induce 
amino acid starvation and presents compelling evidence that membrane damage 
could play a major role(Tattoli et al., 2012b, Tattoli et al., 2012a). Interestingly, 
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Salmonella could reverse this amino acid starvation, which activated mTOR and 
inhibited autophagy, ultimately restoring bacterial growth. When the authors 
overrode the starvation-induced autophagy block, Salmonella growth was 
restored (Tattoli et al., 2012b). 
In addition to general amino acid depletion, host cells can also specifically 
deplete intracellular tryptophan during pathogen invasion(Hayashi et al., 2001, 
Silva et al., 2002). Tryptophan depletion as an anti-bacterial mechanism was first 
described in Chlamydia-infected cells(Beatty et al., 1994, Byrne et al., 1986, 
Murray et al., 1989). The addition of interferon-gamma (IFN-γ) to infected cells 
almost completely abolishes intracellular chlamydial growth. Stunningly, simply 
adding tryptophan reverses the anti-chlamydial effect of IFN-γ(Beatty et al., 1994, 
Byrne et al., 1986, Leonhardt et al., 2007).  IFN-γ activates indoleamine-2,3-
dioxygenase (IDO), the enzyme responsible for the first step in kynurenine 
synthesis from tryptophan(Zelante et al., 2009, Leonhardt et al., 2007). When 
strongly induced—as in the case of IFN-γ activation—IDO can deplete about 
95% of intracellular tryptophan (Fujigaki, 2002). Thus, IDO is required for limiting 
the growth of tryptophan-requiring intracellular pathogens, such as some 
Chlamydia species, Leishmania donovani, Toxoplasma gondii, as well as lab-
generated strains tryptophan-auxotrophic bacteria(Daubener et al., 2001, 
Fujigaki, 2002, Leonhardt et al., 2007, Ibana et al., 2011b, Ibana et al., 2011a).  
It is worth noting, however, that the effect of IDO on pathogen growth is 
multi-faceted(Medzhitov et al., 2011). The first appreciated role for IDO in 
pathogen defense was intracellular tryptophan depletion. Recently, the role of its 
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enzymatic products, kynurenines, has also been characterized. Kynurenines are 
potent negative regulators of inflammation and T cell activity(Munn et al., 2005, 
Zelante et al., 2009, Medzhitov et al., 2011, Favre et al., 2010). So while the role 
of IDO on intracellular tryptophan is clear, its pleiotropic effects in pathogen 
defense have been more difficult to pin down(Blumenthal et al., 2012). 
Nevertheless, IDO represents a mechanism by which an infected host can 
drastically reduce the amounts of an often-essential amino acid available to 
pathogen. 
Pathogen Responses to Host AA Starvation 
 Many pathogens are able to synthesize the full set of amino acids. It would 
be reasonable to think, given how common amino acid depleted environments 
are, that amino acid biosynthetic pathways would be a requirement for being an 
intracellular human pathogen. However, many known successful human 
pathogens are auxotrophic for some amino acids. How can this be?  Some 
bacteria are simply able to escape by altering their metabolic requirements.  For 
example, they can differentiate into non-replicating, less metabolically demanding 
cells. Other organisms are able to avoid amino acid starvation altogether by 
manipulating host amino acid uptake and production systems to increase 
available amino acids in the pathogen’s intracellular niche. We will review three 
model pathogens that fit these three molds: 1.) Chlamydia, which employs 
growth arrest and differentiation; 2.) Mycobacterium tuberculosis, which 
exemplifies amino acid self-sufficiency; and 3.) Legionella pneumophila, which 
exploits host machinery to extract amino acids from the host cell.   
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Chlamydia: Hiding out and holding out for a better day—growth arrest and 
differentiation 
 Chlamydia trachomatis causes a variety of human diseases, including the 
leading cause of infectious blindness and genital tract infections that can have 
long-term severe consequences for infected individuals. All members of the 
Chlamydia family are intracellular pathogens that share two distinct 
developmental stages. Elementary bodies (EB) initiate the intracellular infection 
through endocytic uptake. In optimal growth conditions, the metabolically inert 
EBs then differentiate into metabolically active reticulate bodies (RB), which then 
replicate and grow within the bacterial vacuole. Eventually RBs develop back into 
EBs, which upon release, go on to infect other cells.  
 When stimulated with IFN-γ, the host cell imposes a much greater stress 
upon the bacteria. Chlamydia responds to this stress by morphing into a third, 
aberrant form(Leonhardt et al., 2007, Beatty et al., 1994). The aberrant form cells 
are similar to reticulate bodies in morphology, but are unable to divide or 
differentiate back to EBs. In some studies, adding tryptophan restores growth of 
these aberrant RBs, demonstrating that persistence is driven by tryptophan 
starvation(Byrne et al., 1986, Beatty et al., 1994, Leonhardt et al., 2007, Ibana et 
al., 2011a). Differentiation into this aberrant RB form allows the pathogen to hide 
from its tryptophan-depleted environment until tryptophan availability resumes 
(Figure 1.1). Isoleucine also seems to be limited during infection, and Chlamydia 
growth in one intracellular infection model could be restored upon the addition of 
isoleucine (Hatch, 1975). Interestingly, Chlamydia does not encode the classical 
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bacterial stringent response, which enables many bacteria to sense amino acid 
starvation and enter into persistent states(Ouellette et al., 2006). Thus, 
Chlamydia must utilize a unique mechanism to sense tryptophan depletion and 
differentiate into these aberrant forms.   
 Early investigations on the role of tryptophan and IDO in driving aberrant 
form differentiation yielded mixed results. While some groups found tryptophan 
supplementation alone could reverse the effects of IFN-γ, others found no 
effect(Murray et al., 1989). When the Chlamydia trachomatis genome was 
sequenced—and especially when multiple clinical strains were sequenced—a 
major clue emerged. As expected, Chlamydia lacks the full suite of tryptophan 
biosynthetic enzymes, and thus cannot synthesize tryptophan from chorismate or 
most other biosynthetic precursors(Stephens, 1998). It does, however, encode 
tryptophan synthase (TrpAB), a more limited enzyme that allows the organism to 
synthesize tryptophan from indole.   In addition Chlamydia encodes TrpR, a 
tryptophan-dependent aporepressor, which enables the pathogen to react 
specifically to environmental tryptophan availability(Stephens, 1998, Wood et al., 
2003, Belland et al., 2003). Interestingly, C. trachomatis strains isolated from 
ocular infections and synovial tissue contain frameshift mutations in trpAB, while 
strains from genital infections do not(Caldwell et al., 2003, Fehlner-Gardiner et al., 
2002, Gerard et al., 2010). Within strains isolated from sexually transmitted 
infections, there are three trpAB variants; while the effect of each trpAB variant 
on tryptophan synthesis is unknown, identity of the trpAB allele correlates 
perfectly with IFN-γ susceptibility.in vitro(Morrison, 2000 
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, Caldwell et al., 2003, Fehlner-Gardiner et al., 2002, McClarty et al., 2007). So 
while all all C. trachomatis contain the trpAB gene, not all strains are able to 
make tryptophan, and the ability to make tryptophan appears to track with STI 
virulence. 
 Is the C. trachomatis response to tryptophan starvation differentiation to a 
non-growing cell type or regulated tryptophan biosynthesis? It appears that 
tryptophan biosynthesis is possible, but under a limited number of circumstances. 
First, the strain has to encode a functional enzyme. Second, it has to have a 
source of indole, which the host does not make. Some investigators have noticed 
that many functional TrpAB-containing strains were isolated from patients with 
bacterial vaginosis, and thus hypothesize that the vaginal flora might be a source 
of indole(McClarty et al., 2007). So some C. trachomatis strains can synthesize 
tryptophan in certain environments, increasing their resistance to IFN-γ mediated 
immunity(Belland et al., 2003). Where tryptophan biosynthesis is not available, 
Chlamydia use their ability to enter into a persistent form that enables it to 
survive when all sources of tryptophan are lost. 
M. tuberculosis: Energy independence—making its own amino acids in an 
unreliable environment 
 Whereas Chlamydia tryptophan biosynthesis is limited in scope, 
Mycobacterium tuberculosis seems to leave nothing up to chance. It contains the 
entire biosynthetic toolset for all 20 amino acids(Cole et al., 1998). During 
infection of both mice and macrophages, it appears that M. tuberculosis 
constitutively expresses amino acid biosynthesis genes(Schnappinger et al., 
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2003, Rohde et al., 2012, Talaat et al., 2004, Talaat et al., 2007). Even when 
grown in vitro, where tryptophan is freely available, the tryptophan biosynthetic 
locus continues to be expressed [unpublished data, Y. Zhang and E. Rubin]. 
Thus, M. tuberculosis seems to choose to independently synthesize amino acids 
regardless of environmental availability (Figure 1). M. tuberculosis does the same 
with energetic sources as well—unlike E. coli, M. tuberculosis will continue to 
metabolize energy-poor carbon sources even in the presence of more energy 
efficient carbon sources(de Carvalho et al., 2010).  
The M. tuberculosis intracellular niche is similar to Chlamydia’s. M. 
tuberculosis is taken up by phagocytosis and enters into a vacuole that escapes 
lysosome fusion. As with Chlamydia, there is strong evidence that IFN-γ 
activation of infected macrophages plays a major role in controlling M. 
tuberculosis growth(Flynn et al., 1993, Fabri et al., 2011). Unlike Chlamydia, M. 
tuberculosis is always able to make tryptophan, which is essential for its survival 
of IDO activation by IFN-γ. Its ability to make other amino acids is also crucial for 
virulence, as lysine, proline and leucine auxotrophs also fail to grow normally in 
macrophages and are severely attenuated in mice(Hondalus et al., 2000, Smith 
et al., 2001, Parish, 2003, Pavelka et al., 2003a). Perhaps because amino acid 
biosynthesis is constitutive in M. tuberculosis, amino acid biosynthesis has not 
been seen as a virulence factor. However, these processes are clearly essential 
and, in fact, could serve as the basis for drug design. 
If amino acid production is constitutive, is there any role for amino acid 
sensing during infection? M. tuberculosis does have a stringent response, and it 
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encodes a RelA homologue, which in E. coli and other organisms responds to 
amino acid starvation(Primm et al., 2000).  RelA knockouts are attenuated for 
growth in mice and guinea pigs(Primm et al., 2000, Klinkenberg et al., 2010, Dahl 
et al., 2003).  It is likely that RelA can respond to amino acid levels—this is true 
in a related species, Mycobacterium smegmatis—but neither RelA sensing of 
amino acid starvation nor RelA-dependent coordination of amino acid synthesis 
is well documented in M. tuberculosis(Dahl et al., 2005). The stringent response 
signals through ppGpp, which in E. coli requires DksA to be fully 
active(Magnusson et al., 2005, Paul et al., 2004). M. tuberculosis encodes CarD, 
an alternative DksA, which is also required for the stringent response to 
starvation, and mutants are slightly attenuated in mice(Connolly et al., 2009). 
However, CarD is essential in rich media, suggesting a role outside of the 
stringent response that might explain its requirement for growth in vivo(Connolly 
et al., 2009, Stallings et al., 2009). Notably, RelA mutants are far less attenuated 
than amino acid auxotrophs(Primm et al., 2000). It is most likely that the stringent 
response in M. tuberculosis is primarily responsible for sensing and responding 
to other forms of starvation or immune-mediated stress. Thus, M. tuberculosis is 
an example of a pathogen that has decoupled amino acid metabolism from host 
availability. It persists in making its own amino acids, making it resistant to host 
mechanisms of amino acid starvation. 
Legionella: Host exploitation—extracting amino acids from a stingy host 
Not all bacteria are as energy independent as M. tuberculosis. The host, 
after all, is a tremendous resource for essential nutrients if the pathogen can 
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manage access(Rohmer et al., 2011). In this respect, Legionella pneumophila 
has been quite successful. Like M. tuberculosis and Chlamydia, L. pneumophila 
replicates in an intracellular vacuole, the Legionella-containing vacuole (LCV). 
The LCV avoids lysosomal fusion and further develops by recruiting mitochondria 
and rough ER-derived vesicles. L. pneumophila translocates ~300 effectors into 
the host cell cytoplasm via its type IV secretion system to specifically refine its 
intracellular niche(Al-Quadan et al., 2012).  
Unlike its other intracellular pathogen cousins, the evidence seems to 
suggest that L. pneumophila does not face an amino acid starved milieu. L. 
pneumophila does employ the stringent response, which is necessary for survival 
during infection. In fact, the stringent response in L. pneumophila drives the 
expression of most known virulence factors(Hammer et al., 1999, Molofsky et al., 
2004). However, in macrophages, its stringent response machinery does not rely 
on RelA, suggesting that sensing amino acid starvation is unimportant during 
infection(Dalebroux et al., 2009, Dalebroux et al., 2010). Instead L. pneumophila 
responds to fatty acid starvation through another stringent response sensor, 
SpoT, and uses this as a signal to turn on its intracellular pathogenesis 
program(Dalebroux et al., 2009). Amino acid catabolism is necessary for growth 
in vivo and some evidence points to serine as a key intracellular carbon source 
for L. pneumophila(Eylert et al., 2010). Finally, a bacterial transporter, PhtA, is 
used by L. pneumophila as a high-affinity threonine transporter and is necessary 
for growth in cells, showing that at least one amino acid is acquired from the 
host(Sauer et al., 2005). 
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The LCV, then, seems to be an amino acid rich environment designed for 
a hungry bacterium. How then, does L. pneumophila manipulate host cells, 
normally stingy with their amino acids, to serve up amino acids into the LCV? 
After all, it is likely that amino acid starvation programs are triggered in host cells 
infected with L. pneumophila. The bacterium has at least two characterized 
mechanisms of reversing this starvation.  
First, L. pneumophila upregulates a host neutral amino acid transporter, 
SLC1A5, during macrophage infection (Figure 1.1) Knockdown of the transporter 
does not affect host cell viability, but limits Legionella growth(Wieland et al., 
2005). Even when cells were grown in amino acid rich media, an 80% decrease 
in SLC1A5 expression resulted in ~1000 fold decreased L. pneumophila 
growth(Wieland et al., 2005). The same transporter is specifically upregulated 
during infection with another intracellular pathogen, Francisella, and is also 
required for bacterial replication in THP-1 cells(Barel et al., 2012). It is unclear 
whether SLC1A5 exists on the LCV membrane, the plasma membrane, or both, 
but it is essential in providing amino acids to L. pneumophila. 
Second, a recent study of host-pathogen interactions at the LCV 
membrane revealed that L. pneumophila utilizes the host proteasome to 
generate free amino acids for bacterial growth(Price et al., 2011). The authors 
noted that the LCV is decorated with Lys48-linked polyubiquitinated proteins 
anchored to the bacterial virulence factor AnkB(Price et al., 2011). These 
polyubiquitinated proteins recruit the host proteasome, generating small peptides 
at the LCV membrane. Inhibition of both the proteasome and amino acid-
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releases peptidases results arrests L. pneumophila growth, a phenomenon that 
is reversed by the addition of excess free amino acids(Price et al., 2011). Using a 
standard transcriptional reporter of amino acid starvation (green fluorescent 
protein fused to the flaA promoter), the authors found that while wildtype L. 
pneumophila did not experience amino acid starvation during infection—
confirming previous stringent response studies—AnkB null mutants did. AnkB 
growth was not further suppressed by proteasome inhibition, and was rescued by 
amino acid supplementation. Thus, by recruiting proteins and targeting them for 
proteasomal degradation, AnkB provides a ready source of amino acids(Price et 
al., 2011). L. pneumophila actively molds the LCV into a growth-supporting niche, 
subverting host amino acid starvation machinery and exploiting host AA-
acquisition mechanisms(Al-Quadan et al., 2012). 
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Concluding Remarks 
Many of us take a very pathogen-centric view of host defense.  However, 
the vast majority of bacteria encountered by humans are incapable of causing 
infection.  “Non-specific” defenses, such as nutrient deprivation, play a large role 
in eliminating organisms that are not specifically adapted to a pathogenic niche.  
Pathogens, therefore, have evolved specific mechanisms to subvert these 
defenses and to take advantage of the nutrient rich human host. Amino acids, 
necessary for protein synthesis and, sometimes, as a carbon source, are often 
depleted in the intracellular environment as a means of starving the pathogen. 
Pathogen responses range from growth suppression to manipulating host 
pathways to reverse amino acid starvation.  
Understanding the interplay between host and pathogen could prove to be 
useful in designing new therapies(Rasko et al., 2010, Escaich, 2008). The three 
bacteria discussed in this review, C. trachomatis, L. pneumophila, and M. 
tuberculosis are major human pathogens that, for various reasons, have proven 
to be difficult to control. All three represent organisms for which new antibacterial 
therapies are needed. By knowing how our immune system tries to kill these 
bacteria as well as the bacterial evasion strategies, we could target these 
processes to synergize with the immune system to kill invading pathogens. For 
example, blocking tryptophan biosynthesis, could increase IFN-γ- mediated killing 
of M. tuberculosis. Amino acid biosynthesis genes could be reasonable drug 
targets. It is already targeted by many herbicides, and a small molecule used to 
treat mouse Pseudomonas aureginosa infection was shown to have activity 
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against bacterial tryptophan biosynthesis(Lesic et al., 2007, Epelbaum et al., 
1996). Furthermore, host tryptophan needs are supplied through the diet, 
suggesting that, barring off-target effects, small molecules targeting tryptophan 
synthesis will not be toxic to the host. Alternatively, the susceptibility of 
Legionella to the inhibition of the proteasome suggests that host-directed 
therapies could alter that balance in virulence(Price et al., 2011, Al-Quadan et al., 
2012). Thus, altering both bacterial and host responses critical for amino acid 
starvation could provide new avenues for the development of therapeutics.  
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Figure 1.1: Three bacterial strategies for evading amino acid starvation 
Chlamydia trachomatis responds to amino acid starvation by differentiating to 
aberrant reticulate bodies, viable but metabolically inactive forms that can 
differentiate back to active forms when amino acid become available again. 
While Mycobacterium tuberculosis faces amino acid starvation during infection, 
its constitutive expression of amino acid synthesis makes it generally resistant to 
host-driven starvation. Legionella pneumophila exploits host proteins to override 
starvation and deliver free amino acids into its intracellular niche. AnkB, a 
secreted virulence factor, drives the polyubiquitination of LCV membrane 
proteins. The host proteasome is then recruited to proteolyze ubiquinated targets, 
producing free amino acids that are transported into the LCV by the upregulated 
host transporter, SLC1A5. 
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Section 1.4: Therapeutic Strategies for improving 
immune clearance of Mycobacterium tuberculosis 
Overview 
Despite the fact that treatment options for tuberculosis have existed for the last 
six decades, the disease remains one of the main global health threats. The 
need for new drugs is urgent, since shortening the current drug regimen would 
be beneficial, and since drug resistance cases are increasing in prevalence. After 
completely drying for many decades, the tuberculosis drug development pipeline 
has started to flow again, with one new FDA approved drug in the last year and 
many more in clinical trials. All of these potential therapeutics, however, target 
processes required for Mtb growth in vitro, likely due to the screening strategies 
employed to discover these growth-inhibiting compounds. Bacterial survival 
during infection, however, requires many other determinants, including targeted 
suppression of adaptive and innate immune responses, exploited host proteins 
used to create a more conducive milieu for the pathogen, and pathogen 
processes required to survive the stresses imposed by the host. Small molecules 
that induce protective host defenses or inhibit mycobacterial survival 
determinants will help the immune system kill Mtb more effectively. In order to 
explore the entire space of potential therapeutic strategies, we need to move 
beyond targeting essential genes and include virulence factors and host 
defenses as areas of chemical intervention. In this section, we review the 
mycobacterial adaptation to the host and discuss work that has led to the 
discovery of potential drugs that help improve the efficacy of host defenses, 
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either by inducing better (or more) host defense mechanisms or by making the 
bacterium more susceptible to existing defenses.  
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INTRODUCTION 
Tuberculosis (TB), the disease caused by Mycobacterium tuberculosis (Mtb), has 
been treatable by antibiotics for over 50 years. Despite this, TB continues to be 
one of the deadliest infectious diseases in the world. In 2010, there were an 
estimated 8.8 million new cases of TB and 1.45 million deaths from TB 
worldwide1.  Efforts aimed at global control of TB face multiple hurdles, including 
the long duration of treatment and the increasing incidence of drug resistant 
cases. Multidrug-resistant (MDR) TB caused an estimated 440,000 cases in 
2010, and only 1% of these cases were treated with the regimen recommended 
by the World Health Organization1. New drugs are needed in the fight against TB 
to stem the tide of difficult-to-treat MDR cases and hopefully shorten the time 
needed to treat. Luckily, after a 45-year TB drug-development drought, a new TB 
drug, Bedaquiline, has been approved by the United States Food and Drug 
Administration, and multiple others are currently in Phase II or Phase III clinical 
trials2, 3. However, the long-term efficacy of these drugs depends on unknown 
factors such as their long-term toxicity and the speed with which new resistance 
develops. So it is crucial that the TB drug development pipeline does not dry up 
and that new drugs and new strategies for control continue to be identified.  
When thinking about strategies for TB control, it is interesting to note that our 
immune systems usually do an adequate enough job to control disease. The 
adaptive immune system and the pathogen reaches an equilibrium, known 
clinically as latency, wherein disease is prevented but bacteria are not completely 
cleared4. Drugs that improve immunity or block pathogen strategies of survival 
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might be able to break this détente and spur pathogen clearance. Certainly in the 
5-10% of infected individuals where immunity fails to prevent disease, potential 
immune-boosting strategies could be useful.  
Most drugs target proteins that are essential for bacterial viability in laboratory 
culture conditions. Here, we highlight another strategy—therapeutics that help 
the immune system kill Mtb more effectively—and review promising targets and 
recent advances in drug development. There are two main ways to aid 
antimycobacterial immunity. First, we can design therapeutics to increase or 
induce effective immune control mechanisms. Interestingly, many of these 
strategies ultimately kill Mtb by putting the bacterium into lysosomes, overriding 
the key Mtb survival strategy of avoiding lysosomal delivery.  Second, we can 
target Mtb proteins required for bacterial growth during infection—virulence 
factors and other proteins essential for its adaptation to the host—to make Mtb 
more susceptible to host immunity. By inhibiting mycobacterial processes that 
neutralize host defenses, we can turn these ineffective host mechanisms into 
strategies for control. 
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OVERVIEW OF HOST DEFENSES AND MTB RESPONSES 
Mycobacterial adaptations to intracellular host defenses 
Mycobacterium tuberculosis has adapted to survive its infectious niche and the 
pressures of host immunity. In this section, we provide a brief overview to 
immune-mediated stresses and Mtb adaptations to these stresses.  
Mtb adaptations to the intracellular niche and innate immunity 
Host vesicular trafficking is responsible for sequestering infecting microbes into 
lysosomes, where the pathogens are subjected to an arsenal of host defenses, 
including acid, oxidative stress, and antimicrobial peptides. Mtb is able to block 
this process, and during infection of macrophages in cell culture, Mtb survives 
primarily in unacidified phagosomes5, 6. Interestingly, the induction of autophagy 
can overcome this block and kill intracellular Mtb7-10. The exact mechanism by 
which Mtb blocks vesicular trafficking is unclear, but the many components 
required for this block have been elucidated. These include both bacterial 
virulence factors and exploited host proteins, and any of these determinants of 
phagolysosome fusion blockade could serve as potential therapeutic targets6, 11, 
12.  
Mtb adaptations to metabolite starvation—scavenging and biosynthesis 
While Mtb avoids many noxious agents by blocking delivery to lysosomes, it still 
faces metabolite starvation during infection. The intracellular environment seems 
to be relatively lacking in carbohydrate sources of carbon, and Mtb survives in 
the host by utilizing fatty acids. This is evidenced by the need for the glyoxylate 
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shunt, cholesterol catabolism and gluconeogenesis during infection of both 
macrophages and mice13-17. Furthermore, intracellular amino acid availability is 
limited during bacterial infection, and amino acid biosynthesis is active and 
required during Mtb infection18-21. These metabolic demands imposed by the 
immune system are successfully met by Mtb synthetic pathways, but blocking 
these pathways can restore the efficacy of immune-mediated starvation.  
Mtb survival of reactive oxygen and nitrogen species 
Reactive oxygen intermediates (ROI) and to a larger extent reactive nitrogen 
intermediates play important roles in limiting Mtb growth and maintaining latency 
in mice, but are also insufficient to clear bacteria22-25. Mtb can sense oxidative 
stress through a two component system called DosRS, and coordinate a 
protective response that is crucial for its survival during infection26. It employs an 
army of detoxifying enzymes and agents, protects from oxidatively damaged 
proteins using its proteasome, and repairs DNA, all processes that are required 
for survival during infection26-29.  
Mycobacterial adaptations to intracellular host defenses 
Mtb manipulates the adaptive immune response through a myriad of different 
strategies. Through an unknown mechanism, it delays both antigen presentation 
to T cells in the lymph node and arrival of T cells to the locus of infection, thus 
slowing the initiation of adaptive immunity30, 31. Mtb also seems to manipulate 
adaptive immunity by limiting the expression of protective antigens, and 
overexpression of one particular antigen, Antigen 85B, improves CD4 activation 
and control of Mtb32. Furthermore, a study of Mtb genetic diversity revealed that 
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T cell antigens are more conserved than essential genes, suggesting that Mtb 
may have evolved ways to exploit T cells for its own survival33. Clever vaccine 
strategies that elicit protective responses at the expense of these Mtb-driven 
non-protective responses could be fruitful in shifting the host-pathogen 
equilibrium to the host’s advantage. Mtb vaccine design is a rich and well-
reviewed topic. While therapeutic strategies to boost adaptive immunity against 
Mtb are important, this review will focus on strategies that improve intracellular 
host defenses or increase Mtb susceptibility towards these defenses.  
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THERAPEUTIC STRATEGIES TO IMPROVE INTRACELLULAR HOST 
DEFENSES 
Autophagy induction reduces mycobacterial survival in macrophages 
Autophagy is an essential tool of cellular physiology. It occurs at a basal level in 
eukaryotic cells, but is especially important for maintaining homeostasis during 
certain physiologic stresses, such as starvation, organelle damage, or pathogen 
infection34. It was first identified as having anti-mycobacterial potential in a study 
that induced autophagy and observed decreased growth of Mycobacterium bovis 
BCG 7. Later groups noticed that the anti-mycobacterial activity of two classes of 
IFN-γ-responsive GTPase, LRG-47 and Gbps, as well as the Vitamin D-induced 
antimicrobial peptide Cathelicidin, were all autophagy-dependent9, 10, 35-37. The 
formation of autophagosomes around Mtb and other bacterial pathogens, also 
called xenophagy, leads to lysosomal fusion and delivers Mtb to the toxic 
environment that it otherwise avoids9, 19. Thus, therapeutics that enhance 
autophagy could promote an effective host defense for Mtb control. 
Autophagy-inducing peptides 
Many existing therapeutics have autophagy-inducing effects, but these drugs all 
have autophagy-independent effects that may limit their clinical use as 
autophagy inducers38. Recently a group has developed a specific autophagy-
inducing peptide that limits Listeria monocytogenes growth in cell culture 
models39. The peptide was derived from the Nef-binding region of an autophagy-
related protein, Beclin1. In addition to its efficacy in inhibiting L. monocytogenes 
growth in macrophages, it also decreased replication of pathogenic viruses in 
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vivo39. The main advantage of an autophagy-specific therapeutic is the lack of 
off-target effects as would be seen with other autophagy-inducing drugs. The 
peptide was well tolerated by mice during the two-week-long daily treatment, with 
no histological damage seen in their vital organs39. This peptide is a promising 
candidate for TB treatment, and should be tested in a mouse model of Mtb 
infection. 
Vitamin D 
The role of autophagy in a host of different diseases has heightened the interest 
in developing autophagy-inducing drugs38. For inducing autophagy during TB, 
however, an inexpensive and safe treatment option might already exist. Vitamin 
D works through the antimicrobial peptide Cathelicidin to induce autophagy in 
Mtb-infected macrophages10, 37, 40. Along with IFN-γ, Vitamin D is able to kill both 
HIV and Mtb in macrophages in an autophagy-dependent manner40. Interestingly, 
the amount of Vitamin D in human serum varies substantially, and in one study, 
donated human serum with 48 nM of 25-hydroxyvitamin D3 was permissive of 
mycobacterial growth, while another human serum sample with 96 nM was able 
to kill 90% of mycobacteria in macrophages37.  
There is strong epidemiological evidence that low Vitamin D levels increase TB 
risk in human patients as well41. We get most of our Vitamin D through a 
synthetic process that begins in keratinocytes exposed to ultraviolet B radiation, 
although dietary sources of Vitamin D also exist. Thus, a lack of sunlight 
exposure and low dietary intake can easily result in Vitamin D insufficiency. Many 
cross-sectional and case-control studies, as well as a recent meta-analysis, have 
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linked low levels of Vitamin D with clinical TB42-44. Interestingly, groups in Cape 
Town and New York have also reported seasonal variability in TB incidence, as 
we might expect given that differences in sunlight exposure is one of the greatest 
sources of Vitamin D variability in the human population43, 45. In addition, 
polymorphisms that decrease activity of the Vitamin D Receptor (VDR), which 
governs immune cell responses to Vitamin D, also increases TB risk44, 46.  
The mounting evidence suggests a clear association between Vitamin D and TB 
risk, but a causal link, much less a directional one, has not yet been established. 
Cell culture models support the hypothesis that Vitamin D boosts immunity to TB, 
but reasonable alternative hypotheses exist, such as the possibility that TB 
causes ill patients to stay indoors and lose sunlight exposure. Randomized 
control trials (RCTs) assessing Vitamin D as adjunctive therapy have mostly 
failed to demonstrate an effect in the primary treatment outcomes41, 47-50. Each 
study looked to measure either faster or increased sputum culture clearance in 
their measurement arms, but none found a statistically significant improvement. 
Coussens et al. found a small effect in a subgroup with a recessive allele of VDR, 
but it is important to note that randomization is compromised in subgroup 
analyses, making them difficult to interpret47.  
Vitamin D has a clear anti-mycobacterial effect in cell culture models, and 
observational epidemiology has proven a clear link between Vitamin D deficiency 
and TB risk. The failure of RCTs so far to show clinical efficacy of Vitamin D 
during treatment is unfortunate, but hardly spells the end of Vitamin D as a 
potential tool against TB in the future. Firstly, the RCTs were attempting to 
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measure improvement in clinical outcome beyond that seen in first-line treatment 
regimens. The effects were likely to be small, and these studies were not 
powered to find small effects. Secondly, the cell biology models of suggest that 
Vitamin D works best against Mtb contained in macrophages. While this is true of 
many bacilli in active disease, Mtb containment within macrophages is most 
evident early in infection, and it is possible that we should be investigating 
Vitamin D as a nutritional supplement for prevention rather than for treatment. To 
perform such a study, even amongst HIV positive patients, would require huge 
cohorts. But while the costs would be huge, the upside of proving that a cheap 
dietary supplement could prevent TB would be tremendous.  
Inhibition of host proteins exploited by Mtb 
Mtb exploits multiple host proteins for survival11, 51, and inhibiting these proteins 
could remove an important survival tool for Mtb during infection.  
Akt kinase inhibitor 
Intracellular pathogens require many host factors in order to replicate in the host 
cell. Realizing this, researchers performed both genetic and chemical screens to 
identify these exploited host factors. One screen done in Salmonella yielded a 
host target and chemical inhibitor that also worked in for Mtb infection52. Using a 
kinase inhibitor library, the authors found that one compound, HA-89 effectively 
inhibits both Salmonella and Mtb growth in cell culture. They tested HA-89 
against an in vitro panel of human kinases and determined that the only kinase 
inhibited by HA-89 that as required for Salmonella growth in their genetic screen 
was Akt. Of note, Akt was also found to be required for Mtb growth by an 
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independent screen11, 51. While this is suggestive of Akt being the target, 
inhibition of a bacterial kinase (Mtb expresses two essential serine/threonine 
kinases) or another human kinase could also be responsible for the effect on 
bacterial growth. The mechanism by which Akt supports mycobacterial growth is 
unclear, but the authors suggest a link to vesicular trafficking and 
phagolysosome fusion. Akt inhibitors have been used in mice to treat cancers, 
but at least a few reports have noted general toxicity. Regardless, inhibition of 
Akt is a proof of concept for targeting exploited host proteins, and efficacy studies 
in mice would provide additional insight into Akt as a potential target in TB 
therapy. 
Imatinib 
Imatinib was one of the first rationally-designed drugs for cancer, and was made 
to inhibit the Abl kinase, which is activated by a chromosomal translocation in 
chromic myeloid leukemia53. Investigators have recently shown that imatinib and 
another Abl inhibitor decrease Mtb growth in macrophages and in mice54. 
Imatinib treatment of inhibited macrophages also increases bacterial 
colocalization with lysosomal markers, suggesting that Abl is exploited by Mtb to 
affect vesicular trafficking54, 55. Furthermore, Mtb killing with imatinib is dependent 
on the vacuolar ATPase and acidification of the phagosome. Interestingly, 
imatinib also has an effect on mycobacterial growth in Abl knockout 
macrophages, suggesting that it has non-Abl targets as well.  
None of the therapeutics mentioned so far have been tested in model systems in 
the presence of first-line TB drugs, and so interactions with existing treatments is 
	  48	  
an unknown, but crucial piece of the puzzle. There is no a priori assumption; 
many of the potential therapeutics discussed so far change the intracellular 
milieu of Mtb, and this change in environment could improve or hamper the 
activity of current anti-mycobacterials. In this study, interaction with an existing 
drug, rifampin, is directly addressed. Interestingly, the authors show that imatinib 
acts synergistically with rifampin, though the reason is unclear. This is a clear 
argument for modeling the interaction of new therapies with existing ones. This is 
especially true with the molecules in this review; since they affect the host-
pathogen interface, many result in driving the bacterium out of its self-crafted and 
relatively bacteria-friendly niche, and into a more stressful environment where 
existing drugs could have greater efficacy. 
Summary 
Mtb lives in an infectious niche that it is tolerates perfectly, and for the most part, 
our bodies tolerate Mtb without any consequences to our health. However, this 
equilibrium permits the survival of bacilli that could cause disease in the future. A 
small nudge in this equilibrium could provide the tipping point needed to improve 
disease and treatment outcomes. In addition to the ideas and potential 
therapeutics outlined above, there are many other possibilities. Arginine, a 
compound that theoretically increases nitrc oxide, has been tested in infected 
people, although the results from those studies have been largely inconclusive56. 
Important cytokines have also been used to treat TB in animal models and in 
humans. Recombinant cytokines, however, remain fairly expensive and thus 
difficult to imagine as a strategy against global TB. Furthermore, many of the 
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host-friendly cytokines, such as IFN-γ, are already at a high enough level upon 
infection, and there are possibly decreasing margins-of-return with what amounts 
to an incremental increase. But while recombinant proteins or other biologics 
might not be feasible, small molecule agonists of pattern recognition receptors 
have been tailored to increase cytokine release, and these might prove useful in 
the future.  
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THERAPEUTIC STRATEGIES THAT MAKE MTB MORE SUSCEPTIBLE TO 
HOST DEFENSES 
Bacterial pathogens and their hosts have engaged in an evolutionary arms race, 
and it’s likely that both have weapons in their arsenal that have been rendered 
ineffective by the opposing side. If we can understand and block the mechanisms 
that TB uses to neutralize host defenses, we can turn an otherwise ineffective 
host process into a pathway that kills Mtb. In this section, we will review three 
broad categories of mycobacterial adaptations to the host environment. First, we 
will discuss inhibitors of the determinants of the phagolysosome block. Second, 
we will review inhibitors of mycobacterial protection against nitric oxide. Finally, 
we will review small molecules that take aim at infection-specific metabolism.  
Targeting mycobacterial mechanisms that inhibit phagolysosome fusion 
PtpA and PtpB 
Of the many mycobacterial factors that are purported to be involved blocking 
phagolysosome fusion, the secreted phosphatases have attracted the most 
attention as targets for chemical inhibition12. Mtb expresses two secreted 
phosphatases, PtpA and PtpB57. Both are required for survival in macrophages58, 
59, although only PtpB is required for growth in an animal model60, 61. Both 
phosphatases were first identified through genome sequencing and their 
similarity to eukaryotic low molecular weight phosphatases (LMW-PTP). 
Furthermore, despite the fact that neither phosphatase has a recognizable 
secretion signal, both phosphatases can be found in culture filtrates, and 
antibodies against PtpA can detect its presence in macrophages during a cell 
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culture infection57, 58, 62. Upon secretion into the host cell, PtpA dephosphorylates 
VPS33B and excludes the vATPase proton pump from the phagosome 
membrane, preventing phagosome acidification58, 63. Host-pathogen protein 
interactions are difficult to study in physiological conditions, as the pathogen 
protein often has to be overexpressed in the host cell in order to perform 
immunoprecipitation-Western blots or fluorescent microscopy with sufficient 
resolution. In the case of PtpA, however, genetic evidence also supports the 
importance of its interaction with the vATPase. A phosphatase-competent point 
mutant that cannot interact with vATPase has impaired growth in macrophages 
and ends up in acidic phagosomes63. The target of PtpB has not yet been 
established, but expression of PtpB in macrophages suggests that it may activate 
kinase pathways that eventually lead to decreased IL-6 secretion59. It has also 
been shown in vitro to have phosphatase activity at both serine/threonine and 
tyrosine residues64. But while intracellular secretion and activity of PtpB is not 
established, it has been shown to be required for growth in an animal model60, 61. 
There are many attractive things about targeting these phosphatases for 
therapeutic intervention. Both are required for macrophage growth; while similar 
to eukaryotic phosphatases, neither has a human ortholog, suggesting that 
target-specificity is achievable with small molecule inhibitors; and secretion into 
the host might make them more exposed to inhibitors, which do not have to cross 
the formidable barrier of the mycobacterial cell wall. There have been many 
reports of PtpA inhibitors, though the best molecules have been from a series of 
chalcones with Ki values ranging from 4.9 to 21.3 µM in vitro65-67. Importantly, the 
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chalcones have been tested in macrophages and have been shown to be potent 
inhibitors of Mtb growth in cells67. Chemical inhibition of PtpB activity in vitro has 
been studied by many groups, but only a few have tested its efficacy on live 
bacteria59, 64, 65, 68-75. The structure of PtpB has been used as used as a scaffold 
for informed drug design, and some groups have even used the existence of a 
secondary site to design bidentate inhibitors, resulting in some of the most potent 
inhibitors to date69, 70. Efficacy studies in macrophages have been done for only a 
small fraction of the compounds with known in vitro activity, but a few promising 
molecules, including two dual-site inhibitors, an isoxazole derivative and a 
salicylate-based compound, can significantly decrease mycobacterial growth in 
macrophages59, 64.   
The large number of in vitro inhibitors of these enzymes is encouraging, but 
many challenges lie ahead. Since PtpA is non-essential in mice, there is no good 
animal model for further testing of PtpA inhibitors. However, PtpB is essential in 
guinea pigs, and inhibitor efficacy in this model would be critical for determining 
the true promise of this phosphatase as a drug target.  
PknG 
Protein Kinase G (PknG) is a kinase that appears to help support the growth of 
Mycobacterium bovis BCG in macrophages by blocking lysosomal fusion76-79. 
Interestingly, Mtb PknG appears to be either essential or at least required for 
optimal growth in vitro, so its role in Mtb compared to its role in BCG is unclear80. 
Small molecule inhibitors, the best of which is a tetrahydrobenzothiophene called 
AX20017, of PknG that limit both Mtb and BCG growth in macrophages have 
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been described76. While these inhibitors have been tested against a panel of 
bacterial and human kinases, it is worth noting that the in vivo target has not 
been definitively characterized, and AX20017 has not been tested in mice81.  
Targeting Mtb proteins that guard against oxidative stress 
Reactive oxygen and nitrogen species are an integral part of the host response 
against Mtb, especially in mice22-26. Damage mediated by ROI and RNI is 
complex, and Mtb encodes multiple sensing and damage response pathways to 
help it survive oxidative damage.  
RNI detoxification 
Sulfate transport and reduction as well as cysteine biosynthesis is upregulated 
and during dormancy and required in long-term survival models27. Interestingly, 
cysteine auxotrophs are attenuated in wildtype mice, but almost fully virulent in 
Rag-/- mice, which lack adaptive immunity82. The mechanism for this adaptive 
immunity-driven requirement for cysteine is not fully characterized, but it is 
thought to relate to the need for cysteine in the synthesis of mycothiol, a reducing 
agent that protects the bacterium from oxidative damage. Inhibitors of cysteine 
biosynthesis have been identified, and it would be interesting to test these 
inhibitors in infection models83, 84. 
Proteasome inhibitors 
A screen for mycobacterial survival determinants in nitric oxide (NO) revealed 
that the mycobacterial proteasome was required for NO resistance and survival 
during mouse infection28. Proteasome knock strains were later shown to be 
required for persistence in the later stages of mouse infection as well85. 
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Interestingly, when these same strains were used to infect mice lacking the 
inducible nitric oxide synthase (iNOS), the expected rescue of virulence was not 
seen, suggesting that the proteasome might be important for additional reasons 
in vivo28. Nevertheless, the mycobacterial proteasome remained a promising 
target for drug development since proteasomes from other species had been 
successfully targeted. In 2009 an inhibitor was described that was selective for 
the mycobacterial proteasome and had very little activity against the human 
proteasome, demonstrating that species-specificity was possible86. The same 
group also described a more potent proteasome inhibitor that did have cross-
species activity, showing that selectivity is a major issue when designing 
proteasome drugs87.  
DNA damage response inhibitors 
Another hit from the NO survival screen was DNA damage repair. UvrB, a 
component of the nucleotide excision repair machinery, was also found to be 
important for surviving NO-stress28. UvrB knockouts are attenuated in mice and 
macrophages29. Growth of the UvrB mutants is somewhat restored in iNOS-/- 
mice, although increased growth is no larger an effect than seen in wt Mtb29. 
Recently, a whole-cell screen for small molecules inhibitors that resulted in 
hypersusceptibility to UV resulted in the discovery of UvrB inhibitors88. While the 
effects of the inhibitor on NO survival was not shown, this study demonstrates 
that DNA excision repair can be targeted. Coupled with genetic evidence for its 
need during infection, UvrB inhibition could be a promising target moving forward. 
Targeting mycobacterial metabolism during infection 
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It is thought that one of the advantages of being an intracellular pathogen is the 
abundance of nutrients inside host cells, since the host itself needs a steady 
supply of energy-rich metabolites89. However, it is clear that the metabolic 
demands of Mtb in vitro and in vivo are very different, and that immune-mediated 
starvation can drive this change in metabolic requirements90. Targeting these 
metabolic pathways then, can help turn the immune system’s futile starvation 
attempts into real mechanisms of Mtb control. 
Glyoxylate shunt inhibitors 
Isocitrate lyase (Icl) and the glyoxylate shunt are required for mycobacterial 
growth in macrophages and mice, presumably because fatty acids are needed as 
a carbon source because glycolytic sources are unavailable or glycolysis 
intermediates are being shunted away from the TCA cycle13, 14. One of the first 
reports of Icl essentiality in vivo also presented a chemical inhibitor, which 
decreased growth in macrophages, albeit at high, millimolar concentrations14. 
The authors note that the active site of Icl is very polar and small, and is thus a 
relatively difficult enzyme to inhibit. There are other reports of Icl enzymatic 
inhibition, but interestingly many of these have low MIC values in vitro. Since Icl 
is not essential for Mtb growth in vitro, these molecules likely have off-target 
effects that limit mycobacterial growth91-93. While Icl seems to be a poor target for 
chemical inhibition, the second enzyme in the pathway, malate synthase (GlcB), 
has an active site structure more conducive to drug design. While there are 
conflicting reports on whether or not GlcB is required for survival in vitro, its 
inhibition should terminate flux through the in vivo essential glyoxylate shunt. 
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Recently, a GlcB inhibitor has been described that had a 2-log reduction in 
mycobacterial growth after 9 days of infection and treatment, showing early 
promise as a possible therapeutic strategy16.   
Amino Acid biosynthesis inhibitors 
Amino acid biosynthesis is required for Mtb growth in vivo, and it has been 
shown in many other bacterial infection models that host cells are able to starve 
intracellular bacteria of amino acids18-21. Amino acid biosynthesis inhibitors have 
been utilized in many other organisms, and researchers have speculated that the 
shikimate pathway (responsible for the synthesis of aromatic amino acids), which 
has been successfully targeted in other organisms, might be a good target for 
Mtb94, 95.  
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CONCLUDING REMARKS 
The growing problem of drug resistance demands new drugs and new targets for 
the global fight against TB. One of the key challenges in developing truly new 
drugs is identifying new pathways to target. Expanding the list beyond proteins 
required for growth in laboratory conditions can help. In this review, we have 
given an overview of current and future strategies aimed at helping the immune 
system kill Mtb more effectively. The therapeutics described include compounds 
that target host proteins, inducers of host defenses, and inhibitors of bacterial 
survival determinants during infection. Also key in TB drug design are the 
overlapping challenges of decreasing treatment time and killing non-replicating 
bacteria. Although non-replicating populations are complex and poorly 
understood, it is not difficult to imagine that drugs designed to limit bacterial 
growth in vitro might not be optimized for killing non-replicating bacteria. While 
this will vary case by case, it is possible that treatments aiming to boost immune 
clearance of bacteria might have better efficacy against these difficult bacterial 
subpopulations, and thus accelerate treatment.  
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Section 2.1: Overview and Attributions 
Overview. Discovering genes required for bacterial growth is foundational for 
both basic and applied biology. It provides key biological insight into bacterial 
physiology and identifies potential drug targets. This chapter contains two 
manuscripts that define genetic requirements for Mycobacterium tuberculosis 
(Mtb) growth in laboratory culture conditions. Both manuscripts analyze the same 
data—the number of insertions sequenced from an Mtb transposon mutant 
library grown on the standard solid rich-media in the field, 7H10 supplemented 
with glycerol. Previous analyses of transposon insertion counts from deep-
sequencing focused on measuring the underrepresentation of insertion counts 
across annotated genes. Both manuscripts tackle an important oversight in this 
strategy: genes are often multi-component units, and the individual units could be 
differentially required. The first manuscript treats the genome as a series of 
random windows, and analyzes the requirement of each of these random 
windows. Most genes are composed completely of non-required windows; a 
smaller fraction is composed entirely of required windows. This paper highlights a 
third possibility—genes that contain both required and non-required windows. 
These genes could be representative of multimodular proteins wherein only 
some domains are required for growth, or non-required protein-coding genes that 
encode a required antisense RNA on the complement strand. Importantly, these 
are required genetic elements that are missed when genes are assessed for 
requirement as a single unit. The second paper also acknowledges that essential 
genes might be essential only because of a short essential stretch of coding 
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sequence. The task, then, is to find essential stretches of genetic code 
regardless of their length relative to the gene as a whole. By looking for 
continuous runs of potential insertion sites that lack insertions, this paper defines 
an essential gene as a gene that contains a statistically significant stretch of 
insertion-less sites.  
Attributions. The two papers in this chapter are published, the first in PLoS 
Pathogens and the second in Bioinformatics.  The work is primarily a 
collaboration between our lab and the talented bioinformatics crew led by 
Thomas Ioerger at Texas A&M University.  With help from Ed Long in Chris 
Sassetti’s lab at the University of Massachusetts Medical School in Worcester, I 
made the transposon libraries in Mtb and did the DNA preparation for sequencing. 
The bioinformatic analyses were a joint effort by Chris Sassetti, Curtis 
Huttenhower in the Biostatistics Department at HSPH, Thomas Ioerger and his 
student Michael DeJesus, and Jim Sacchettini. I drafted the first manuscript and 
Michael and Tom drafted the second manuscript, and we were all involved in 
editing the manuscripts. Since Michael was the primary author on the second 
manuscript, it is appended in this thesis in its final publication formatting. 
However, because it is a natural extension of this chapter, it is included here 
(rather than as an appendix) for narrative continuity. 
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Abstract 
Identifying genomic elements required for viability is central to our understanding 
of the basic physiology of bacterial pathogens. Recently, the combination of high-
density mutagenesis and deep sequencing has allowed for the identification of 
required and conditionally required genes in many bacteria. Genes, however, 
make up only a part of the complex genomes of important bacterial pathogens. 
Here, we use an unbiased analysis to comprehensively identify genomic regions, 
including genes, domains, and intergenic elements, required for the optimal 
growth of Mycobacterium tuberculosis, a major global health pathogen. We found 
that several proteins jointly contain both domains required for optimal growth and 
domains that are dispensable. In addition, many non-coding regions, including 
regulatory elements and non-coding RNAs, are critical for mycobacterial growth.  
Our analysis shows that the genetic requirements for growth are more complex 
than can be appreciated using gene-centric analysis.  
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Author Summary 
The significant rise in drug resistant strains of Mycobacterium tuberculosis has 
highlighted the need for new drug targets. Here, we present a novel method of 
defining genetic elements required for optimal growth, a key first step for 
identifying potential drug targets. Similar strategies in other bacterial pathogens 
have traditionally defined a set of essential protein-coding genes. Bacterial 
genomes, however, contain many other genetic elements, such as small RNAs 
and non-coding regulatory sequences. Protein-coding genes themselves also 
often encode more than one functional element, as in the case of multi-domain 
genes. Therefore, instead of assessing the quantitative requirement of whole 
genes, we parsed the genome into comprehensive sets of overlapping windows, 
unbiased by annotation, and scanned the entire genome for regions required for 
optimal growth. These required regions include whole genes, as expected; but 
we also discovered genes that contained both required and non-required 
domains, as well as non protein-coding RNAs required for optimal growth. By 
expanding our search for required genetic elements, we show that 
Mycobacterium tuberculosis has a complex genome and discover potential drug 
targets beyond the more limited set of essential genes.  
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Introduction 
Mutagenesis has long been a powerful tool for understanding the roles of 
genes and other chromosomal elements.  Recently, high-density transposon 
insertion mutagenesis coupled with deep sequencing has enabled 
comprehensive identification of the required genes in many important bacterial 
pathogens [1-6].  Defining the protein-coding genes required for bacterial growth 
identifies both key biological processes and potential targets for drug 
development. However, protein-coding genes are not the only genetic elements 
that code for required functions. In densely packed bacterial genomes, many 
regulatory regions are required for appropriate expression of genes [7].  
Moreover, all organisms produce large numbers of non-coding RNAs that can be 
important under a variety of growth conditions [8-10]. Gene-oriented analyses 
also look past cases wherein a single gene encodes several differentially 
important protein domains. 
Here, rather then focusing on genes, we take an unbiased approach to 
create a comprehensive understanding of genomic requirement in 
Mycobacterium tuberculosis (Mtb). We model the Mtb genome as made up of 
“functional units”, a term that encompasses both genes and other genetic 
elements, many of which have yet to be annotated. By not limiting our analysis to 
whole-gene regions, we can find otherwise unidentified functional units while also 
gaining a more nuanced view of the genes required for mycobacterial growth, 
including critical domains within proteins and non-protein-coding regions that play 
important roles.   
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We find approximately 300 protein-coding genes wherein only portions of 
the coding sequence are required. These include genes, such as ppm1 and fhaA, 
where we demonstrate that one domain is required for optimal growth whereas 
other domains are not. Our unbiased analysis also revealed required genomic 
elements in regions sitting between protein-coding genes. These include two 
RNAs, the tmRNA and the RNA component of RNaseP, which are required for 
optimal growth. In addition, we find a number of other regions that influence 
viability by uncharacterized mechanisms, but whose effects have previously been 
overlooked by gene-centric analyses. 
Results 
Deep sequencing for transposon insertion mapping 
To perform a comprehensive assessment of Mtb's genetic requirements 
for growth, we used two ~100,000-clone Mtb libraries generated through high-
density transposon mutagenesis of the H37Rv strain [11]. We generated a library 
of single-insertion mutants by phage delivery of the Himar1 transposon, which 
randomly inserts into the genome at sites recognized by the TA dinucleotide 
(Figure 2.1A). We then created transposon-mapping probes by selectively 
amplifying and sequencing transposon-genome junctions using an Illumina 
Genome Analyzer 2. Using genome sequences adjacent to the transposon 
genomic sequences, we were able to map the insertion site of mutants in the 
library (Figure 2.1B) and count the reads mapped to each insertion site (insertion 
count, Table S1). 
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We reasoned that the insertion count should reflect the number of 
corresponding mutants in the library. To demonstrate this, we picked twelve 
individual transposon mutants and added each at a known quantity to a manually 
constructed library. Insertions were again mapped and counted by deep 
sequencing, and the insertion counts for each site was compared to the known 
relative quantities of each mutant in the pool (Figure 2.1C). Insertion counts were 
highly correlated with the known relative amount of each mutant (Pearson R = 
0.880, p-value < 0.0001, n = 14). Additionally, we confirmed that insertion counts 
accurately reflected the library’s genome composition by counting the genome-
transposon templates represented in our Illumina reads. Since random shearing 
events create the genome-transposon templates for amplification, the distance 
between the transposon and the sheared end represents a unique identifier for 
each template. We assessed the relationship between estimates of unique 
template molecules for each TA site and the read count for that site (Figure 2.1D), 
revealing excellent correlation (Pearson R  = 0.945 p-value < 0.0001 n = 36,488). 
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Figure 2.1. Transposon junction sequencing accurately reflects true library 
content A. A Mtb mutant library is created by phage-delivery of transposons, 
disrupting each genome with a single insertion. Shown is a schematic of 6 
mutant chromosomes spanning three genes (A-C), with transposons—red 
arrows—disrupting one of the three genes. After growing the library on 7H10 
media, we pooled surviving mutants. In this schematic, gene C is required for 
optimal growth and thus mutants with transposons in gene C are lost. We 
isolated genomic DNA from the survivors for transposon site mapping. B. We 
sheared the genomic DNA by sonication, and repaired frayed ends to create 
blunt ends. We then used Taq polymerase to generate A-tails, allowing the 
ligation of T-tailed adapters. Finally, we selectively amplified transposon junctions 
using primers recognizing the transposon end and the adapter. Primers used for 
amplification contain all requisite sequences to permit direct sequencing of 
amplicons on an Illumina Genome Analyzer 2. C. We created a library of 
identified transposon insertion mutants in known relative quantities. DNA from 
the library was prepared for transposon junction sequencing. Insertion counts 
were plotted against the known relative quantity of the mutant in the library. D. To 
further confirm that read counts were a representation of the number of genomes 
in the library, we estimated the number of PCR template molecules. For each 
gene, we plotted the estimate of template molecule count against the read counts. 
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Comprehensive map of genetic requirement in Mtb 
In our Mtb library, transposon insertions occurred at 36,488 of the 72,927 
possible insertion sites (TA dinucleotides). Each library generated an average of 
2.3 million reads, resulting in a mean insertion count of 64 per hit-site. We 
counted the number of sequencing reads from each site in the two libraries and 
compiled the counts correcting for each library’s total insertion count.  
Having demonstrated that insertion counts faithfully represent mutant 
numbers (Figure 2.1C), we used insertion counts to comprehensively assess the 
relative importance of selected genomic regions. We defined a region as required 
for optimal growth if total regional insertions were statistically underrepresented 
compared to genomic controls (Figure 2.2A). Required regions, therefore, are 
those in which mutations result in a statistically validated growth defect.  We 
employed a non-parametric test to assess statistical underrepresentation and 
regions with a p-value of less than 0.01 and a false discovery rate (Benjamini-
Hochberg) of less than 0.1 were defined as required for optimal growth in vitro.  
Instead of assessing the requirement for growth of genomic regions based 
on predetermined gene coordinates, we divided the genome into contiguous 
overlapping windows to assess a comprehensive set of potential functional units. 
Our non-parametric test was powered to find significant regions containing at 
least 7 TA sites (6 or fewer precluded confident rejection of a null hypothesis of 
variation by chance alone). Thus, we focused on regions of sizes likely to contain 
7 or more TA sites. The mean number of TA sites in windows of 400, 500, and 
600 bp was 6.75, 8.45 and 10.12, respectively, and were thus used for our sliding 
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window analysis of functional requirement for growth. Intergenic (IG) regions are 
relatively AT-rich in the Mtb genome, allowing us to add a 250 bp sliding window 
(mean of 6.20 TA sites in IG regions) to the analysis of IG regions. To lower the 
computational demands of this analysis, we chose to analyze every tenth window, 
reasoning also that functional units were unlikely to be smaller than 10 base pairs. 
Thus, we assessed the requirement for growth of every tenth 400, 500, and 600 
bp window in the genome, along with every tenth 250 bp window in regions 
between protein-coding genes (Figure 2.2B).  
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Figure 2.2.	  Functional requirement testing and mapping 
A. Required regions were defined as regions with a statistical 
underrepresentation of insertion counts compared to the rest of the genome. To 
test this, we applied a non-parametric test for regions of increasing size, as 
described in B. Every 250, 400, 500, and 600 bp region (large enough for 
statistical power) was tested for insertion count underrepresentation, generating 
a comprehensive map of required regions in the Mtb genome. Tracks on the 
circularized genome, from inner-most to outer-most: 1. Histogram of insertion 
counts, 2. Annotated genes, forward direction, 3. Annotated genes, reverse 
direction, 4. All required regions. 5. Required intergenic regions. 
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Genes required for optimal growth 
We overlaid the coordinates of known genes on the generated results to 
find those that contained regions required for optimal growth. Of the 3,989 
annotated genes, 698 contained required functional units, 3,071 contained no 
required functional units, while 210 did not sustain insertions but also did not 
contain enough TAs to meet statistical requirements (Figure 2.3A). As a screen 
for genes with multiple functional units of varying requirement, we searched for 
genes that contained both required and non-required regions. A total of 365 
genes met these criteria (Figure 2.3A).  
Our finding that many genes contain both required and non-required 
regions suggested that using only whole genes for analysis could misrepresent 
their importance for growth.  Either the entire gene could appear required for 
optimal growth or the entire gene would be considered dispensable, leaving no 
room for the possibility that only a segment of the gene might be required.  To 
determine how our results would compare to a gene-centric analysis, we 
calculated the requirement for growth of each gene by applying the non-
parametric test to the gene as a whole. As expected, genes with required 
segments had a wide range of p-values when assessed using annotated 
boundaries instead of unbiased overlapping windows (Figure 2.3B, dark blue 
bars). A total of 151 out of the 365 (41.3%) had p-values above 0.01, 
demonstrating that our sliding window strategy accounted for a significant 
number of required functional units that would be ignored by gene-only strategies 
(Figure 2.3B).  
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A transposon insertion into the 5’ end of a gene will often block production 
of the encoded protein, either by attenuating transcription or disrupting ribosome 
binding sites and initiation codons.  Thus, we expected that regions required for 
optimal growth would tend to be found at the 5’ ends of predicted genes.  
Surprisingly, a plot of the likelihood of discovering an required functional region 
as a function of the intragenic location revealed a symmetric curve, 
demonstrating that the required regions discovered have an equal likelihood of 
residing on either end of the gene (Figure 2.3C).  We hypothesized that this may 
be because the transposon contains a promoter that can direct downstream 
transcription.  To test this, we took two strains that contained transposon 
insertions and measured mRNA expression upstream and downstream of the 
transposon (Figure 2.4A). In both cases, expression upstream of the transposon 
did not significantly change, while downstream expression increased (Figure 
2.4B). This is consistent with the observation that downstream genes can be 
transcriptionally activated by transposon insertions [12]. In addition, mycobacteria 
are able to use several initiation codons thus making it more likely that truncated 
but functional proteins can be produced from internal start sites. 
While we were able to use this analysis to make many novel observations, 
we also found that our results supported previous findings. The majority of genes 
(63%) described as fully required for growth were similarly required in 
microarray-based studies using transposon site hybridization (TraSH) (Figure 
S1A, Table S2) [13]. The increased resolution from deep sequencing 
demonstrated that genes with fewer than 7 TAs resulting in an undersampling 
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that prevented statistically confident requirement assessments (a separate 
category for genes with 6 or fewer TAs that did not contain insertions is noted in 
Figure 2.3A). Since this was not known previously, we predicted that the 
microarray-determined set of required genes would be biased towards small 
genes. This proved to be true. In genes predicted to be required by TraSH but 
not in this study, the average number of TAs was 9.90 (Figure 2.5B). In contrast, 
the average number of TAs in fully required genes from this study was 19.42, a 
fair representation of the average of all genes assessed (19.47). In fact, of the 
genes only determined to be required in TraSH and not in this study, 43% had 7 
or fewer TAs, accounting for much of the discordance between the two methods.  
A more nuanced analysis of Mtb transposon insertion maps defined 
essential genes as those that contained “gaps,” any statistically significant runs 
of potential insertion sites lacking transposon insertions [3]. As expected, genes 
found in our sliding window analysis to have both required and non-required 
regions were more concordant with essential genes found by sequencing using 
this gap analysis than with microarray approaches or whole-gene analyses of 
insertion counts. Of genes described in our approach as fully required, 97.2% 
were described as “essential” by Griffin et al (Figure 2.5A), a remarkable level of 
agreement given the differences in growth media between the two studies. The 
increased concordance extended to genes containing both required and non-
required regions. Griffin et al. described 185 of these genes as essential, while 
microarray methods only deemed 134 to be essential. The search for required 
regions within genes, a feature of both analyses, allowed for the discovery of 
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these regions in longer genes, as evidenced by the increase in average number 
of TAs within these genes (Figure 2.5B).  
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Figure 2.3. Domain Discovery 
A. Genes categorized by domain-level resolution of regional requirement. B. 
Genes categorized as containing only required regions (blue), containing both 
required and non-required regions (navy) and containing no required regions 
(yellow) were assessed for requirement along the entire length of the gene, 
creating a single p-value describing the statistical underrepresentation of 
insertion reads within the whole gene. For each category, the number of genes 
across the range of p-values are plotted. C. For genes with both required and 
non-required regions, the likelihood that the relative position within the gene 
resides in a required region.  
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Figure 2.4 
A. For both fully required and partially required genes, the agreement with the 
essential gene set from Griffin et al. and with the required gene set from TraSH 
was calculated. B. Average length of genes (by number of TAs) are plotted for 
the following gene sets: required genes in TraSH, genes determined to be 
required in TraSH but not this analysis, fully required genes in this analysis, all 
genes assessed in this analysis, essential genes in Griffin et al., and all genes 
with required regions in this analysis.  
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Figure 2.5 
A. Primer design for measuring expression upstream and downstream of the 
transposon. B. Relative expression of gene segments upstream and downstream 
of the transposon in transposon strains and H37Rv controls. C. Directional 
footprinting of transposon insertion. Lad: 1 kb DNA ladder, 1: wt Mtb transposon 
library, sense insertions, 2: ppm1-complemented Mtb transposon library, sense 
insertions, 3: wt Mtb transposon library, anti-sense insertions, 4: ppm1-
complemented Mtb transposon library, anti-sense insertions. 
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Identification of the required glycosyl transferase domain in Ppm1 
We find that, in some genes, encoded domains have different effects on 
growth, accounting for the varying degrees of requirement across the gene’s 
open reading frame. For example, the gene encoding Ppm1, an enzyme in the 
lipoarabinomannan (LAM) synthesis pathway, encodes a protein with two distinct 
domains. The region encoding the carbon-nitrogen hydrolase domain of Ppm1 
sustained many insertions, while the region encoding the C-terminal glycosyl 
transferase was required for optimal growth (Figure 2.6A). While the specific 
requirement of the glycosyl transferase is a novel finding, it resonates with a 
previous report that only the glycosyl transferase was required for the synthesis 
of LAM, thought to be an essential cell wall component [14]. Another study 
revealed that Ppm1 has N-acyltransferase activity, which could be the non-
required function of this two-domain protein [15]. 
To confirm that the lack of insertions in this domain was due to a 
functional requirement and not to insertional bias or the generation of toxic 
fusions or truncations, we created transposon libraries in the presence of a 
second copy of ppm1. We reasoned that a second copy would render the 
endogenous gene non-required and thus permissive for transposon insertion. We 
designed footprinting PCR primers upstream of the original ppm1 to specifically 
generate amplicons containing transposon insertions into the endogenous copy 
(Figure 2.6B). Footprinting of the original library confirmed our sequencing results, 
as no insertions were found in the region encoding the glycosyl transferase. 
However, in the complemented library, that region did contain insertions, 
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suggesting the glycosyl transferase is functionally required for growth. We further 
reasoned that only sense insertions—that is, insertions wherein the transposon’s 
internal promoter is oriented in the same direction as the disrupted gene—would 
be tolerated in the 5’ end of ppm1 to allow for the expression of the C-terminal 
required domain. To assess this, we used primers specifically designed to 
amplify sense and anti-sense insertions, and noted only sense insertions in the 5’ 
end (Figure 2.5C). In addition, we confirmed that many in-frame internal start 
sites exist between 5’ transposon insertion sites and the beginning of the 3’ 
domain. 
The MviN-binding domain of FhaA is required for growth 
A recent report showed that FhaA was required for optimal growth of 
Mycobacterium smegmatis and postulated that the importance of the interaction 
of FhaA with the essential protein MviN for appropriate regulation of growth and 
peptidoglycan synthesis [16]. These processes are essential for mycobacterial 
cell division and cell wall biosynthesis. This work further demonstrated the C-
terminal forkhead associated (FHA) domain of FhaA was required for MviN-
binding, while an N-terminal domain of unknown function was dispensable for 
this interaction. In agreement with these findings, we show here that the region of 
fhaA encoding the FHA domain cannot sustain insertions, while the remainder of 
the gene is dispensable (Figure 2.6C). We used insertion footprinting to confirm 
these results, and found that the C-terminal insertion mutants were rescued for 
growth in the presence of a second copy of fhaA (Figure 2.6D).  
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Notably, both ppm1 and fhaA, which we predict to be required for optimal 
growth based on the presence of a required region within these genes, were 
classified as non-essential in a previous microarray-based screen [13]. In fact, 
231 of the 365 genes containing both required and non-required regions were not 
previously described as necessary for growth, likely due to the decreased spatial 
resolution of microarray-based methods. Microarrays limited the resolution of 
requirement testing to genes, and each gene received a single metric describing 
its requirement for growth. In addition, as our approach is not confined to gene 
boundaries, we have the additional resolution to identify domains within genes, 
as exemplified by ppm1 and fhaA.  
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Figure 2.6. ppm1 and fhaA each code for two domains with varying 
requirements for growth 
A. IGV plot for genomic region containing ppm1. Tracks, from top to bottom: 1. 
Histogram of insertion counts, 2. Comprehensive heat-map of requirement of 
500-bp windows, 3. Position of annotated genes, 4. TA sites, 5. Position of 
known domains within ppm1. B. PCR footprinting for insertions was performed 
using primers against the an upstream genomic region and the transposon end, 
resulting in amplicons spanning ppm1 to various inserted transposons. Lad: 1 kb 
DNA ladder, 1: wt Mtb transposon library, 2: ppm1-complemented Mtb 
transposon library. C. IGV plot for genomic region containing ppm1. Tracks, from 
top to bottom: 1. Histogram of insertion counts, 2. Comprehensive heat-map of 
requirement of 500-bp windows, 3. Position of annotated genes, 4. TA sites. D. 
PCR footprinting for insertions was performed using primers against the an 
upstream genomic region and the transposon end, resulting in amplicons 
spanning fhaA to various inserted transposons. Lad: 1 kb DNA ladder, 1: wt Mtb 
transposon library, 2: fhaA-complemented Mtb transposon library.  
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The RNA components of RNaseP and the Clp quality control system are 
required for growth 
Because we are not limited to annotated regions we were also able to 
probe the importance of intergenic regions. By scanning the genome for required 
250, 400 and 500 bp regions, we found 25 intergenic regions required for optimal 
growth (Figure 2.2B). These required intergenic regions contained many 
components of known essential cellular functions to be required for in vitro 
growth. These included 10 tRNAs as well as the RNA catalytic unit of RNaseP, 
which has been shown to be required for tRNA processing in other bacteria 
(Figure 2.7A). Additionally, one required intergenic region contained the tmRNA, 
a molecule required to release stalled ribosomes and to tag polypeptides for 
proteolytic degradation through an essential protease (Figure 2.7B) [17-18]. Of 
the intergenic segments containing functionally required regions, 11 had 
annotated functions and an additional 6 were adjacent to genes assessed as 
required for growth and, therefore, might contain promoters or other 
transcriptional regulatory elements. The remaining 19 required segments are 
situated between two non-required genes and, as yet, have no ascribed function. 
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Figure 2.7. RNAs required for growth in vitro 
A. IGV plot for genomic region containing the rnpB, the RNA component of 
RNaseL. Tracks, from top to bottom: 1. Histogram of insertion counts, 2. 
Comprehensive heat-map of requirement of 500-bp windows, 3. Position of 
annotated genes, 4. Position of TA dinucleotide sites, 5. Position of rnpB. B. IGV 
plot for genomic region containing the tmRNA. Tracks, from top to bottom: 1. 
Histogram of insertion counts, 2. Comprehensive heat-map of requirement of 
500-bp windows, 3. Position of annotated genes, 4. Position of TA dinucleotide 
sites, 5. Position of the tmRNA. 
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Discussion  
Finding genetic loci that are required for optimal growth under specific 
conditions helps inform the basic understanding of bacterial physiology and 
efforts to develop new therapeutics for pathogens.  Previously, we and others 
have used transposon mutagenesis to infer the requirement for genes under 
different growth conditions by utilizing the information provided by genome 
annotations [1-6]. Deep sequencing, which allows us to map precisely the 
insertion site of every mutant, affords a higher resolution assessment of genetic 
requirement, beyond just genes. Here, we demonstrate that an unbiased sliding 
window approach harnesses the full potential of this increased resolution. This 
approach identified not only whole genes required for optimal growth but also 
other required elements, such as non-protein coding RNAs and protein domains 
within insertion-containing genes, which would otherwise obscured by gene-
centric analysis. An alternative analysis that uses significant gaps in insertion—
rather than quantitative insertion counts—was also able to assess the 
requirement of protein domains (DeJesus et al., unpublished data, submitted). 
This analysis likely identifies regions absolutely essential for viability rather than 
all regions required for optimal growth.  
We found that many genes contain elements that are important for growth 
even though other regions are not required.  In at least two cases, ppm1 and 
fhaA, published data have shown that the required regions encode specific 
protein domains.  However, in other cases, these might represent non-protein-
coding RNAs or cis regulatory elements.  Bacteria encode many small RNAs 
many of which could be required for optimal growth and some of which are 
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embedded within genes [8-10]. In addition, most genes have been annotated 
computationally, an uncertain pursuit that clearly can lead to misannotated start 
sites [19]. Genes with only 5’ insertions could fall into this category. 
Similarly, important non-protein-coding regions could have multiple roles.  
In some cases, we found that known RNAs, such as rnpB, the catalytic RNA 
component of RNase P, and the tmRNA were required for optimal growth, 
supporting previous speculation [20-21]. Again, some other required regions 
might encode as yet unidentified non-coding RNA molecules.  Still others might 
be promoters or other regulatory regions.  
 In this study, our resolution was limited by the specific properties of the 
Himar1 transposon in mycobacteria.  Our previous studies have shown that 
insertions are randomly distributed apart from the desired selection against 
insertion in essential regions [11, 22]. Despite this, we cannot assume that all 
sites lacking insertions represent required regions since unknown insertional 
biases of the transposon may exist. Thus, we defined a required region as one 
with a statistically underrepresented insertion count using a non-parametric test 
to account for such potentially unique biases within these data (Figure 2A). This 
allowed us to exclude, for example, windows with 6 or fewer TA sites, which 
demonstrably lacked power to distinguish a region as essential for growth relative 
to background variation. In GC-rich protein-coding regions, this limited our scope 
to windows of greater than 400 bp; less GC-rich intergenic regions allowed the 
assessment of windows greater than 250 bp. Thus, while we were able to identify 
many required protein domains and RNAs, it is certainly possible that smaller 
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elements required for growth were missed due to these size constraints.  This is 
a particular problem for non-coding RNAs that are often very small.  For 
example, while we found 10 tRNAs required for growth, the remaining tRNAs 
reside in non-coding regions that did not have the requisite number of TA sites to 
determine requirement. Using the Himar1 transposon in organisms with less of a 
GC bias, or in organisms in which a less restricted transposon exists, should 
result in increased resolution [4]. 
 The analysis we used provides a powerful tool to perform functional 
genome analysis.  Importantly, this type of approach is useful not only for single 
conditions, as we described but can also be used to identify elements critical 
under one growth condition but not another [23-25].  This is particularly important 
in organisms like Mtb, an obligate pathogen that never grows under conditions 
precisely comparable to those we use in vitro.  Coupling high-density insertion 
libraries with deep sequencing and analytic methods such as that described here 
provides a powerful experimental tool for functional genome annotation. 
Methods and Materials 
Genomic Library Creation 
Two independent libraries of 100,000 mutants were generated in the Mtb 
strain H37Rv as previously described on 7H10 agar [11].  Independent libraries 
were also generated in Mtb strains overexpressing ppm1 and fhaA. Genomic 
DNA was isolated from each library and randomly fragmented to 400-600 bp 
pieces by sonication with a Covaris E220. Nicked ends were repaired (Epicentre 
end repaired kit), and A-tails were added with Taq polymerase to allow the 
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ligation of T-tailed adapters. Transposon-junctions were amplified for 30 cycles 
(94 degrees, 30 seconds; 58 degrees, 30 seconds; 72 degrees, 30 seconds) 
using a primer recognizing the transposon end (5’-
AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTC
CGATCCGGGGACTTATCAGCCAACC-3’) and one recognizing the adapter (5’-
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCT
CTTCCGATCGTCCAGTCTCGCAGATGATAAGG-3’). Primers used during 
amplification contained all the requisite sequence for binding to the Illumina 
sequencing platform. A 250-400 bp fragment of the amplicon was isolated from a 
gel and sequenced on an Illumina GA2 instrument with a custom sequencing 
primer (5’-TTCCGATCCGGGGACTTATCAGCCAACC-3’).  
Sequencing analysis 
Reads from the Illumina sequencing run were first screened for the 
presence of sequence from the end of the Himar1 transposon. The following 35 
bases were mapped to the Mtb genome, allowing for 2 mismatches. Reads that 
mapped to the genome at a TA site were designated as mapped insertions. 
Reads that mapped to multiple sites were randomly assigned to one of the 
mapped sites. For each library, the number of reads mapping to each site 
(insertion counts) was counted. Insertion counts were plotted on IGV and 
CGViewer [26-27]. 
Requirement Testing 
For every possible region size containing x potential insertion sites, a null 
distribution of mean read counts was generated by calculating the mean read 
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counts from a set of 10,000 randomly selected sets of x sites. The 10,000 
randomly generated means were sorted and the rank of the test region’s mean 
insertion count within the ordered null distribution was determined. The p-value 
was calculated as the rank of the test mean divided by the size the null 
distribution (10,000). Multiple test correction was performed by calculating the 
Benjamini-Hochberg false discovery rate over all regions tested. Regions 
containing 7 TA sites with no insertions had a p-value of 0.008 and an FDR of 
0.06, while regions containing 6 TA sites with no insertions had a p-value of 
0.018 and an FDR of 0.12. In order to power our study to detect required regions 
containing at least 7 TAs, we determined a region to be required for optimal 
growth if it had a p-value less than 0.01 and an FDR less than 0.1. 
DNA footprinting 
Footprinting of transposon insertion sites was performed by PCR using a primer 
recognizing the Himar1 ITR sequence (5’-
CCCGAAAAGTGCCACCTAAATTGTAAGCG-3’) and primers recognizing a 
genomic segment just upstream of the gene of interest. For directional 
footprinting, we used one primer to amplify sense insertions (5’-
TTTTCTGGATTCATCGACTGTGGC-3’)—where the kanamycin resistance gene 
on the transposon was oriented in the same direction as the disrupted gene—
and another for antisense insertions (5’-CAGCTCATTTTTTAACCAATAGGCCG-
3’). Standard PCR conditions were used for long amplification with Phusion 
polymerase (94 degrees, 15 seconds; primer-dependent annealing temperature, 
30 seconds; 72 degrees, 2 minutes).   
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ABSTRACT
Motivation: Next-generation sequencing affords an efficient analysis
of transposon insertion libraries, which can be used to identify essen-
tial genes in bacteria. To analyze this high-resolution data, we present
a formal Bayesian framework for estimating the posterior probability
of essentiality for each gene, using the Extreme Value distribution to
characterize the statistical significance of the longest region lacking
insertions within a gene. We describe a sampling procedure based on
the Metropolis-Hastings algorithm to calculate posterior probabilities
of essentiality while simultaneously integrating over unknown internal
parameters.
Results: Using a sequence dataset from a transposon library for M.
tuberculosis, we show that this Bayesian approach predicts essential
genes that correspond well with genes shown to be essential in pre-
vious studies. Furthermore, we show that by using the Extreme Value
Distribution to characterize genomic regions lacking transposon inser-
tions, this method is capable of identifying essential domains within
genes. This approach can be used for analyzing transposon libra-
ries in other organisms, and augmenting essentiality predictions with
statistical confidence scores.
Availability: A python script implementing the method described is
available for download from http://saclab.tamu.edu/essentiality/
Contact: michael.dejesus@tamu.edu; ioerger@cs.tamu.edu;
Supplementary Information: Supplementary data is available at
Bioinformatics online.
1 INTRODUCTION
Transposon mutagenesis is a frequently used laboratory method for
determining essential genes in bacterial organisms. Essential genes
are those genes necessary for growth under a wide variety of envi-
ronmental conditions. Knowledge of essential genes is important
for the discovery of new antibacterial drugs because these genes
are potential targets for inhibitors (Hasan et al., 2006). One way
of determining essential genes is to identify regions of the genome
in which insertional mutations produce nonviable cells. To do this,
∗to whom correspondence should be addressed
a high-density library of transposon mutants is constructed. The
synthetic transposons used in these studies are small fragments of
DNA (typically 1-2 kb), which can be inserted into different loca-
tions in the chromosome through the action of a distally-encoded
transposase enzyme (Hayes, 2003). For example, derivatives of the
Himar1 transposon are widely used and have been characterized
to insert at arbitrary TA dinucleotides without any other obvious
sequence specificity bias (Lampe et al., 1996; Rubin et al., 1999).
The total number of TA sites within a gene often varies around
10-100 sites depending on gene length and GC content. When a
transposon inserts at one of these TA sites within a gene, it pre-
sumably disrupts the function of the gene. In a large library of
transposon insertion mutants, genes harboring insertions are presu-
med to be non-essential. Genes lacking insertions may be essential
as they cannot tolerate disruption, however this depends on the
size of gene and degree of saturation of the library (Lamichhane
et al., 2003). Typically 10-15% of ORFs in a bacterial genome are
found to be essential (Gerdes et al., 2003), including genes invol-
ved in core metabolism, cell-wall biosynthesis, protein translation,
and DNA replication (all of which are known targets of existing
drugs). Differential analysis of essential genes in bacteria passaged
through a host could be used to identify genes specifically required
for infection (Sassetti and Rubin, 2003).
In the original implementation, the location of transposon inser-
tions in individual mutants were read out via microarray hybridiza-
tion. A primer-extension step, using a primer complimentary to one
end of the transposon, was used to amplify the adjacent genomic
region, and the relative abundance of these nucleic acid probes was
quantified via hybridization to oligonucleotide representing each
gene (Sassetti et al., 2003). Both the resolution and the quantitative
accuracy of this method were limited. More recently, use of hybri-
dization to analyze transposon libraries has been replaced by deep
sequencing using next-generation sequencers, which yield millions
of short reads (typically 50-100 bp). Mapping of reads amplified
from transposon boundaries can give precise coordinates of inserti-
ons within the genome (Gawronski et al., 2009; Langridge et al.,
2009; Griffin et al., 2011). The high-resolution data afforded by
deep sequencing presents some unique challenges for analysis of
1
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gene essentiality. It has previously been observed that even essen-
tial genes can tolerate transposon insertions in the extreme N- and
C-termini of the ORF (Smith et al., 1996; Akerley et al., 1998; Chri-
sten et al., 2011)). Previous analyses have often used an ad hoc
criterion, such as exclusion of insertions in the first/last 5-20% of the
coding region (Gawronski et al., 2009). For similar reasons, inser-
tions are sometimes tolerated in linker regions between domains,
or one domain but not another of an essential protein (Lamichhane
et al., 2005). For example, transposon insertions in the N-terminus
of Mmpl5 caused attenuation of infection in mouse lungs, whe-
reas insertions in the C-terminus did not (Lamichhane et al., 2005).
Thus it is inaccurate to assume that only genes completely lacking
transposon insertions are essential.
In previous work, we described a novel statistical method for ana-
lyzing transposon insertion data to characterize the essentiality of
genes within an organism (Griffin et al., 2011). The method was
based on identifying the longest consecutive stretch of TA sites
lacking insertions in a gene, and estimating the likelihood of such an
open region occurring by chance through the Extreme Value (Gum-
bel) distribution. This model was based on an analogy to runs of
tails in a sequence of coin tosses, where each TA site is viewed as
an independent Bernoulli trial given the background insertion fre-
quency in non-essential genes. This analysis was shown to correlate
well with previous characterizations of genes essential for in vitro
growth of M. tuberculosis. The primary advantage of this method
is that essentiality is based on statistically significant stretches of
TA sites lacking insertions, regardless of the presence of inserti-
ons at other regions within the gene. This is in contrast to other
models, such as a multinomial model, where the order of inserti-
ons is not taken into consideration (Blades and Broman, 2002), and
may miss regions characteristic of essential domains. One limitation
of our previous method is that it depends on an a priori estimate
of the insertion frequency in non-essential genes. While this can be
approximated (over all TA sites in the whole genome) or tuned itera-
tively (by separating out essential genes), a more rigorous statistical
treatment is desirable.
One possible way to approximate the parameters of this model
and find estimates of essentiality is to use the Expectation Maxi-
mization (EM) algorithm. Although the EM algorithm converges
relatively quickly, it depends on maximizing the likelihood of the
given distribution. This is not feasible for the product of Gumbel
distributions, as no closed-form expression for the derivative exists.
In this paper, we present a formal Bayesian analysis of transpo-
son insertion data that simultaneously estimates the likelihood of
essentiality for each gene and the non-insertion frequency for each
class, given the data. We develop a formula for the joint and condi-
tional densities based on the likelihood for each gene. We describe
how to use a Metropolis Hastings sampling procedure to estimate
the parameters from the data, by sampling from the joint probability
densities. This method produces a formal estimate of essentiality for
each gene from the posterior probability given the observed inser-
tion data, marginalizing over the unknown insertion frequencies in
essential and non-essential genes.
2 METHODS
The sequence data obtained from transposon mutagenesis experi-
ments consists of a set of reads mapping to TA dinucleotides sites
within the genome. The read counts at each TA site are discretized
to a binary value of 1 (“insertion”) or 0 (“non-insertion”) depen-
ding on the presence or absence of transposon reads mapping to
those locations. While the number of reads mapping to a location
may contain useful additional information about essentiality, it can
also be subject to variability due to phenomena such as PCR bias.
Thus we take the presence/absence of insertions within genes to be
sufficient for identifying essential regions in our model. TA sites
are assumed to be independent from each other and treated as a set
of Bernoulli trials (analogous to coin-tossing, with insertions and
non-insertions representing outcomes of Tails or Heads), which is a
reasonable assumption in non-essential genes, where the probability
of insertion at adjacent sites is thought to be independent.
From this data we obtain the maximum number of consecutive TA
sites lacking insertions within the genes and the number of nucleo-
tides spanned by this sequence. While the geometric distribution
governs the distribution of the number of non-insertions observed in
a row, the Gumbel (Extreme Value Distribution) can be used to cha-
racterize the longest run of non-insertions observed in a gene. The
Gumbel distribution serves as a likelihood function for non-essential
genes, as the longest runs of non-insertion should follow what we
expect given the global non-insertion frequency. On the other hand
essential genes, whose maximum runs of non-insertions should be
longer than expected, are instead modeled through a normalized sig-
moid function. This likelihood function reflects the fact that any
gene can be essential (with more or less uniform probability), except
those genes with spans of non-insertion that are too small to repre-
sent a domain. Using this model of the data we derive posterior
densities for the essentiality of each gene and use the Metropolis-
Hastings algorithm to obtain a MCMC sample of values of these
densities from which to estimate their posterior probabilities.
2.1 Bayesian Mixture Model
Let Yi = {ni, ri, si} represent our observations for the i-th gene
for i = 1...G, where ni represents the total number of TA sites, ri
represent the longest run of non-insertions observed, and si repres-
ents the span of nucleotides of the longest run of non-insertions.
Each gene is modeled as coming from one of two classes, 1 and 0,
representing essential and non-essential genes. The complete set of
essentiality assignments is represented by the latent variable Z =
〈Z1, Z2, ...ZG〉 (Boolean vector), with the essentiality assignment
of an individual i-th gene represented by the boolean variable Zi
which takes on binary values of 1 and 0 for the two possible clas-
ses. We assume a Bernoulli probability, φ0, that governs probability
of non-insertion across non-essential genes. Finally, ω = 〈ω1,ω0〉,
the mixing coefficient, represents the prevalence of essential and
non-essential genes within the mixture (with ω0 = 1− ω1).
2.1.1 Likelihood for Non-Essential Genes The data, Yi, for each
gene consists of observations ri and si, representing the maximum
run of non-insertions (TA sites without insertions) in a row, and the
number of nucleotides spanned by this gap of non-insertions. The
joint likelihood of these observations is:
p(ri, si|Zi = 0,φ0,ω1) =
p(ri|Z = 0,φ0,ω1)× p(si|ri, Z = 0,φ0,ω1)
2
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To The likelihood of observing a maximum run of non-insertions,
ri, is modeled through the Gumbel distribution:
p(ri|Zi = 0,φ0,ω1) = Gumbel(ri;m, τ ) = 1
τ
e−z−e
−z (1)
where z = ri−mτ , and m and τ are the location and scale parame-
ters of the underlying distribution. In analogy to coin-tossing, these
parameters are functions of the probability of non-insertion, φ0, and
of the total number of trials, n, derived by determining the expected
maximum value in a series of independent samples from a geometric
distribution (Schilling, 1990):
m = log 1
φ0
(n(1− φ0)) τ = 1
log 1φ0
(2)
Note that the expected length of the maximum run of non-
insertions scales up logarithmically with n (the total number of TA
sites in the gene).
Since ri and si are highly correlated (see Figure 1), we model
their dependence as linear-Gaussian, with covariance matrix Σ =ˆˆ
σ2r ,σr,s
˜
,
ˆ
σr,s,σ
2
s
˜˜
estimated a priori from empirical data:
p(si|ri, Z = 0,φ0,ω1) ∼ N(si − λrri,σ2r) (3)
were λr and σr are the parameters of the Normal distribution, deri-
ved from the Linear Gaussian relationship (i.e. λr = σr,sσr ) observed
in the data.
Fig. 1. Relationship Between Length of Run of Non-Insertions (# TA Sites)
and Span (nucleotides).
The joint likelihood of the observations at non-essential genes is
therefore:
p(ri, si|Zi = 0,φ0,ω1) = Gumbel(ri;m, τ )×N(si − λrri, σ2r)
(4)
2.1.2 Likelihood for Essential Genes We model the likelihood
at essential genes based on a sigmoid function that is uniform as
long as the gene contains a gap that is as large as a typical protein
domain, since a gap could be any size, even as large as the entire
ORF. Using this likelihood allows our method to disambiguate those
cases where the run of non-insertions actually represents a smaller
or larger segment of the genome than suggested by the number of
consecutive TA sites without insertions.
p(ri, si|Zi = 1,φ0,ω1) =
p(si|Z = 1,φ0,ω1)× p(ri|si, Z = 1,φ0,ω1)
The number of nucleotides spanned by a given run on non-
insertions, si, is modeled by a normalized sigmoid (logistic)
function:
p(si|Zi = 1) = Ω(si; δ) = C
1 + eκ∗(δ−si)
(5)
where δ is the mean number of nucleotides spanned by an average
protein domain, κ is equal to 0.1, and C is a normalization constant.
Previous studies of the length of domains within proteins have found
the average size to be roughly 100 amino-acids or 300 bp (Wheelan
et al., 2000). Using this threshold for δ, the likelihood of observing
a given span si is more or less uniform, except it is near 0 if the the
longest run of non-insertions spans less than about 300 bp. Figure
S2 in the Supplementary Material shows how sensitive the model is
to the these parameters.
As with non-essential genes, the likelihood of observing a span
of nucleotides ri given si is modeled through a linear-Gaussian
dependence similar to Equation (3), but with an inverse relationship
(i.e. N(ri − λssi,σ2s)). The joint likelihood of the observations at
essential genes is therefore:
p(ri, si|Zi = 1,φ0,ω1) = Ω(si)×N(ri − λssi,σ2s) (6)
2.1.3 Prior Distributions Our prior expectation for the probabi-
lity of non-insertion at non-essential genes, φ0, is represented by a
Beta distribution, with hyper-parameters α0 and β0:
pi(φ0) = Beta(φ0;α0,β0) =
Γ(α0 + β0)
Γ(α0)Γ(β0)
φα0−10 (1− φ0)β0−1
The prior probability of a individual essentiality assignment, Zi,
depends on the probability that the i-th gene is essential or non-
essential, and therefore is characterized by a Bernoulli distribution
with that depends on ω1:
pi(Zi | ω1) = Bernoulli(Zi;ω1) = ωZi1 (1− ω1)1−Zi
Similarly, the prior probability of an essentiality assignment for
all genes, Z is a product of Bernoulli trials with probability ω1:
pi(Z | ω1) =
GY
i
Bernoulli(ω1) = ω
Kz
1 (1− ω1)G−Kz
where G is the total number of genes, and Kz is the sum of the
binary vector of essentiality assignments (i.e., Kz = ΣZi ). Finally,
our prior expectations for the mixing coefficient ω1 are given by a
Beta distribution:
pi(ω1) = Beta(ω1;αw,βw) =
Γ(αw + βw)
Γ(αw)Γ(βw)
ωαw−11 (1−ω1)βw−1
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2.1.4 Joint Distribution To derive the posterior probability den-
sity functions necessary for our Bayesian inferences of essentiality,
we first define the full joint distribution, p(Z, Y,φ0,ω1). The full
joint distribution is equal to the product of the data-likelihood
and the prior expectations for the variables: p(Z, Y,φ0,ω1) =
p(Y |Z,φ0,ω1) p(φ0) p(Z|ω1) p(ω1). We assume independence
among genes, therefore the likelihood can be written as a product
of the observations over individual genes:
p(Y,Z,φ0,ω1) = p(Y | Z,φ0,ω1)× pi(φ0)× pi(Z | ω1)× pi(ω1)
=
"
nonY
i=1
Gumbel(ri|µ, σ)×N(si − λrri,σ2r )
#
×
"
essY
i=1
Ω(si)×N(ri − λssi,σ2s)
#
×Beta(φ0;α0,β0)
× Binomial(Kz;G,ω1)× Beta(ω1;αw ,βw)
(7)
2.1.5 Conditional Distributions Using the full joint probability
(7) we derive a conditional distribution for the probability of non-
insertion at non-essential genes, φ0, using proportionality to cancel
out those parameters that are constant with respect to φ0:
p(φ0 | Y,Z,ω1) ∝ p(Y | Z,φ0,ω1)× pi(φ0)× pi(Z | ω1)× pi(ω1)
∝
GY
i
p(ri, si | Zi,φ0,ω1)× pi(φ0)× pi(Z | ω1)× pi(ω1)
∝
nonY
i=1
Gumbel(ri | m, τ )× pi(φ0)
(8)
Similarly, we derive a conditional distribution for the indivi-
dual essentiality values Zi, specifying both possible essentiality
assignments (i.e., Zi = 1 and Zi = 0):
p(Zi = 1 | Y,Z{−i},φ0,ω1)
∝ p(si | Zi = 1) × p(ri | si, Zi = 1)× pi(Zi = 1 | ω1)
∝ Ω(si)×N(ri − λssi, σ2s)× ωZi=11 (1− ω1)1−Zi=1
(9)
p(Zi = 0 | Y,Z{−i},φ0)
∝ p(ri | Zi = 0,φ0)× p(si | ri, Zi = 0) × pi(Zi = 0 | ω1)
∝ Gumbel(ri | m, τ )×N(si − λrri)× ωZi=01 (1− ω1)1−Zi=0
(10)
2.2 Metropolis-Hastings Sampling
We wish to obtain posterior estimates of essentiality for all genes,
integrating over possible values of the unknown variables (e.g. φ0).
In order to accomplish this, we generate a Markov-Chain Monte-
Carlo sample of values from the conditional densities of interest. By
sampling from these conditional densities we can obtain posterior
estimates of essentiality, Zi, without having to know or calcu-
late the probability of non-insertions, φ0, before hand; effectively
integrating over this parameter.
Because the conditional distribution of Zi admits only two possi-
ble outcomes (i.e., essential and non-essential), this density can be
sampled from a Bernoulli distribution with outcomes proportional
to the normalized conditional probability (9, 10):
Z(j)i ∼ Bernoulli(
p1
p1 + p0
)
p1 = p(ri, si|Z{−i},φ0)× ω1
p0 = p(ri, si|Z{−i},φ0)× (1− ω1)
However, the posterior distribution for the parameter φ0 (8) is
the product of multiple Gumbel distributions and a Beta distribu-
tion, which are not conjugate with each other, and cannot be easily
sampled. In order to sample from this posterior density, we utilize a
random-walk Metropolis Hastings (MH) algorithm. The MH algo-
rithm is capable of sampling from arbitrary distributions of interest
by proposing new candidate values from a Gaussian distribution
centered on the last accepted value, φ(j−1)0 , with small variance, v,
and accepting or rejecting candidate values probabilistically. Algo-
rithm 1 presents the sampling scheme used to sample the posterior
densities of φ0 and Zi. A MH step is taken to sample φ0, and then
we sample Zi for each gene.
Algorithm: Random-Walk Metropolis-Hastings
Result: MCMC Samples of density p(Z|Y,φ0) and p(φ0|Y, Z)
Assign starting value to φ0, and initialize Z based on
proportion of insertions within individual genes (i.e. If
|TA|i
ni
< 0.1 then Zi = 1 else Zi = 0);
for j=1 to desired sample size do
Draw candidate parameter φc0 from Normal distribution,
N(φj−10 , v);
Compute ratio R = p(φ
c
0|Y,Z)
p(φj−10 |Y,Z)
;
Draw u from uniform distribution on [0,1] ;
if u < R then
Set φ(j)0 = φc0;
else
Set φ(j)0 = φ
j−1
0 ;
end
Let Kz equal the number of genes with Zji = 1;
Let G be the total number of genes;
Sample ω(j)1 ∼ Beta(αw +Kz,βw +G−Kz);
for i← 1 to G do
p1 = p(ri, si|Zi = 1, Z{−i},φ0)× ω1 ;
p0 = p(ri, si|zi = 0, Z{−i},φ0)× (1− ω1) ;
Sample Z(j)i ∼ Bernoulli( p1p1+p0 ) ;
end
end
Algorithm 1: Random-Walk Metropolis-Hastings Algorithm for
Sampling φ0 and Z
After the samples of parameter value, φ0, and essentiality assi-
gnments, Zi, are obtained, their posterior estimates can be obtained
by averaging over the final sample, minus a burn-in stage to ensure
the sampling procedure has mixed well.
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3 RESULTS
We applied our method to deep-sequencing data from transposon-
insertion libraries of the H37Rv strain of M. tuberculosis. The full
details of the construction of this library is presented in Griffin et al.
(2011). Briefly, the libraries were prepared by transforming H37Rv
using the MycoMarT7 phage, leading to approximately 105 inde-
pendent insertion events. Colony forming units were inoculated into
200 ml of minimal media and 0.1% glycerol, and grown at 37◦C.
The libraries were sequenced with an Illumina GAII sequencer, and
a read length of 36 bp (6-8 million reads per library).
The H37Rv genome has 4,411,654 bp, and contains a total of
3,989 open reading frames (ORFs) (Cole et al., 1998). This equa-
tes to an average of 15.9 TA sites per ORF, spaced roughly 61 bp
apart on average. Reads from two independent libraries were obtai-
ned, which were then summed together to achieve a higher sampling
density of the TA sites. Of the 74,605 total TA sites in the genome,
38,984 (53.12%) had reads mapping to them, showing evidence of
a transposon insertion at those locations. Of these insertion sites,
32,701 of them occurred within ORFs. We assume that sites with a
small number of reads (i.e., 1) could represent spurious reads possi-
bly due to sequencing errors, and therefore those sites were treated
as lacking any insertions. However, Figure S9 shows the read counts
fit an overdispersed Poisson distribution, suggesting most are legiti-
mate insertions. Sites with just 1 insertion are discarded anyway to
be safe, requiring insertions to be confirmed by at least 2 reads. This
might lower the effective density of the dataset, however this does
not affect the method. Of the 3989 ORFs in H37Rv, 41 do not con-
tain any TA sites. An additional set of 237 genes were deemed too
short due to the fact that they do not contain enough TA sites (i.e,
ni < 3) or the span of nucleotides was too short (i.e. si < 150bp
). Therefore a total of 278 genes are reported as ‘No-Data’ because
our analysis is not appropriate for these genes.
The sampling procedure was run for 50,000 iterations, providing
estimates of essentiality for all viable genes, as well as estimates of
the parameter φ0. To ensure that the algorithm mixed well and the
samples obtained were uncorrelated, the first 1,000 samples were
treated as a “burn-in” period and discarded; only keeping every 20th
sample after there. Section 2 of the Supplementary Material contains
an analysis of the convergence of the Metropolis-Hastings procedure
used. The value for φ0 (non-insertion frequency in non-essential
genes) was estimated to be 0.290 ± 0.004 (std. dev.). Performance
on a lower-density dataset, also H37Rv grown on glycerol, is descri-
bed in Section 3 of the Supplementary Material. This lower-density
library contains fewer transposon insertions in coding regions (i.e.,
23,399 (36.3%) compared to 31,715 (50.4%) in the library descri-
bed above), and has longer runs of non-insertions among the genes
(φ0 = 0.592). Rather than predicting more essential genes, our ana-
lysis is more conservative in its predictions as it is less confident of
the essentiality of the genes given the sparsity of the insertions.
3.1 Essentiality Results
After obtaining the sample from the MH procedure, the posterior
probability of essentiality for all genes is estimated by averaging
over the sample of essentiality values, Z¯i. To set significance thres-
holds while correcting for multiple comparisons (i.e. to control false
discovery rate, FDR), we utilize a method described by Muller
et al. (2006) which emulates the Benjamini-Hochberg procedure for
Bayesian posterior probabilities. Limiting the FDR at 0.05, genes
with Z¯i < 0.0371 are classified as non-essential, and genes with
Z¯i > 0.9902 are classified as essential. Table S1 of the Supple-
mentary Material contains our predictions for all 3989 ORFs in
H37Rv. In total, 667 genes are categorized as essential and 2693
are non-essential by this criterion. These include genes experimen-
tally validated to be essential for growth in vitro (i.e. prrA and prrB
(Haydel et al., 2012), phoP (Goyal et al., 2011), and mshA and mshC
(Buchmeier and Fahey, 2006)) and genes known to be non-essential
(i.e. rpfA (Kana et al., 2008), glnD (Read et al., 2007), echA5 and
fadB3 (Williams et al., 2011)) The remaining genes represent those
for which the method is unable to reach an essentiality assignment
with confidence. Figure 2 shows a cumulative plot of the Z¯i values
for all the genes, with the blue lines representing the thresholds of
essentiality and non-essentiality. To assess the sensitivity of this
result to the fixed parameters in the likelihood function for essen-
tial genes, we obtained results for different values of of δ and κ
parameters of the sigmoid function. Figure S2 of the Supplementary
Material shows a cumulative plot of Z¯i values for different combi-
nations of these parameters. The κ parameter has little effect on
the final result. On the other hand, a two-fold increase and decre-
ase of the δ parameter significantly changes the slope of the graph
as well as then number of non-essential genes estimated. This is
consistent with the fact that the δ parameter represents the expected
span of nucleotides for essential domains. This has been empirically
determined to be approximately 300 nucleotides.
Fig. 2. Cumulative plot of posterior probabilities Z¯i. The average Zi value
for each gene was plotted in ascending order, for each of the different
combinations of parameters investigated. The blue lines represent the final
thresholds for essentiality: Z¯i > 0.9902 and Z¯i < 0.0371
Table 1 reports statistics for the different categories of genes.
On average essential genes contained significantly longer maxi-
mum runs of non-insertion (17.57) than non-essential genes and
these runs spanned a larger number of nucleotides (1039.81 bp),
which is consistent with our expectations for essentiality. Non-
essential genes contained a larger number of insertions on average
(15.69). Although essential genes contained only a small number
of insertions (1.68) this number was greater than zero, indicating
that the method is capable of detecting essential genes with a small
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number of insertions, provided they contain a long enough run of
non-insertions suggestive of an essential region.
Table 1. Statistics for Essentials, Non-Essentials and Uncertain Genes. Non-
Essential genes are those with Zi < 0.0371, Essential genes are those with
Zi > 0.9902. Average span is in nucleotides.
Total Average
Genes TA Sites Insertions Max Run Span
Essentials 667 21.32 1.68 17.57 1039.8
Uncertain 342 16.61 6.45 5.75 410.4
Non-Essentials 2693 15.69 10.78 2.05 54.5
3.2 Concordance with Previous Results
The essentiality of the entire M. tuberculosis H37Rv genome has
been characterized previously using transposon-site hybridization
(Sassetti et al., 2003; Sassetti and Rubin, 2003). We compare our
essentiality inferences to previous results to verify that our method
achieves results that are consistent with expectations of the essen-
tiality in M. tuberculosis. Sassetti et al. utilized Transposon Site
Hybridization (TraSH) to characterize the genes necessary for opti-
mal growth in vitro, for a library of transposon mutants grown on
0.02% glucose and rich-media (7H10). While our method analyzes
deep sequencing of transposon libraries, TraSH utilizes hybridiza-
tion of gene-specific probes to quantify the level of fluorescence
being emitted by hybridization probes to determine which genes
are being interrupted in the library of mutants. Table 2 contains a
comparison between the two methods.
Table 2. Comparison of Essentiality Predictions with TraSH analysis. The results obtai-
ned by Sassetti. et. al are compare with those obtained with our Bayesian method for all
3989 genes in M. tuberculosis
Bayesian Method
Essential Uncertain Non-Essential No-Data Total
Sa
ss
et
ti-
03 Essentials 429 75 81 29 614
Growth-Defect 9 4 28 1 42
Non-Essential 94 151 2131 144 2520
No-Data 135 112 453 113 813
Total 667 342 2693 287 3989
Sassetti et al. also included an additional category of genes repre-
senting those whose interruption causes growth-defects (i.e. slower
growth); our method does not make this distinction. Excluding
these, the two methods show agreement in 69.9% of essentials, and
84.6% of non-essentials for a total of 81.7% across both categories.
There were only 81 genes predicted to be essential by TraSH but not
by our method, and 94 genes predicted to be non-essential by TraSH
but found to be essential by our method.
Some of these differences could be due to the different growth
conditions of the libraries. For example, because our library was
grown on glycerol we find genes necessary for glycerol metabo-
lism as essential, such as GlpK (glycerol kinase). Other differences
may be due to incomplete sequence coverage (e.g. gaps in PE PGRS
genes, which are highly GC-rich and hard to sequence). Two out of
62 PE PGRS genes in the H37Rv genome were classified as essen-
tial by our model because of large regions without insertions, though
genes in this family are generally believed to be non-essential (Banu
et al., 2002). Over-representation of PE PGRS gene among essen-
tials was also noted in other transposon library analyses using
sequencing (Lamichhane et al., 2003).
One notable difference is that Sassetti et al. found glcB to be non-
essential, however the insertion pattern shown in Figure 3 clearly
indicates that this gene was unable to tolerate insertions in the libra-
ries of mutants analyzed. GlcB encodes for malate synthase in M.
tuberculosis, which was originally thought to be necessary only for
growth on fatty-acids as part of a glyoxylate shunt (McKinney et al.,
2000), but has recently been shown to be essential on other carbon
sources like dextrose by chemical inhibition (Krieger et al., accep-
ted). A complete absence of transposon insertions in Rv1837c was
also observed in the DeADMAn studies (Lamichhane et al., 2003).
Our data suggests that GlcB is also essential for growth on glyce-
rol (in liquid culture with minimal media), showing a significant
run of non-insertions (25 out of 27 - spanning 2078 nucleotides,
p(Zi = 1)=1.0). It should be be noted that in the original TraSH
data, GlcB had a hybridization ratio of 0.41, which was near the
threshold for essentiality (< 0.20).
Fig. 3. Insertion Pattern for Rv1837c. Figures created using IGV - distribu-
ted by the Broad Inst. http://www.broadinstitute.org/igv/
3.3 Comparison to Other Statistical Models
In contrast to other models where the order of insertions does not
matter, the Gumbel distribution is capable of identifying regions
lacking insertions within genes that are significantly longer than
expected, despite the presence of insertions elsewhere in the gene.
Models of essentiality that focus solely on the proportion of inserti-
ons or the number of reads within genes, may miss these essential
regions if enough insertions are observed elsewhere within the gene.
To evaluate this important distinction, we compare our method to
the method proposed by Blades and Broman (2002). This method
does not take the order of insertions into consideration but instead
is based on a multinomial likelihood function that characterizes the
number of mutants with insertions unique to a gene, as well the
number of mutants with insertions that occur in regions that over-
lap with adjacent genes (which adds uncertainty as to which gene
was disrupted). Using this multinomial likelihood, Blades and Bro-
man implement a Gibbs Sampling procedure that estimates posterior
probabilities of essentiality for all the genes.
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We obtained the R package “negenes” which contains the
implementation of this method maintained by Karl W. Bro-
man (http://www.biostat.wisc.edu/ kbroman/software/). The Gibbs
sampler was run on the same H37Rv glycerol dataset analyzed
above, for a total of 50,000 iterations. The first 1,000 samples were
ignored as part of the burn-in period, and only every 22th sample
was kept to remove any auto-correlation in the sampling process.
Following Lamichhane et al. (2003), we used the number of inserti-
ons within the N-terminal 80% of the ORF, as representative of the
number of viable mutants with insertions in genes.
After obtaining the probability of essentiality from the Gibbs
sampler, we set thresholds for essentiality by correcting for mul-
tiple comparisons and controlling the false discovery rate as we did
for the Gumbel method (implementing a procedure analogous to the
one proposed by Benjamini and Hochberg). We use these thresholds
to classify the genes as essential, non-essential or uncertain.
The Blades and Broman method predicts a total of 244 essen-
tial genes and 3195 non-essential genes. As the small number of
essential genes could be due to the selected threshold, a less con-
servative threshold for essentiality (posterior probability > 0.95)
results in 458 genes being predicted as essential, still well below the
614 essential genes characterized by Sassetti et al. (2003). A full
breakdown of the results is found in table S5 in the Supplementary
Material.
The lower number of essentials predicted by the Blades and Bro-
man method is due to the fact that the presence of even a few
insertions in a gene (i.e. ≥ 1) is enough to make it seem non-
essential under this multinomial model. For example, GyrB (β
subunit of DNA gyrase) a known essential gene and target of fluoro-
quinolones, is found to be non-essential by the Blades and Broman
method as it is observed to have insertions at the N-terminus. In
contrast our method finds GyrB to be essential as it contains a signi-
ficant stretch of TA sites lacking any insertions (40 consecutive TA
sites lacking insertions out of a total of 43 TA sites in the gene)
which is what we would expect from an essential gene. Although
this could be potentially overcome by ignoring insertions at the very
ends of the N- and C- termini (for example, considering only 5-80%
of the coding region as recommended by Gawronski et al. (2009)), a
strength of our model is that it does not need to discard these regions
a priori.
The dataset was also analyzed with the ESSENTIALS soft-
ware, which utilizes a negative binomial distribution to analyze
read counts within each gene (Zomer et al., 2012). ESSEN-
TIALS only predicts 434 genes in the H37Rv genome to be
essential (using a -8.13-fold-change cutoff determined by the
software), and 3363 genes to be non-essential. Thus, similar
to the Blades and Broman method, the ESSENTIALS software
also under-predicts the number of essential genes compared to
what is expected for this organism (i.e. ∼600, based on prior
TraSH studies). However, 93.5% of the genes predicted to be
essential by the ESSENTIALS software (406/434) overlap with
the genes predicted to be essential by our Bayesian method,
effectively representing a subset (60% of our 667). 311 of the
434 genes were correctly labeled as essential according to the
original TraSH experiments, capturing 50% of the 614 essen-
tial genes previously characterized. The primary reason that
other genes that are believed to be essential are not identified
as such by the ESSENTIALS software appears to be that many
these genes often contain some insertions at a few sites in the
ORF (such as at the N- and C- terminii, or in a non-essential
domain), and thus their read counts are higher than expected
for an essential gene (according to their model).
3.4 Essential Domains
One of the advantages of our method for analyzing this high-
resolution transposon insertion data is that it can reveal essential
regions or domains within proteins. The regions devoid of insertions
detected by our method often correspond to well-defined protein fol-
ding domains. To date, the X-ray crystallographic structures of only
8.5% of proteins in H37Rv have been determined (Ehebauer and
Wilmanns, 2011). Thus, in order to test the model’s ability to detect
essential domains, we compare these regions to Pfam predictions
of protein domains within H37Rv genes. Pfam is able to make pre-
dictions of domains based on amino-acid sequence homology using
Hidden Markov Models to represent protein families (Finn et al.,
2010).
Using Pfam, we obtained predictions of a total 5,091 protein
domains, 1,126 of which were in genes predicted to be essential
by our method. In order to determine whether the significant runs of
non-insertions observed coincide with protein domain boundaries,
we calculated a ratio of overlap between the nucleotides spanned
by a maximum run of non-insertions and the domain boundaries
predicted by Pfam (Table 3). For a Pfam domain spanning coordi-
nates i..j, if the closest matching region lacking insertions is k..l,
then the overlap score is min(|i− k|, |j − l|)/|i− j|. Of the 1,126
domains found within essential genes, 976 (86.68%) of them over-
lapped significantly (i.e. score > 0.80) with the domain boundaries,
suggesting that the majority of Pfam domains are contained within
the runs of non-insertions observed. Another set of 104 domains
(9.24%) had no significant overlap (i.e. score < 0.20), potentially
representing those domains that are within non-essential regions of
essential genes. The remaining 46 (4.08%) domains, represent those
with an intermediate overlap (i.e. score between 0.20−0.80), repre-
senting a small set of genes for which the Pfam boundary prediction
may be inconsistent.
Table 3. Statistics for Pfam Domain Predictions.
Total Average
Domains Length TA sites Overlap
Non-Essentials 3240 464.45 7.47 0.28
Uncertain 512 457.90 6.30 0.47
Essentials 1126 518.78 8.31 0.89
In some cases, the pattern of transposon insertions is capable of
identifying individual domains as essential through a sequence of
TA sites lacking insertions that closely matches the boundaries of
the predicted Pfam domain. To identify such cases, we matched
the Pfam domain predictions to the closest run of non-insertions,
and calculated a consistency score that reflects the consistency
between the two regions. This consistency score was based on
comparing the distance (in nucleotides) between the boundaries of
the domain prediction i..j and the boundaries of the run of non-
insertions k..l. We restricted attention to genes for which the run of
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non-insertions corresponding to the domain is statistically signifi-
cant (p<0.05 using a cumulative Gumbel distribution), and whose
distance between boundaries (upstream or downstream) is less than
50 bp (i.e. |i− k|+ |j − l| < 50). We identified 95 known domains
which were mostly devoid of transposon insertions internally, but
for which insertions were observed at TA sites right near the boun-
daries (shown in Table S2 in the Supplementary Material). Many of
these constitute essential single-domain proteins, although several
occur in larger multi-domain proteins with both essential and non-
essential regions. To identify genes that contain both essential and
non-essential domains, we selected a subset of genes that are labeled
as essential by our Bayesian analysis, but for which there is still a
relatively large (i.e. #TAs > 4) area remaining containing an inser-
tion frequency that is not significantly essential (i.e. p-value > 0.05)
according to the cumulative Binomial distribution. This gave a set
of 36 genes (presented in Table S3 of the Supplementary Material)
that represent interesting cases where there is a combination of both
essential and non-essential regions.
Fig. 4. Insertion Pattern for Rv3910. The essential MviN domain is shown
in red, while the non-essential extracellular and intracellular domains are
shown in yellow.
Fig. 5. Insertion Pattern for Rv0018c. The essential catalytic domain is
shown in red.
Among the genes that our method identifies as having both essen-
tial and non-essential domains are Rv3910 and Rv0018c. These
two genes have been shown to be essential for growth in myco-
bacteria, and are involved in regulating cell wall (peptidoglycan)
synthesis. Rv3910 encodes for two C-terminal protein domains
(an intracellular pseudokinase and an extracellular sugar-binding
domain) and a N-terminal, MviN-like, domain which is requi-
red for the late-stages of peptidoglycan biosynthesis (Figure 4).
MviN proteins have been proposed to be involved in the export
of the lipid-II precursor and this Mtb ortholog is regulated by a
phosphorylation-dependent interaction with FhaA (Rv0020c) (Gee
et al., 2012). Insertions in Rv3910 are found only in the C-terminal
domains, but not the N-terminal membrane domain, implying only
the latter domain is necessary for growth (p(Zi = 1) = 1.00)),
based on a run of 34 consecutive non-insertions within its essen-
tial domain, spanning 1439 nucleotides, as significant. This has
been confirmed experimentally by Gee et al. (2012). Rv0018c
(PstP: serine/threonine phosphatase) contains an essential cataly-
tic domain within its N-terminus (Figure 5), and has been shown
to dephosphorylate Rv0020 (FhaA) counteracting phosphorylation
by PknB (Pullen et al., 2004). It contains a run of 12 consecutive
non-insertions in the N-terminal catalytic domain, spanning 695
nucleotides, which our method is identifies as significant (p(Zi =
1) = 0.999)).
4 DISCUSSION
The availability of next generation sequencing data for analyzing
transposon mutagenesis libraries necessitates a new method capable
of analyzing the high-resolution data and determining essentiality.
We developed a Bayesian statistical model that can be used to ana-
lyze this data and make rigorous predictions about the essentiality of
individual genes, as well as identify stretches of non-insertions indi-
cative of essential domains. Using this method we have analyzed
sequence data from a library of mutants of M. tuberculosis bacteria,
and found high concordance with previous results.
The key insight in our method is the use of the Gumbel distri-
bution to assess the statistical significance of runs of non-insertion
that are significantly longer than expected, and therefore indica-
tive of essential regions. By highlighting these essential regions,
our method can help identify essential domains within genes which
might otherwise be missed by characterizing the proportion of inser-
tions alone. An approach based on analyzing the size of insertion
gaps was suggested by Christen et al. (2011), however they used
a simpler exponential model for assessing statistical significance.
Using our method we found multiple genes with essential domains
that match Pfam predictions of domains, and whose essentiality
is supported in the literature (e.g. Rv0018c, Rv3910). Moreover,
because our method depends on consecutive sub-sequences of TA
sites lacking insertions, and not on the simple presence or absence
of insertions within a gene, our method is not sensitive to insertions
at the N- or C- terminus of a gene, which essential genes have been
shown to occasionally tolerate (Akerley et al., 1998; Smith et al.,
1996; Christen et al., 2011).
Although previous analyses have used deep-sequencing data to
determine essentiality, these have relied on ad hoc criteria to ignore
insertions at the N- or C- terminus, or made assumptions about para-
meters to quantify the confidence of their essentiality predictions.
However, by using a Bayesian statistical framework, our method
can simultaneously estimate model parameters and posterior proba-
bilities of essentiality without requiring a priori estimates of these
unknown variables.
While our method can successfully determine regions in the
genome that contain unusually long gaps lacking any insertions, it
does not take the number of reads observed at each site into account
(i.e. read counts). Our binary interpretation of the insertion data is
based on mere presence or absence of reads, and ignores any poten-
tial information that the number of reads mapping to a particular
site might bear. An alternative approach based on quantifying read
counts within genomic regions might yield biologically-relevant
information on essentiality. For example, in another paper (Zhang
et al., 2012), a model was developed which calculates significance
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scores for sums of read counts at TA sites using a non-parametric
test. This approach yields qualitatively similar results to our model
in terms of which genes are classified as essential and non-essential.
One advantage of an approach based on read counts is that it could
potentially detect genes whose disruption leads to growth defects,
in that slower-growing mutants might produce fewer (but non-zero)
read in a disrupted gene compared to the expected value. This was
exploited to infer genes that play a role in cholesterol catabolism by
Griffin et al. (2011). On the other hand, a single over-amplified TA
site in a region (with an excess of reads due to PCR bias) could lead
to misinterpretation, whereas our model would be less sensitive to
this kind of noise.
The method we have presented can be used to assess essentiality
of genes, as well as inter-genic (e.g. regulatory) regions and assign
statistical confidence scores, in any organism, provided a transposon
mutant library can be constructed and sequenced. Although mutant
libraries analyzed were constructed using the Himar1 transposon,
this method could be used to analyze libraries constructed using
the Tn5 transposon, where every nucleotide is a possible insertion
site (Langridge et al., 2009). By sampling the probability of non-
insertion from its posterior distribution, we can calculate estimates
of essentiality for a diversity of mutagenesis experiments.
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Mycobacterial Determinants for Survival of the CD4 T 
Cell Response 
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Section 3.1: Overview and Attributions 
Overview. In this chapter we determined the genetic requirements for 
mycobacterial survival during infection, as well as the specific determinants of 
surviving the CD4 T cell response. We describe 576 genes required for growth in 
vivo, determined by comparing the insertion profiles of inoculum libraries to the 
surviving pools. CD4 T cells are crucial in anti-mycobacterial immunity, but are 
unable to completely clear the pathogen. Thus, we hypothesized that many of 
these genes required during infection would be responsible for helping Mtb 
survive CD4-mediated immunity. We screened for these CD4 survival 
determinants and found 58 genes wherein significantly more insertions were 
found from the surviving pools in MHC Class II knockout mice (which lack CD4 T 
cells) compared to wild type mice. Through pathway enrichment and further gene 
requirement profiling, our results suggest that bacterial tryptophan biosynthesis is 
specifically required to combat CD4 mediated immunity. We conclude that CD4 T 
cells induce tryptophan starvation, and Mtb survival of the CD4 response is 
dependent on its ability to respond to that starvation through tryptophan 
biosynthesis. 
 
Attributions. The following Chapter is an expanded version a manuscript, which 
also includes most of Chapter 4. I wrote the manuscript and we aim to submit in 
the next month. I made the mycobacterial transposon library with help from Ed 
Long, and performed the mouse infections and bacterial harvests. I made the 
DNA transposon junction libraries, and Thomas Ioerger and colleagues 
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sequenced them. The statistical analysis was a joint effort with many 
collaborators, including Thomas Ioerger, Curtis Huttenhower, Ed Long, Chris 
Sassetti, Chris Ford, and Sarah Fortune. This was an especially dedicated and 
talented community, and I am grateful to have been a part of it. It is also an 
expanding community. Statistical modeling of the data can always be improved 
and continues to be a work in progress, and Jeremy Rock, Justin Pritchard and 
Michael DeJesus are spearheading these efforts.  
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Section 3.2: Genetic determinants of Adaptive Immune 
Evasion by Mycobacterium tuberculosis 
 
 
Abstract 
Tuberculosis remains a key global health threat, claiming 2 million lives each 
year. A staggering 2 billion people are estimated to be infected with 
Mycobacterium tuberculosis (Mtb), serving as an abundant reservoir for potential 
disease. The endurance of Mtb as a human pathogen owes in large part to its 
ability to adapt to host adaptive immunity. Upon infection of the host lung, 
bacteria divide exponentially until the peak of the CD4 response. The importance 
of CD4 immunity is further supported by the rapid death of infected mice lacking 
CD4 cells as by the increased susceptibility to Mtb of HIV-positive patients. While 
CD4 cells are crucial for surviving Mtb infection, they are unable to clear the 
bacteria.  Here, we seek to identify the bacterial genetic determinants of 
combating CD4-mediated immunity. We infected both wildtype and MHC Class II 
KO mice with high-density Mtb mutant libraries. In comparing the surviving 
mutants from both groups, we identified Mtb genes that are required for bacterial 
survival in wildtype mice but not in mice lacking CD4 cells. Among these are 
genes that encode for gluconeogenesis and tryptophan synthesis, suggesting 
that CD4 cells mediate key differences in metabolite availability to the bacterium. 
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Introduction 
Mycobacterium tuberculosis (Mtb), the etiologic agent of tuberculosis (TB), is one 
of the world’s most successful bacterial pathogens. After a centuries-long decline 
in TB, the last few decades has seen a resurgence in TB, with an estimated 2 
billion people infected and about 1.7 million deaths per year1. The success of Mtb 
as a pathogen lies in its specific adaptation to the human host and to the many 
arms of anti-bacterial immunity2. Its ability to survive host defenses is directly 
responsible for the large reservoir of infected people, and its ability to subvert 
bactericidal mechanisms allows it to replicate in vivo and cause disease3. 
Elucidating these mechanisms will help us understand the complex host-
pathogen interface, and targeting these mechanisms will help us develop 
therapeutics that help the immune system kill Mtb.  
 
Of the components of host immunity to Mtb, CD4 T cells have emerged as one of 
the most biologically and epidemiologically important. While neither humans nor 
mice, the most commonly used infectious model for Mtb, can completely clear 
Mtb during infection, both are able to limit bacterial growth, and in the case of 
immunocompetent humans, prevent disease2, 4. This response is dependent on 
CD4 T cells. The CD4-deficient MHC Class II knockout mice, and other mice that 
lack CD4 T cells, cannot stop mycobacterial growth and succumb to disease and 
death about a year ahead of their wildtype counterparts5-9. In human disease, 
progressive CD4 T cell loss due to HIV infection also increases the risk for TB 
disease and death10-13.  
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However, crucial as they are for normal TB immunity, CD4 T cells ultimately fail 
to kill all bacilli. Survivors remain latent, with the potential to cause disease in the 
future2, 4. The nature of the environment imposed by CD4 T cells, enough to limit 
growth but not kill Mtb, is not well characterized. Reports have shown that the 
Th1 subset is especially effective in limiting Mtb growth, and cytokines such as 
IFN-γ and TNF-α are needed in certain models, though not all, of CD4 T cell 
mediated defenses8, 14-19. But the exact nature of CD4-mediated stress, the 
repertoire anti-pathogen effectors that the bacillus must survive, is poorly 
understood.  
 
In this study, we profile the mycobacterial requirements for surviving the CD4 
response. 58 genes were shown to be required for mycobacterial survival of the 
CD4 response. Two pathways were enriched in these genes, including 
gluconeogenesis and tryptophan biosynthesis, suggesting that CD4 cells altered 
the in vivo metabolite availability for Mtb. In addition to describing the nature of 
CD4-mediated stress, the results of this Chapter also identify potential drug 
targets whose inhibition could result in restoration of susceptibility to CD4 
immunity. 
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Results 
Genes required for survival during infection 
In order to define the set of genes required for surviving the CD4 T cell response, 
we infected both wildtype and MHC Class II knockout (MHCII-/-) mice with a 
library of Mtb transposon mutants20. We injected 106 bacteria intravenously and 
plated surviving bacteria from infected spleens at 10 days and 45 days after 
infection (Fig 3.1A). To identify mutant Mtb in the surviving pools, we deep 
sequenced transposon junctions to map the insertion site of each mutant. For 
each time point, we made two comparisons. First, we compared the surviving 
pool of mutants from wildtype mice (wt output library) to the inoculating pool 
(input library), defining genes with a statistically validated decrease in output 
library as required for growth during infection. Second, we compared the output 
library from wt mice to the output library from MHCII-/- mice. We reasoned that 
genes required for surviving the CD4 T cell response would be required for 
growth in wt mice, while mutants with disruptions in those genes would be 
rescued in MHCII-/- mice, which lack CD4 T cells (Fig 3.1B). 
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Figure 3.1. A.) Wildtype and MHC Class II knockout mice were infected via 
intravenous injection with 106 CFU of the Mtb transposon library. The inoculum 
was plated on the day of infection. On days 10 and 45 post-infection, 4 mice in 
each group were sacrificed and surviving mutants from the spleens were plated. 
Transposon junctions were prepped and deep sequenced from all plated libraries. 
B.) We searched for differentially required genes by comparing insertion counts. 
Genes A and C are examples of non-essential genes that are not required for 
growth in vivo. Gene B is an example of a gene required for growth in vivo but 
not required for growth in MHCII-/- mice. Gene D is an essential gene.
10 d p.i.:  
sacrifice 4 mice per group 
45 d p.i.:  
sacrifice 4 mice per group 
d0: infect 8 mice 
per group 
Define 
inoculum 
Plate 
inoculum and 
isolate genomes 
Plate 
output library and 
isolate genomes 
Plate 
output library and 
isolate genomes 
A wt 
MHC II -/- 
wt 
MHC II -/- 
wt 
MHC II -/- 
B 
A B C D 
A B C D 
A B C D 
wt 
MHC II -/- 
Inoculum: 
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We found 576 genes that were required for growth during infection (Fig 3.2). 
These genes had a statistically significant (FDR q-value < 0.01) 10-fold or more 
decrease in insertion counts across the gene. On d10, 405 genes were required 
for growth in vivo, and on d45, 317 genes were required. A total of 146 genes 
were required at both time points (Fig 3.2A and B, Table 3.1). Genes required 
late but not early could represent mutants that are able to establish infection but 
unable to sustain long-term in vivo growth. Genes required early but not late 
could represent mutants that grow slowly in mice. These mutants would be 
underrepresented at d10, but catch up by d45 post infection. In fact, genes that 
were required at d10 but not at d45 were enriched for loss-of-insertions (Fig 
3.3B). The average in vitro:in vivo ratio for these genes was 4.3, compared to the 
non-required average of 1.3 (P-value < 0.001) (Fig 3.3C).  
 
While this set significantly overlapped with a previously defined set of genes 
required for growth in mice (Gene Set Enrichment Analysis P-val < 0.01), it also 
includes more than 400 newly discovered genes required for in vivo growth (Fig 
3.4A). Despite the significant overlap, genes marked as essential in Sassetti et al. 
but not in this study did not enrich for high in vitro:in vivo ratio, unlike the non-
overlapping sets between the two time points in this study. This is likely an 
indication of many different phenomena. The screens were performed with 
different libraries and mice were sacrificed and different time points. Both 
screens, as is true for most genome-wide studies, have high background noise, 
and many of the non-overlapping genes represent this noise. 
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Figure 3.2. We compared insertions from wildtype mouse output libraries and 
MHCII-/- mouse libraries at d10 (A) and d45 (B) post-infection. After adjusting 
insertion counts for total reads in the sequencing runs, we calculated the ratio of 
insertions for each gene and calculated a P-value (Mann-Whitney U). 
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Figure 3.3. Log(2) ratios and Log(10) P-values of d45 wildtype mouse output 
libraries compared with inoculum libraries are plotted, each dot representing one 
gene. Red dots represent: A.) genes required for growth in vivo at d45 and B.) 
genes required for growth in vivo at d10. C.) Distributions of Log(2) ratios for 
genes tagged as essential for in vivo growth at both time points, essential only at 
day 10, and non-essential at both time points.  
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As discussed in Chapter 2, transposon mapping affords greater sensitivity 
compared to the microarray methods employed in Sassetti et al., and it is 
possible that many of the genes found only in this study represent the sensitivity 
space covered by deep sequencing and missed by microarrays21. Supporting this 
argument are the many metabolic pathways and known protein complexes, even 
those not encoded as an operon, wherein multiple components were tagged as 
required in vivo. These include the nucleotide excision repair pathway (uvrA, 
uvrB, uvrC); the glyoxylate shunt (icl, glcB); gluconeogenesis (pca, pckA); 
tryptophan biosynthesis (trpD, trpE, trpB); the bc cytochrome (cydA, cydB, cydC, 
cydD); mycobactin biosynthesis (mbtA, mbtB, mbtD, mbtE, mbtF); and the F420 
synthetic pathway (fbiA, fbiB, fbiC), many of which have been shown to be 
required in other independent studies22-26.  
	  125	  
 
 
Figure 3.4. A.) Gene Set 
Enrichment Analysis (GSEA) using 
genes required in vivo in Sassetti et 
al. as a comparison gene set.  For 
each time point, a list ranked by p-
values and ratios was used to 
perform GSEA, and enrichment 
Family Wise Error Rate P-values 
were calculated. Enrichment plots 
represent running score determined 
by enrichment of the gene set in the 
ranked list. B.) Distributions of 
Log(2) ratios for genes tagged as 
essential in both studies, only in 
Sassetti et al., and non-essential in 
both studies. 
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Genes specifically required for surviving CD4-mediated stress 
By comparing the wildtype output libraries to the MHCII-/- output libraries, we 
found that 58 genes had a statistically validated increase in insertions in MHCII-/- 
mice compared to wt mice. These genes had at least a 5-fold increase in 
insertions and a Mann-Whitney U P-value of less than 0.05 (Fig 3.5A and Table 
3.2). Two biochemical pathways, gluconeogenesis and tryptophan biosynthesis, 
were enriched in this list, suggesting that CD4 T cells were responsible for 
inducing a shift in Mtb metabolic demands (Table 3.2).  
 
Searching for gene sets that are enriched in high-throughput screen hit lists can 
help determine the biological functions uncovered in these screens. By looking 
for biochemical pathways enriched in our MHCII-/- rescue gene set, we 
determined that bacterial gluconeogenesis and tryptophan biosynthesis might be 
necessitated by CD4-dependent host defenses. We sought to further 
characterize CD4-mediated stress by more similar profiling, and we reasoned 
that conditionally required gene sets would be fitting comparison groups. To that 
end, we selected our Mtb transposon library through a series of in vitro stress 
conditions, expecting that conditions that most similarly resembled CD4-
mediated stress would produce the most similar conditionally required gene sets.  
 
Using the same transposon mapping technique on our selected library, we tested 
carbon starvation, amino acid starvation (and isolated tryptophan starvation), iron 
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depletion, acid stress and nitrosative stress. We created conditionally required 
gene sets as well as ranked gene lists for each condition, which allowed us to 
compare gene sets using the running-sum enrichment analysis in the Gene Set 
Enrichment Analysis (GSEA) tool27. Interestingly, while we found that both 
nitrosative stress and acid stress had significantly similar profiles to genes 
required for in vivo growth, only tryptophan starvation was enriched in the MHCII-
/- rescue gene set (Fig 3.5B). Indeed, two genes in the tryptophan biosynthesis 
pathway, trpD and trpE, had no insertions in the wt output library but multiple 
insertions in the MHCII-/- output library (Figure 3.6).  Tryptophan auxotrophs and 
their complemented strains have been generated and are currently being tested 
for growth in wildtype and MHCII-/- mice. We expect that growth of the auxotrophs 
will be severely limited in wildtype mice but restored in MHCII-/- mice. 
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Figure 3.5. A.) Insertion counts ratios and P-values (Mann-Whitney U) were 
created for each gene between MHCII-/- and wt mice. P-values above the axis 
denote a MHCII-/- : wildtype ratio > 1, and P-values below the axis denote a ratio 
< 1 for total-read-count-adjusted insertion counts. B.) GSEA Family-Wise Error 
Rate P-values for each pairwise comparison between libraries. Gene sets for 
each condition noted were used to perform GSEA on ranked lists from the same 
conditional essentiality experiments. 
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Figure 3.6. Insertion counts in the regions surrounding trpE and trpD. Both 
genes were required for growth in vivo, yet mutants in each gene were rescued 
for growth in MHCII-/- mice.  
trpE 
C57BL6: 
MHC II-/-: 
Inoculum: 
trpD 
C57BL6: 
MHC II-/-: 
Inoculum: 
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Discussion 
CD4 T cells are paramount in the host defense against TB, but are insufficient to 
clear the bacteria from a diseased patient. We reasoned that genes required to 
survive the CD4 T cell response would be excellent drug targets. Inhibiting these 
CD4 survival determinants would restore CD4 T cell potency and help these cells 
clear the pathogen. Here we show that tryptophan biosynthesis is one of these 
determinants of survival, and inhibition of the pathway increases Mtb 
susceptibility to host immunity, ultimately leading to death of the pathogen in vivo. 
It is important to note that while the lack of CD4 T cells rescues growth of 
tryptophan auxotrophs early in infection, these mutants eventually do die in 
MHCII-/- mice, suggesting that compensatory CD4-independent mechanisms can 
also starve Mtb of tryptophan. Importantly, this shows that targeting tryptophan 
biosynthesis would be effective even in patients, such as HIV-positive individuals, 
who lack a normal CD4 compartment. 
 
We started our study by profiling mycobacterial genes required for survival during 
infection. To determine the conditional requirement of genes, we compared the 
number of transposon insertions between conditions for each gene. Each gene 
has multiple potential insertion sites, and most insertion count comparisons sum 
counts across each gene to compare between conditions. However, in 
reasonably saturated libraries, treating each potential insertion site as an 
independent assessment of gene requirement drastically increased the statistical 
power of such comparisons. Most transposon insertion sequencing techniques 
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currently use insertion count totals, summed across insertion sites in a gene28-31. 
We found that this drastically decreases the power of statistical hypothesis 
testing, and increases the likelihood that a single differential site could make the 
entire gene look differentially required. Using a non-parametric test to compare 
the distribution of insertion counts (rather than the sums of insertion counts) 
across a gene, we were able to assess genetic requirement across a host of 
different conditions. 
 
In contrast to similar microarray-based screens, deep sequencing allowed us to 
directly map insertion sites for each surviving mutant, and thus improved 
significantly on the sensitivity and specificity of insertion count comparisons. We 
found 576 genes that were required for growth in vivo, most of which are newly 
described as required. Furthermore, by searching for mutants rescued for growth 
in MHCII-/- mice, we described 58 genes that were likely required for surviving 
CD4-mediated host defenses. In addition to using these screening results to 
identify candidate genes, we also appreciated they could also be used as 
environmental profiles. We showed that the in vivo environment as a whole, as 
well as the specific CD4-generated component of that environment, could be 
understood by comparing multiple gene-requirement profiles. Using GSEA to 
compare in vivo profiles to in vitro profiles confirmed that Mtb’s infectious niche is 
characterized by acidic and oxidative stress, and that CD4 T cells impose 
tryptophan starvation. We show that gene-requirement signatures are an 
effective way to understand both mycobacterial physiology as well as the 
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environments created by components of host immunity. Further profiling of in 
vitro stresses and altered in vivo environments will help us better understand the 
tug-of-war between host and pathogen.   
 
In this study, high-throughput profiling also helped us narrow our search for 
candidate virulence factor drug targets.  Targeting virulence factors has been 
touted recently for many reasons, including i.) expansion of the potential target 
list beyond in vitro essential genes, ii.) protection for the host against virulence 
factor toxicity, and iii.) reduction of resistance development for drugs whose 
targets do not affect viability32, 33. By searching for mycobacterial processes that 
protect Mtb from CD4 T cell-mediated killing, we hoped to identify drug targets 
whose inhibition made Mtb more susceptible to antimycobacterial immunity. 
Since tryptophan auxotrophs, which could not survive in wt mice, were rescued in 
the absence of CD4 T cells, we determined that blocking tryptophan biosynthesis 
would allow CD4 T cells to kill Mtb.  
 
Methods and Materials 
Library generation. Transposon libraries were created as described in Chapter 
2, but plated on 7H10 plates with glycerol, OADC, tween80, Cas-amino acids 
and tryptophan. 500,000 mutants were scraped, frozen and saved for future use. 
Mouse infections and harvests. Wildtype mice (C57BL/6) were obtained from 
Jackson Laboratory. MHC Class II knockout mice (Abb H2-Ab1) were obtained 
from Taconic Farms. These mice have a disruption in the H2-Ab gene, do not 
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express any MHC Class II molecules, and lack CD4 T cells. Mice were infected 
with 106 bacteria via tail vein injection. At 10 days and 45 days post-infection, 
spleens were harvested and plated for bacteria. For each mouse, 106 surviving 
colonies were scraped and DNA was extracted for analysis. 
In vitro transposon library selections. For acid stress, the library was 
suspended in liquid media at a starting concentration of 108 CFU/ml and selected 
in 7H10 with tyloxapol (in place of tween80) buffered to pH 6.5 or pH 4.5, and in 
phosphate-citrate buffer at pH 4.5. Bacteria was plated after 6 days and scraped 
for DNA prep. For nitrosative stress, the library was suspended in 5 mM DETA-
NO for 3 days. Tryptophan starvation and amino acid starvation was measured 
using libraries that were created either on normal 7H10, or on 7H10 
supplemented with 1 mM tryptophan or 1% Cas-amino acids, respectively. Iron 
supplemented libraries were plated on 7H10 with 450 µM and 1.5 mM iron.  
DNA library prep and sequencing. See Chapter 2, Section 2.2 Methods and 
Materials. 
Statistical Analysis. For each insertion count comparison, the control libraries 
were combined using a script that normalized insertion counts to the sequencing 
run’s total read counts. This combined control library was then used to compare 
to each experimental library. For each gene, we treated the insertion counts at 
sites within the middle 90% of the gene as non-parametric distributions, and 
assumed the null hypothesis that the distributions would be the same between 
conditions. We used a Mann-Whitney U test for hypothesis testing. A P-value 
was thus calculated for each replicate, and a composite P-value was generated 
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by using a Bonferroni correction and Fisher’s method. We then generated 
Benjamini-Hochberg false discovery rates using the composite P-values. Ratios 
were calculated by averaging the read counts per gene for all replicates and 
comparing to the combined control library, after normalizing for total read counts. 
Gene Set Enrichment Analysis was performed using the pre-ranked tool in GSEA. 
Genes were stratified by P-value (< 0.01 or 0.05 and > 0.01 or 0.05), and then 
ranked by ratio within the strata. For each conditional gene-requirement 
experiment, a ranked list and a conditional essential “calls” gene set was created. 
Each ranked list was then assessed against each gene set, and Family-wise 
Error Rate was used to generate the P-values for significant enrichment.
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Section 3.3: Tables 
Table 3.1. Genes required for growth in vivo 
	   	   Day	  10	   Day	  45	  
Rv	  Number	   Gene	   MWU	  P-­‐val	   in	  vitro:in	  
vivo	  ratio	  
FDR	  (q-­‐val)	   MWU	  P-­‐val	   in	  vitro:in	  vivo	  
ratio	  
FDR	  (q-­‐val)	  
Rv0003	  	   recF	  	   2.75E-­‐10	   7.41E+01	   8.82E-­‐09	   6.06E-­‐06	   9.34E+00	   8.70E-­‐05	  
Rv0007	  	   -­‐	  	   4.08E-­‐05	   165.4828612	   2.51E-­‐04	   3.27E-­‐07	   4.87E+02	   7.26E-­‐06	  
Rv0009	  	   ppiA	  	   0.002283889	   32.50011905	   7.53E-­‐03	   7.04E-­‐05	   22.03468221	   0.000725051	  
Rv0012	  	   -­‐	  	   7.02E-­‐05	   6.698676895	   0.000401215	   0.000567599	   18.5988609	   0.004086613	  
Rv0016c	  	   pbpA	  	   2.00E-­‐12	   1.47E+02	   1.11E-­‐10	   2.26E-­‐13	   1.56E+02	   2.47E-­‐11	  
Rv0017c	  	   rodA	  	   5.53E-­‐15	   4.40E+02	   4.78E-­‐13	   3.57E-­‐12	   3.43E+01	   2.94E-­‐10	  
Rv0018c	  	   ppp	  	   1.92E-­‐05	   45.07609164	   1.35E-­‐04	   2.78E-­‐08	   1.79E+02	   7.68E-­‐07	  
Rv0019c	  	   -­‐	  	   6.82E-­‐06	   1.04E+02	   5.68E-­‐05	   0.000803865	   14.46224068	   0.005346102	  
Rv0021c	  	   -­‐	  	   0.014070389	   1.026198811	   3.55E-­‐02	   2.68E-­‐05	   21.72475907	   0.000316903	  
Rv0040c	  	   mtc28	  	   0.002210434	   144.3599587	   0.007325746	   0.001705832	   31.7316938	   0.009991304	  
Rv0050	  	   ponA1	  	   2.69E-­‐12	   2.48E+02	   1.43E-­‐10	   3.30E-­‐05	   2.565713435	   0.000374744	  
Rv0057	  	   -­‐	  	   0.000101612	   128.6272784	   0.000549813	   0.01353601	   4.037367438	   0.052264768	  
Rv0066c	  	   icd2	  	   0.000343063	   26.58650071	   1.56E-­‐03	   8.07E-­‐05	   39.8296882	   0.000802171	  
Rv0067c	  	   -­‐	  	   4.68E-­‐06	   4.37E+01	   4.11E-­‐05	   0.000101293	   43.48519017	   0.000973047	  
Rv0078	  	   -­‐	  	   0.005494691	   31.56679751	   0.015743794	   0.00076471	   61.57866239	   0.005137249	  
Rv0078A	  	   -­‐	  	   0.000273864	   22.9086043	   0.001270805	   0.700761503	   0.501885082	   1	  
Rv0086	  	   hycQ	  	   0.000769024	   27.60259804	   0.003034135	   0.033906377	   27.88025856	   0.108049409	  
Rv0088	  	   -­‐	  	   0.000995672	   123.5393202	   0.003746252	   0.293015882	   5.335606181	   0.558264046	  
Rv0090	  	   -­‐	  	   0.000522176	   142.7371277	   0.002197558	   0.160992854	   1.114289613	   0.36173366	  
Rv0098	  	   -­‐	  	   0.012198635	   0.622890636	   0.031319542	   0.000614377	   106.0472191	   0.004345516	  
Rv0099	  	   fadD10	  	   6.81E-­‐07	   1.80E+00	   7.76E-­‐06	   3.35E-­‐08	   2.02E+01	   9.13E-­‐07	  
Rv0120c	  	   fusA2	  	   2.63E-­‐05	   19.60701472	   0.00017441	   0.001127472	   0.546650247	   0.007050248	  
Rv0125	  	   pepA	  	   0.354404986	   0.878989384	   0.531542111	   0.000198711	   11.00532858	   0.001729265	  
Rv0126	  	   treS	  	   1.68E-­‐08	   1.21E+00	   3.34E-­‐07	   4.73E-­‐11	   4.08E+01	   2.77E-­‐09	  
Rv0127	  	   -­‐	  	   0.000268335	   66.94165164	   1.25E-­‐03	   6.70E-­‐05	   97.57529103	   0.000695936	  
Rv0155	  	   pntAa	  	   1.46E-­‐07	   1.56E+02	   2.19E-­‐06	   2.41E-­‐09	   4.99E+01	   8.55E-­‐08	  
Rv0157	  	   pntB	  	   0.001096655	   2.155590627	   4.04E-­‐03	   4.65E-­‐10	   5.77E+02	   2.01E-­‐08	  
Rv0158	  	   -­‐	  	   2.91E-­‐06	   1.18E+01	   2.76E-­‐05	   0.053962132	   0.336749401	   0.150075105	  
Rv0162c	  	   adhE1	  	   2.72E-­‐05	   4.329033185	   0.000180434	   0.00019089	   21.21771789	   0.001679576	  
Rv0163	  	   -­‐	  	   1.22E-­‐06	   2.42E+02	   1.32E-­‐05	   0.080347229	   1.562050066	   0.207224988	  
Rv0177	  	   -­‐	  	   1.98E-­‐05	   163.7601987	   0.000138694	   0.874087111	   0.652052843	   1	  
Rv0180c	  	   -­‐	  	   1.09E-­‐14	   7.73E+02	   8.49E-­‐13	   9.14E-­‐16	   1.16E+03	   1.45E-­‐13	  
Rv0184	  	   -­‐	  	   0.000900199	   124.3165166	   0.003465723	   0.085557982	   2.154079144	   0.218031397	  
Rv0188	  	   -­‐	  	   0.00096369	   112.7027378	   0.003667381	   0.066778806	   1.596251034	   0.178961801	  
Rv0199	  	   -­‐	  	   0.000198556	   220.5808513	   0.000967718	   0.003227811	   9.317452657	   0.016957733	  
Rv0204c	  	   -­‐	  	   8.27E-­‐08	   1.68E+00	   1.35E-­‐06	   8.65E-­‐13	   3.25E+02	   8.19E-­‐11	  
Rv0205	  	   -­‐	  	   4.68E-­‐07	   2.09E+02	   5.72E-­‐06	   0.032118785	   1.125850373	   0.103598061	  
Rv0207c	  	   -­‐	  	   0.001020724	   13.90234298	   0.003829643	   0.134663586	   18.15535353	   0.313191275	  
Rv0208c	  	   trmB	  	   0.025952798	   39.80561504	   5.95E-­‐02	   8.78E-­‐06	   118.2176481	   0.000119948	  
Rv0211	  	   pckA	  	   4.69E-­‐05	   62.24241199	   2.83E-­‐04	   4.69E-­‐05	   62.24241199	   0.000502656	  
Rv0216	  	   -­‐	  	   0.00105034	   0.873481161	   3.93E-­‐03	   5.12E-­‐06	   1.49E+02	   7.54E-­‐05	  
Rv0222	  	   echA1	  	   0.000605379	   96.97821916	   0.002469325	   0.030769299	   10.1190144	   0.100385154	  
Rv0234c	  	   gabD1	  	   1.13E-­‐09	   2.00E+01	   3.14E-­‐08	   0.000482442	   4.100464405	   0.003635004	  
Rv0235c	  	   -­‐	  	   2.59E-­‐07	   2.25E+02	   3.63E-­‐06	   0.006352202	   2.384618234	   0.028707623	  
Rv0238	  	   -­‐	  	   0.001112296	   120.8288942	   0.004084582	   0.001112296	   120.8288942	   0.006988313	  
Rv0241c	  	   -­‐	  	   0.000496346	   98.6854895	   0.002115721	   0.002587152	   51.5530908	   0.014133382	  
Rv0242c	  	   fabG	  	   8.78E-­‐06	   2.38E+02	   7.03E-­‐05	   8.78E-­‐06	   238.2157481	   0.000119948	  
Rv0243	  	   fadA2	  	   2.23E-­‐07	   1.33E+00	   3.19E-­‐06	   8.12E-­‐11	   2.23E+01	   4.25E-­‐09	  
Rv0244c	  	   fadE5	  	   2.07E-­‐14	   5.91E+00	   1.58E-­‐12	   4.30E-­‐18	   3.30E+02	   1.55E-­‐15	  
Rv0247c	  	   -­‐	  	   8.28E-­‐05	   52.712884	   0.000463176	   0.000569269	   35.98114003	   0.004086613	  
Rv0248c	  	   sdhA	  	   1.44E-­‐09	   8.81E-­‐01	   3.82E-­‐08	   4.52E-­‐14	   1.05E+02	   5.80E-­‐12	  
Rv0249c	  	   -­‐	  	   1.64E-­‐10	   1.83E+00	   5.68E-­‐09	   1.53E-­‐10	   2.73E+01	   7.51E-­‐09	  
Rv0273c	  	   -­‐	  	   9.89E-­‐06	   3.67E+01	   7.82E-­‐05	   0.002231639	   4.556535679	   0.012500319	  
Rv0310c	  	   -­‐	  	   0.019069064	   1.314234537	   0.04571288	   0.000240422	   121.9703665	   0.002056252	  
Rv0312	  	   -­‐	  	   4.01E-­‐07	   8.89E+01	   5.19E-­‐06	   0.004134052	   8.531905093	   0.020680662	  
Rv0324	  	   -­‐	  	   3.50E-­‐06	   5.30E+01	   3.18E-­‐05	   1.02E-­‐08	   1.14E+02	   2.98E-­‐07	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Rv0332	  	   -­‐	  	   0.000397655	   39.85350113	   0.001765037	   0.486375016	   1.304701861	   0.814447763	  
Rv0343	  	   iniC	  	   0.000347157	   46.51695526	   0.001572489	   0.145393843	   1.568392488	   0.333274533	  
Rv0360c	  	   -­‐	  	   0.000514951	   18.72520201	   0.002181002	   0.003684332	   9.347407664	   0.01878537	  
Rv0361	  	   -­‐	  	   4.11E-­‐05	   230.8451543	   0.0002527	   0.000185305	   95.60089516	   0.001634056	  
Rv0363c	  	   fba	  	   0.001816367	   22.71285069	   6.16E-­‐03	   1.87E-­‐05	   212.4761307	   0.000234445	  
Rv0370c	  	   -­‐	  	   1.94E-­‐06	   1.35E+01	   1.99E-­‐05	   4.80E-­‐06	   6.17E+01	   7.18E-­‐05	  
Rv0380c	  	   -­‐	  	   0.000868876	   108.5586577	   0.00337453	   0.385100891	   4.536104725	   0.687147528	  
Rv0381c	  	   -­‐	  	   6.32E-­‐07	   4.35E+00	   7.26E-­‐06	   1.30E-­‐05	   14.04295565	   0.000169782	  
Rv0384c	  	   clpB	  	   4.36E-­‐05	   52.98164753	   2.67E-­‐04	   4.36E-­‐05	   52.98164753	   0.000472597	  
Rv0392c	  	   ndhA	  	   3.50E-­‐05	   4.797618132	   2.21E-­‐04	   5.93E-­‐05	   18.69234918	   0.000620347	  
Rv0403c	  	   mmpS1	  	   0.000420961	   100.2089866	   0.001845824	   0.066977975	   1.211391861	   0.179041117	  
Rv0407	  	   fgd1	  	   9.27E-­‐09	   1.02E+01	   1.99E-­‐07	   5.15E-­‐07	   5.69E+00	   1.04E-­‐05	  
Rv0409	  	   ackA	  	   0.002351459	   93.15167151	   0.007709608	   0.066961057	   17.84988228	   0.179041117	  
Rv0412c	  	   -­‐	  	   7.84E-­‐07	   6.38E+01	   8.74E-­‐06	   1.49E-­‐05	   27.81299966	   0.000191144	  
Rv0432	  	   sodC	  	   3.88E-­‐05	   161.137982	   0.00023995	   0.002296804	   2.983265128	   0.012811206	  
Rv0436c	  	   pssA	  	   5.24E-­‐09	   2.29E+02	   1.19E-­‐07	   1.90E-­‐11	   4.88E+02	   1.26E-­‐09	  
Rv0438c	  	   moeA2	  	   0.0003709	   50.38692479	   0.001664866	   0.001086181	   11.40040657	   0.006835037	  
Rv0444c	  	   -­‐	  	   0.000936537	   47.16117285	   0.003577914	   0.017013112	   2.907355283	   0.0629406	  
Rv0465c	  	   -­‐	  	   0.055962008	   0.91248773	   1.12E-­‐01	   1.21E-­‐12	   2.01E+01	   1.12E-­‐10	  
Rv0467	  	   icl	  	   3.35E-­‐05	   57.05272778	   2.13E-­‐04	   2.82E-­‐09	   1.70E+02	   9.49E-­‐08	  
Rv0468	  	   fadB2	  	   0.000723572	   16.35307407	   0.002889201	   0.000471952	   9.78064932	   0.003575151	  
Rv0470c	  	   pcaA	  	   3.47E-­‐07	   1.69E+01	   4.61E-­‐06	   5.73E-­‐09	   2.94E+01	   1.82E-­‐07	  
Rv0472c	  	   -­‐	  	   1.48E-­‐06	   5.83E+01	   1.56E-­‐05	   0.000144362	   12.65213846	   0.001316804	  
Rv0485	  	   -­‐	  	   8.78E-­‐08	   2.39E+00	   1.43E-­‐06	   3.82E-­‐13	   6.05E+01	   3.90E-­‐11	  
Rv0489	  	   gpm1	  	   0.001369849	   53.25323406	   4.86E-­‐03	   5.69E-­‐07	   1.59E+02	   1.14E-­‐05	  
Rv0495c	  	   -­‐	  	   2.63E-­‐05	   5.765104995	   1.74E-­‐04	   9.09E-­‐07	   1.76E+02	   1.71E-­‐05	  
Rv0497	  	   -­‐	  	   6.13E-­‐06	   1.42E+02	   5.18E-­‐05	   4.21E-­‐06	   1.33E+01	   6.34E-­‐05	  
Rv0498	  	   -­‐	  	   0.014906151	   2.475370231	   3.72E-­‐02	   1.05E-­‐05	   28.08630138	   0.000140979	  
Rv0504c	  	   -­‐	  	   1.98E-­‐06	   1.96E+02	   2.02E-­‐05	   3.15E-­‐06	   1.40E+02	   4.97E-­‐05	  
Rv0505c	  	   serB1	  	   9.92E-­‐05	   87.47620658	   0.000538246	   0.000448575	   32.84386754	   0.003430733	  
Rv0519c	  	   -­‐	  	   1.75E-­‐05	   62.70160318	   0.000125043	   0.064126643	   2.62953397	   0.172785678	  
Rv0541c	  	   -­‐	  	   7.11E-­‐05	   81.01794719	   4.05E-­‐04	   3.43E-­‐05	   84.73358477	   0.000385271	  
Rv0545c	  	   pitA	  	   0.002723151	   0.787559888	   0.008740899	   0.000400513	   16.86132669	   0.003147906	  
Rv0561c	  	   -­‐	  	   4.91E-­‐07	   9.07E+00	   5.87E-­‐06	   2.34E-­‐09	   1.42E+02	   8.39E-­‐08	  
Rv0563	  	   htpX	  	   0.000225098	   5.659762643	   1.08E-­‐03	   2.66E-­‐05	   124.436535	   0.000316299	  
Rv0579	  	   -­‐	  	   0.000143457	   182.0799364	   0.000737119	   0.073494997	   1.561316106	   0.192295792	  
Rv0580c	  	   -­‐	  	   0.000361546	   48.37762624	   0.001630235	   0.053662934	   5.086990607	   0.149452024	  
Rv0582	  	   -­‐	  	   0.003411848	   7.973850628	   0.01057593	   0.000606287	   17.18665648	   0.004305724	  
Rv0586	  	   -­‐	  	   0.000290157	   72.40495939	   0.001330973	   0.386500105	   2.68813958	   0.68805323	  
Rv0588	  	   yrbE2B	  	   6.35E-­‐05	   125.4924525	   0.000367254	   0.149985326	   7.145603081	   0.341829021	  
Rv0590	  	   mce2B	  	   9.05E-­‐05	   49.90757681	   0.000499699	   0.001491491	   9.488910364	   0.008933223	  
Rv0590A	  	   -­‐	  	   0.000191992	   156.77054	   0.000942659	   0.023064459	   5.829809438	   0.080122354	  
Rv0619	  	   galTb	  	   0.000896658	   76.18171628	   0.003458788	   0.004592089	   18.19973709	   0.022491059	  
Rv0622	  	   -­‐	  	   2.45E-­‐07	   1.58E+02	   3.47E-­‐06	   0.000651904	   15.0401151	   0.004564474	  
Rv0634A	  	   -­‐	  	   0.000284239	   205.0883153	   0.001308355	   0.090420896	   14.67142185	   0.228072538	  
Rv0642c	  	   mmaA4	  	   0.010820312	   0.718342883	   2.84E-­‐02	   2.54E-­‐10	   1.53E+01	   1.18E-­‐08	  
Rv0646c	  	   lipG	  	   0.000444536	   193.5316048	   0.001932151	   0.037371033	   3.669760468	   0.115841463	  
Rv0671	  	   lpqP	  	   0.000449465	   179.1352605	   0.001949315	   0.016674354	   1.740765256	   0.061859985	  
Rv0687	  	   fabG	  	   3.18E-­‐05	   26.92951262	   0.000204734	   0.018688614	   6.234391804	   0.068039921	  
Rv0694	  	   lldD1	  	   6.30E-­‐05	   89.87367635	   0.000364512	   0.369486649	   0.535263766	   0.665511053	  
Rv0695	  	   -­‐	  	   0.00096978	   15.46150479	   0.003680167	   0.370354013	   4.647715607	   0.666283893	  
Rv0712	  	   -­‐	  	   2.67E-­‐06	   1.68E+01	   2.58E-­‐05	   7.25E-­‐05	   10.81016869	   0.000737568	  
Rv0725c	  	   -­‐	  	   0.000892958	   101.0100065	   0.003447856	   0.666636064	   1.228500398	   1	  
Rv0726c	  	   -­‐	  	   0.002562459	   166.1744342	   0.008285284	   0.616362248	   6.917597116	   0.965144631	  
Rv0727c	  	   fucA	  	   0.121338287	   0.742390129	   0.217370435	   0.000333084	   19.1331945	   0.002720075	  
Rv0742	  	   PE_PGRS
8	  	  
0.001610677	   88.57933345	   0.005546029	   0.504014437	   0.885658409	   0.83103873	  
Rv0762c	  	   -­‐	  	   0.001365421	   1.671668775	   0.004857008	   0.000508626	   12.44753532	   0.003766864	  
Rv0764c	  	   cyp51	  	   0.000441403	   112.9603049	   0.001920634	   0.658110484	   0.331691244	   0.999734682	  
Rv0784	  	   -­‐	  	   0.000585995	   21.20835836	   0.002410032	   0.008394253	   14.18861244	   0.035439433	  
Rv0798c	  	   cfp29	  	   0.001163778	   12.83545369	   0.004250088	   0.005473068	   1.757814685	   0.025820154	  
Rv0805	  	   -­‐	  	   7.85E-­‐09	   2.18E+02	   1.71E-­‐07	   0.038598971	   2.742748153	   0.118447614	  
Rv0806c	  	   cpsY	  	   5.04E-­‐14	   2.43E+00	   3.58E-­‐12	   1.36E-­‐21	   1.96E+01	   7.71E-­‐19	  
Rv0833	  	   PE_PGRS
13	  	  
0.003987633	   18.28226649	   0.012078308	   0.000411058	   36.86344148	   0.003200779	  
Rv0835	  	   lpqQ	  	   0.000712602	   25.83296371	   0.002853996	   0.108751074	   2.609726911	   0.264366149	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Rv0858c	  	   -­‐	  	   5.52E-­‐08	   1.95E+02	   9.26E-­‐07	   0.201093347	   1.352853157	   0.429510334	  
Rv0860	  	   fadB	  	   4.43E-­‐07	   8.87E+01	   5.50E-­‐06	   1.02E-­‐08	   1.43E+02	   2.98E-­‐07	  
Rv0861c	  	   ercc3	  	   4.17E-­‐08	   1.36E+00	   7.41E-­‐07	   2.09E-­‐09	   3.92E+01	   7.85E-­‐08	  
Rv0862c	  	   -­‐	  	   1.11E-­‐08	   2.87E+01	   2.35E-­‐07	   3.89E-­‐06	   1.71E+01	   6.06E-­‐05	  
Rv0867c	  	   rpfA	  	   3.07E-­‐05	   87.23068009	   0.00019837	   0.02227905	   86.90146277	   0.077812434	  
Rv0875c	  	   -­‐	  	   3.69E-­‐07	   1.72E+02	   4.86E-­‐06	   2.81E-­‐08	   2.56E+02	   7.71E-­‐07	  
Rv0876c	  	   -­‐	  	   8.03E-­‐12	   1.58E+02	   3.75E-­‐10	   3.62E-­‐12	   1.61E+02	   2.94E-­‐10	  
Rv0893c	  	   -­‐	  	   2.16E-­‐05	   136.1949783	   0.000148206	   0.184790403	   1.504521724	   0.405695946	  
Rv0896	  	   gltA	  	   1.26E-­‐09	   5.52E+02	   3.49E-­‐08	   1.26E-­‐09	   5.52E+02	   5.07E-­‐08	  
Rv0907	  	   -­‐	  	   5.44E-­‐08	   1.20E+02	   9.17E-­‐07	   0.001174723	   5.776100777	   0.007288415	  
Rv0910	  	   -­‐	  	   0.001448861	   130.428645	   0.00508572	   0.001448861	   126.7367803	   0.00870411	  
Rv0918	  	   -­‐	  	   0.000433211	   65.07559223	   0.001893275	   0.035199345	   0.312955745	   0.11095679	  
Rv0923c	  	   -­‐	  	   0.004516974	   0.695026615	   0.013415987	   0.000142739	   15.46469351	   0.001307999	  
Rv0926c	  	   -­‐	  	   1.71E-­‐08	   1.14E+02	   3.38E-­‐07	   8.32E-­‐05	   7.027670586	   0.000818625	  
Rv0928	  	   pstS3	  	   2.76E-­‐08	   5.09E+01	   5.27E-­‐07	   0.000500351	   0.664692361	   0.003712489	  
Rv0929	  	   pstC2	  	   4.16E-­‐09	   2.74E+02	   9.73E-­‐08	   0.000114053	   1.747709843	   0.001074854	  
Rv0940c	  	   -­‐	  	   0.000193404	   120.1858586	   0.000948418	   0.03524559	   22.64126717	   0.11095679	  
Rv0946c	  	   pgi	  	   0.000167262	   168.7991406	   0.000838841	   0.000259959	   110.1212401	   0.00217654	  
Rv0949	  	   uvrD1	  	   5.20E-­‐12	   3.25E+01	   2.59E-­‐10	   3.08E-­‐11	   3.64E+01	   1.92E-­‐09	  
Rv0950c	  	   -­‐	  	   6.99E-­‐12	   2.80E+02	   3.43E-­‐10	   8.37E-­‐11	   2.93E+01	   4.32E-­‐09	  
Rv0955	  	   -­‐	  	   1.27E-­‐05	   1.07E+00	   9.50E-­‐05	   6.67E-­‐11	   3.34E+01	   3.68E-­‐09	  
Rv0959	  	   -­‐	  	   0.000596188	   66.47301885	   0.002439343	   0.903012782	   0.810511296	   1	  
Rv0966c	  	   -­‐	  	   1.91E-­‐05	   123.984868	   0.000134275	   0.00284157	   14.23774336	   0.015266421	  
Rv0972c	  	   fadE12	  	   0.002817522	   18.16702756	   0.009000228	   0.206187067	   3.69820649	   0.435247328	  
Rv0973c	  	   accA2	  	   4.69E-­‐05	   41.8624206	   0.000283412	   0.012559386	   2.097985439	   0.049113745	  
Rv0976c	  	   -­‐	  	   9.13E-­‐06	   2.47E+01	   7.26E-­‐05	   0.003343513	   1.517111467	   0.01747776	  
Rv0981	  	   mprA	  	   0.000257308	   2.204648604	   1.21E-­‐03	   4.00E-­‐06	   5.51E+01	   6.14E-­‐05	  
Rv0983	  	   pepD	  	   2.07E-­‐06	   2.04E+01	   2.08E-­‐05	   2.63E-­‐07	   2.50E+01	   5.94E-­‐06	  
Rv0986	  	   -­‐	  	   3.54E-­‐05	   173.6244585	   0.000222955	   0.01448253	   5.494997494	   0.055275453	  
Rv0988	  	   -­‐	  	   6.81E-­‐05	   153.8500948	   0.00039193	   0.020529093	   15.3964972	   0.073157888	  
Rv0994	  	   moeA1	  	   5.69E-­‐06	   2.09E+02	   4.90E-­‐05	   4.81E-­‐07	   5.65E+01	   9.91E-­‐06	  
Rv0998	  	   -­‐	  	   0.014139765	   28.32611366	   3.56E-­‐02	   9.01E-­‐05	   180.1667934	   0.000880521	  
Rv1010	  	   ksgA	  	   1.18E-­‐05	   5.44E+01	   8.93E-­‐05	   0.000755805	   20.74368577	   0.005094636	  
Rv1028c	  	   kdpD	  	   1.40E-­‐09	   3.89E+01	   3.76E-­‐08	   1.84E-­‐06	   2.05E+00	   3.22E-­‐05	  
Rv1050	  	   -­‐	  	   0.00249897	   89.42252564	   0.008126252	   0.40133088	   1.868675596	   0.706861341	  
Rv1058	  	   fadD14	  	   1.60E-­‐06	   9.22E-­‐01	   1.66E-­‐05	   2.44E-­‐10	   3.96E+01	   1.16E-­‐08	  
Rv1059	  	   -­‐	  	   3.02E-­‐05	   45.63720189	   1.96E-­‐04	   1.41E-­‐05	   52.9199517	   0.00018087	  
Rv1065	  	   -­‐	  	   0.287640083	   0.769698744	   4.46E-­‐01	   7.23E-­‐07	   1.98E+01	   1.42E-­‐05	  
Rv1078	  	   pra	  	   3.32E-­‐05	   152.4491925	   2.12E-­‐04	   3.32E-­‐05	   152.4491925	   0.00037548	  
Rv1080c	  	   greA	  	   0.003097682	   26.45324392	   0.009769614	   0.000434348	   39.38121526	   0.00333475	  
Rv1082	  	   mca	  	   0.0005195	   40.22863497	   0.002188615	   0.077242469	   3.875222083	   0.200680849	  
Rv1086	  	   -­‐	  	   1.39E-­‐06	   2.25E+02	   1.49E-­‐05	   8.10E-­‐09	   5.61E+02	   2.42E-­‐07	  
Rv1096	  	   -­‐	  	   2.51E-­‐07	   2.38E+02	   3.54E-­‐06	   0.000378644	   25.50075559	   0.002999733	  
Rv1097c	  	   -­‐	  	   5.94E-­‐07	   2.00E+01	   6.88E-­‐06	   0.000437491	   1.320897681	   0.003352413	  
Rv1099c	  	   glpX	  	   0.001074004	   1.697939315	   3.98E-­‐03	   5.95E-­‐06	   2.28E+02	   8.60E-­‐05	  
Rv1100	  	   -­‐	  	   9.57E-­‐05	   172.8508281	   0.000523757	   0.257301044	   1.934364361	   0.503585754	  
Rv1105	  	   -­‐	  	   6.16E-­‐05	   421.3731198	   0.000357641	   0.445123998	   3.666284459	   0.761401351	  
Rv1111c	  	   -­‐	  	   0.001899535	   198.3329164	   0.006418396	   0.026378372	   3.297653292	   0.088379769	  
Rv1112	  	   -­‐	  	   2.27E-­‐06	   6.27E+01	   2.24E-­‐05	   4.03E-­‐06	   4.21E+01	   6.16E-­‐05	  
Rv1121	  	   zwf1	  	   3.59E-­‐10	   1.17E+02	   1.13E-­‐08	   0.004589606	   0.708422188	   0.022491059	  
Rv1127c	  	   ppdK	  	   0.008496012	   0.513299159	   2.29E-­‐02	   2.79E-­‐06	   1.35E+02	   4.52E-­‐05	  
Rv1128c	  	   -­‐	  	   2.72E-­‐10	   1.40E+02	   8.78E-­‐09	   4.09E-­‐06	   1.00E+00	   6.21E-­‐05	  
Rv1130	  	   -­‐	  	   4.05E-­‐12	   2.60E+00	   2.04E-­‐10	   4.42E-­‐10	   1.07E+01	   1.93E-­‐08	  
Rv1131	  	   gltA1	  	   1.15E-­‐05	   4.22E+01	   8.83E-­‐05	   4.68E-­‐05	   42.56289383	   0.000502656	  
Rv1144	  	   -­‐	  	   0.000175375	   17.53073343	   0.000871832	   0.692783928	   1.242600502	   1	  
Rv1159	  	   pimE	  	   6.85E-­‐17	   5.43E+02	   8.25E-­‐15	   2.92E-­‐17	   7.79E+01	   7.26E-­‐15	  
Rv1170	  	   mshB	  	   5.69E-­‐07	   3.69E+02	   6.64E-­‐06	   0.000129754	   136.6784709	   0.001197285	  
Rv1173	  	   fbiC	  	   1.29E-­‐09	   4.65E+01	   3.53E-­‐08	   2.29E-­‐13	   6.44E+02	   2.47E-­‐11	  
Rv1178	  	   -­‐	  	   0.003010514	   1.415294442	   9.53E-­‐03	   2.74E-­‐05	   30.81916164	   0.000321583	  
Rv1187	  	   rocA	  	   0.000243532	   117.5299463	   0.00115991	   0.437098773	   6.25302775	   0.750255425	  
Rv1193	  	   fadD36	  	   2.92E-­‐07	   2.00E+02	   4.01E-­‐06	   4.44E-­‐07	   2.05E+02	   9.35E-­‐06	  
Rv1220c	  	   -­‐	  	   0.001325914	   150.1838947	   0.004737529	   0.000646962	   6.985547508	   0.004545879	  
Rv1221	  	   sigE	  	   0.001425758	   70.75179174	   0.005026809	   0.020829827	   2.514868047	   0.073832638	  
Rv1234	  	   -­‐	  	   0.000566159	   106.8842643	   0.002347877	   0.194731094	   3.506406004	   0.421352318	  
Rv1235	  	   lpqY	  	   8.10E-­‐12	   1.61E+01	   3.75E-­‐10	   3.06E-­‐09	   3.48E+00	   1.02E-­‐07	  
Rv1236	  	   sugA	  	   1.43E-­‐05	   21.52972219	   1.05E-­‐04	   3.04E-­‐06	   8.14E+00	   4.83E-­‐05	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Rv1238	  	   sugC	  	   7.04E-­‐05	   6.583728987	   0.00040145	   0.000120739	   23.49807393	   0.001129837	  
Rv1255c	  	   -­‐	  	   0.000506864	   11.05865995	   0.002151332	   0.041978888	   10.21628783	   0.125442379	  
Rv1260	  	   -­‐	  	   0.000446149	   90.17837731	   0.001937047	   0.754435029	   0.705452271	   1	  
Rv1272c	  	   -­‐	  	   2.11E-­‐09	   4.65E+00	   5.27E-­‐08	   7.44E-­‐11	   2.05E+01	   4.00E-­‐09	  
Rv1273c	  	   -­‐	  	   3.00E-­‐11	   3.24E+02	   1.22E-­‐09	   2.48E-­‐11	   1.56E+01	   1.57E-­‐09	  
Rv1278	  	   -­‐	  	   3.11E-­‐06	   1.03E+02	   2.90E-­‐05	   0.005070314	   1.549616001	   0.024265511	  
Rv1282c	  	   oppC	  	   7.72E-­‐07	   2.21E+01	   8.64E-­‐06	   0.002065186	   3.909876582	   0.011683138	  
Rv1285	  	   cysD	  	   0.000127653	   51.34844158	   0.000668873	   0.000658042	   36.62947199	   0.00458814	  
Rv1286	  	   cysN	  	   1.29E-­‐06	   1.18E+02	   1.38E-­‐05	   1.34E-­‐06	   3.12E+01	   2.44E-­‐05	  
Rv1287	  	   -­‐	  	   0.000757372	   182.6118056	   0.003000068	   0.034504029	   7.998162454	   0.109253602	  
Rv1298	  	   rpmE	  	   0.000272518	   48.45318936	   0.001267606	   0.000921524	   34.56414037	   0.006027799	  
Rv1322A	  	   -­‐	  	   0.002476215	   154.1302524	   0.008058843	   0.013184584	   8.865515899	   0.051106327	  
Rv1325c	  	   PE_PGRS
24	  	  
0.000153331	   81.92139492	   0.000781792	   0.005029715	   66.39236647	   0.024114524	  
Rv1333	  	   -­‐	  	   0.000158758	   1.907719682	   0.000805334	   0.000279889	   26.78895918	   0.002328701	  
Rv1337	  	   -­‐	  	   2.72E-­‐06	   3.27E+02	   2.61E-­‐05	   5.50E-­‐06	   7.13E+00	   8.07E-­‐05	  
Rv1339	  	   -­‐	  	   2.23E-­‐06	   2.26E+00	   2.21E-­‐05	   6.29E-­‐07	   1.79E+01	   1.24E-­‐05	  
Rv1340	  	   rph	  	   2.36E-­‐05	   71.03403806	   1.60E-­‐04	   2.88E-­‐06	   1.24E+02	   4.60E-­‐05	  
Rv1346	  	   fadE14	  	   3.04E-­‐05	   119.5263715	   0.000196952	   0.15521003	   0.773174372	   0.350124952	  
Rv1348	  	   -­‐	  	   0.006069997	   1.05278722	   1.72E-­‐02	   8.28E-­‐05	   18.38653974	   0.000817608	  
Rv1349	  	   -­‐	  	   2.96E-­‐05	   82.30513437	   1.93E-­‐04	   2.96E-­‐05	   82.30513437	   0.000340608	  
Rv1350	  	   fabG	  	   0.001627603	   77.95257209	   0.005589792	   0.973463793	   0.631569542	   1	  
Rv1353c	  	   -­‐	  	   0.000104026	   112.4915833	   0.000561346	   0.096117137	   11.18557521	   0.239960987	  
Rv1355c	  	   moeY	  	   5.44E-­‐13	   1.84E+02	   3.09E-­‐11	   2.55E-­‐05	   8.552522872	   0.000304958	  
Rv1361c	  	   PPE19	  	   0.00175089	   11.45422693	   0.005966828	   0.284258259	   2.504790942	   0.545406378	  
Rv1372	  	   -­‐	  	   1.05E-­‐05	   8.48E+01	   8.24E-­‐05	   0.177411657	   0.902159183	   0.393292174	  
Rv1373	  	   -­‐	  	   2.09E-­‐08	   1.48E+01	   4.06E-­‐07	   0.003475798	   1.250882184	   0.017975963	  
Rv1377c	  	   -­‐	  	   1.42E-­‐05	   85.60110447	   0.000104141	   0.02740257	   2.635497478	   0.091120419	  
Rv1400c	  	   lipI	  	   1.15E-­‐05	   5.18E+01	   8.83E-­‐05	   0.000802658	   7.835866081	   0.005346102	  
Rv1405c	  	   -­‐	  	   0.000463534	   15.50688517	   0.002005956	   0.00088063	   11.43197552	   0.005798454	  
Rv1410c	  	   -­‐	  	   5.08E-­‐13	   2.63E+00	   2.93E-­‐11	   1.82E-­‐14	   2.08E+01	   2.50E-­‐12	  
Rv1411c	  	   lprG	  	   0.00483274	   92.94196902	   1.42E-­‐02	   4.11E-­‐05	   276.8804084	   0.000447936	  
Rv1420	  	   uvrC	  	   5.35E-­‐08	   1.28E+02	   9.13E-­‐07	   1.13E-­‐05	   10.39124982	   0.000150298	  
Rv1421	  	   -­‐	  	   0.006686126	   0.508898409	   1.86E-­‐02	   3.87E-­‐08	   1.23E+02	   1.04E-­‐06	  
Rv1430	  	   PE16	  	   1.37E-­‐18	   2.51E+01	   2.38E-­‐16	   8.66E-­‐09	   1.88E+00	   2.57E-­‐07	  
Rv1432	  	   -­‐	  	   1.02E-­‐09	   3.46E+01	   2.91E-­‐08	   1.06E-­‐11	   1.89E+02	   7.52E-­‐10	  
Rv1441c	  	   PE_PGRS
26	  	  
2.86E-­‐08	   1.37E+02	   5.44E-­‐07	   3.34E-­‐05	   3.837722097	   0.000375948	  
Rv1448c	  	   tal	  	   0.000138405	   124.1233542	   0.000714851	   0.002343591	   20.98614209	   0.012999248	  
Rv1458c	  	   -­‐	  	   8.09E-­‐06	   1.04E+02	   6.57E-­‐05	   1.30E-­‐07	   3.03E+02	   3.18E-­‐06	  
Rv1473	  	   -­‐	  	   2.80E-­‐07	   4.42E+00	   3.88E-­‐06	   2.86E-­‐10	   3.10E+02	   1.31E-­‐08	  
Rv1474c	  	   -­‐	  	   1.89E-­‐05	   174.5524349	   0.000133575	   0.033238357	   2.234500009	   0.106261211	  
Rv1490	  	   -­‐	  	   2.53E-­‐07	   1.13E+00	   3.56E-­‐06	   6.59E-­‐06	   1.34E+01	   9.40E-­‐05	  
Rv1492	  	   mutA	  	   0.018948963	   3.695171076	   0.0454798	   0.001440666	   13.98364229	   0.008681104	  
Rv1507A	  	   -­‐	  	   0.001565659	   83.54498737	   0.005419169	   0.474286771	   5.408470316	   0.798576836	  
Rv1507c	  	   -­‐	  	   4.40E-­‐05	   101.6662035	   0.000269509	   0.058660718	   5.949457348	   0.160892189	  
Rv1509	  	   -­‐	  	   0.0005433	   110.772739	   0.002274425	   0.08704672	   11.43586434	   0.221345783	  
Rv1512	  	   epiA	  	   1.27E-­‐06	   2.10E+02	   1.37E-­‐05	   1.27E-­‐06	   2.10E+02	   2.33E-­‐05	  
Rv1530	  	   adh	  	   1.33E-­‐05	   1.59E+00	   9.85E-­‐05	   0.000210687	   11.1819638	   0.001809727	  
Rv1533	  	   -­‐	  	   0.000627625	   82.75201782	   0.002547003	   0.288551744	   4.922238947	   0.551716483	  
Rv1534	  	   -­‐	  	   0.001309805	   1.426053119	   0.00469288	   0.000347703	   19.58657999	   0.002804902	  
Rv1543	  	   -­‐	  	   0.001733072	   1.800649585	   5.92E-­‐03	   6.68E-­‐09	   2.80E+01	   2.06E-­‐07	  
Rv1544	  	   -­‐	  	   0.00063346	   3.226201397	   2.57E-­‐03	   2.43E-­‐06	   3.84E+01	   4.05E-­‐05	  
Rv1552	  	   frdA	  	   9.11E-­‐10	   2.31E+01	   2.62E-­‐08	   0.005214725	   0.80721244	   0.024807369	  
Rv1559	  	   ilvA	  	   9.01E-­‐05	   0.843766208	   4.98E-­‐04	   6.28E-­‐13	   2.89E+02	   6.25E-­‐11	  
Rv1565c	  	   -­‐	  	   6.34E-­‐19	   3.40E+01	   1.20E-­‐16	   2.36E-­‐17	   9.72E+00	   6.25E-­‐15	  
Rv1566c	  	   -­‐	  	   6.02E-­‐06	   1.36E+02	   5.11E-­‐05	   8.39E-­‐07	   1.51E+02	   1.60E-­‐05	  
Rv1568	  	   bioA	  	   2.19E-­‐07	   2.59E+01	   3.15E-­‐06	   6.92E-­‐09	   3.40E+02	   2.10E-­‐07	  
Rv1569	  	   bioF1	  	   0.000105653	   71.91847732	   5.68E-­‐04	   2.40E-­‐05	   105.1965744	   0.000289627	  
Rv1589	  	   bioB	  	   1.48E-­‐06	   2.35E+02	   1.56E-­‐05	   1.03E-­‐07	   1.37E+02	   2.56E-­‐06	  
Rv1592c	  	   -­‐	  	   1.46E-­‐05	   1.975708101	   1.07E-­‐04	   1.27E-­‐10	   3.51E+01	   6.34E-­‐09	  
Rv1604	  	   impA	  	   0.000995672	   156.4735211	   0.003746252	   0.087610469	   10.89264733	   0.222352799	  
Rv1609	  	   trpE	  	   2.32E-­‐05	   39.00349371	   1.58E-­‐04	   1.11E-­‐06	   1.01E+02	   2.07E-­‐05	  
Rv1620c	  	   cydC	  	   0.026461397	   14.60546331	   0.060307722	   0.00073058	   130.5601983	   0.00498444	  
Rv1621c	  	   cydD	  	   6.00E-­‐08	   1.80E+01	   9.99E-­‐07	   1.62E-­‐11	   2.88E+02	   1.11E-­‐09	  
Rv1622c	  	   cydB	  	   5.22E-­‐09	   2.75E+02	   1.19E-­‐07	   2.35E-­‐08	   1.68E+02	   6.62E-­‐07	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Rv1623c	  	   cydA	  	   6.85E-­‐07	   1.43E+02	   7.79E-­‐06	   4.70E-­‐10	   8.12E+01	   2.01E-­‐08	  
Rv1626	  	   -­‐	  	   0.002532833	   33.45778098	   0.00820283	   0.014199242	   1.9892934	   0.054335835	  
Rv1627c	  	   -­‐	  	   3.82E-­‐05	   2.066446924	   2.37E-­‐04	   3.47E-­‐05	   11.06678216	   0.000389046	  
Rv1633	  	   uvrB	  	   1.48E-­‐18	   1.70E+00	   2.45E-­‐16	   2.41E-­‐24	   2.03E+01	   1.92E-­‐21	  
Rv1636	  	   TB15.3	  	   2.40E-­‐05	   253.3424297	   1.61E-­‐04	   2.40E-­‐05	   253.3424297	   0.000289627	  
Rv1638	  	   uvrA	  	   6.56E-­‐16	   3.58E+02	   6.69E-­‐14	   3.35E-­‐17	   3.63E+01	   7.40E-­‐15	  
Rv1660	  	   pks10	  	   0.000714966	   178.7949622	   0.002860583	   0.128040919	   1.048864719	   0.301491257	  
Rv1663	  	   pks17	  	   2.48E-­‐05	   29.91165208	   0.00016552	   0.009373891	   7.066442191	   0.038955033	  
Rv1664	  	   pks9	  	   1.07E-­‐14	   6.27E+00	   8.49E-­‐13	   7.99E-­‐11	   2.49E+01	   4.24E-­‐09	  
Rv1665	  	   pks11	  	   2.18E-­‐07	   2.04E+01	   3.15E-­‐06	   0.003897491	   3.164267179	   0.019745634	  
Rv1683	  	   -­‐	  	   5.37E-­‐10	   2.02E+01	   1.63E-­‐08	   2.67E-­‐06	   4.49E+00	   4.38E-­‐05	  
Rv1688	  	   mpg	  	   0.0012296	   105.6867972	   0.004449607	   0.488866191	   1.382920427	   0.816417255	  
Rv1700	  	   -­‐	  	   0.012390218	   53.13799766	   0.031697488	   0.000241846	   104.8099957	   0.002063995	  
Rv1701	  	   xerD	  	   0.000171187	   76.41493922	   0.000853146	   0.001604793	   32.26030442	   0.009511568	  
Rv1710	  	   -­‐	  	   0.001483132	   11.4846308	   0.005183142	   0.021899888	   1.42284667	   0.07688163	  
Rv1732c	  	   -­‐	  	   0.000881018	   86.78297245	   3.41E-­‐03	   8.19E-­‐06	   176.4966541	   0.000115984	  
Rv1737c	  	   narK2	  	   1.08E-­‐07	   8.83E+01	   1.68E-­‐06	   0.227708393	   2.443722076	   0.464885154	  
Rv1753c	  	   PPE24	  	   7.74E-­‐12	   2.33E+02	   3.70E-­‐10	   0.045184169	   1.046972312	   0.132130471	  
Rv1755c	  	   plcD	  	   0.000284239	   81.94223301	   0.001308355	   0.109135226	   3.008526542	   0.265137932	  
Rv1770	  	   -­‐	  	   0.000161998	   18.99106344	   0.000818745	   0.433899765	   1.073596392	   0.746375158	  
Rv1775	  	   -­‐	  	   2.58E-­‐06	   9.13E+01	   2.50E-­‐05	   0.003344374	   6.840800655	   0.01747776	  
Rv1791	  	   PE19	  	   0.001406876	   50.7165919	   0.004974495	   0.001306523	   51.74632518	   0.007993912	  
Rv1809	  	   PPE33	  	   0.000731983	   2.025702276	   2.91E-­‐03	   1.31E-­‐06	   1.51E+01	   2.38E-­‐05	  
Rv1821	  	   secA2	  	   3.09E-­‐16	   1.05E+01	   3.42E-­‐14	   1.81E-­‐18	   2.82E+01	   7.19E-­‐16	  
Rv1823	  	   -­‐	  	   0.000679145	   15.16134321	   0.002739311	   0.002874935	   15.42203418	   0.015388445	  
Rv1825	  	   -­‐	  	   0.000720664	   141.3189682	   0.002880484	   0.000727629	   11.36242128	   0.00498444	  
Rv1829	  	   -­‐	  	   2.92E-­‐06	   5.33E+02	   2.76E-­‐05	   4.62E-­‐07	   5.40E+02	   9.62E-­‐06	  
Rv1836c	  	   -­‐	  	   5.61E-­‐14	   1.33E+00	   3.92E-­‐12	   1.39E-­‐26	   8.01E+01	   1.84E-­‐23	  
Rv1837c	  	   glcB	  	   1.12E-­‐10	   2.49E+02	   4.15E-­‐09	   1.12E-­‐10	   2.49E+02	   5.62E-­‐09	  
Rv1845c	  	   -­‐	  	   2.06E-­‐08	   1.35E+01	   4.01E-­‐07	   4.91E-­‐11	   2.99E+02	   2.83E-­‐09	  
Rv1854c	  	   ndh	  	   3.22E-­‐07	   2.96E+02	   4.34E-­‐06	   3.22E-­‐07	   2.96E+02	   7.20E-­‐06	  
Rv1860	  	   apa	  	   7.82E-­‐05	   3.967419303	   4.40E-­‐04	   3.89E-­‐08	   1.87E+01	   1.04E-­‐06	  
Rv1908c	  	   katG	  	   7.80E-­‐11	   3.36E+00	   3.01E-­‐09	   2.12E-­‐08	   1.10E+01	   6.07E-­‐07	  
Rv1911c	  	   lppC	  	   0.000243923	   71.09541602	   0.001160384	   0.367344364	   1.06464211	   0.662853237	  
Rv1913	  	   -­‐	  	   2.50E-­‐06	   9.88E+01	   2.43E-­‐05	   0.040177843	   3.993810982	   0.121975023	  
Rv1926c	  	   mpt63	  	   0.003092053	   85.60336653	   0.009769614	   0.608758402	   0.631055109	   0.956551626	  
Rv1928c	  	   -­‐	  	   1.37E-­‐05	   12.6317215	   0.000100855	   0.057567279	   5.03752409	   0.158879299	  
Rv1933c	  	   fadE18	  	   0.002253145	   66.22956157	   0.007442488	   0.541827913	   2.00709469	   0.872897461	  
Rv1961	  	   -­‐	  	   0.000821578	   20.16144658	   0.0032128	   0.006662451	   4.497207509	   0.02964395	  
Rv1962c	  	   -­‐	  	   5.76E-­‐05	   149.3736544	   0.000339903	   0.013176991	   2.074861764	   0.051106327	  
Rv1963c	  	   mce3R	  	   2.75E-­‐06	   1.58E+02	   2.63E-­‐05	   2.31E-­‐05	   109.2228665	   0.000282216	  
Rv2001	  	   -­‐	  	   0.000516202	   121.1763807	   0.002183975	   0.931796493	   0.760246963	   1	  
Rv2004c	  	   -­‐	  	   1.05E-­‐05	   1.29E+02	   8.22E-­‐05	   0.001641507	   25.80962641	   0.009700259	  
Rv2038c	  	   -­‐	  	   0.001602828	   2.744909149	   0.005523784	   0.000330702	   89.54644217	   0.002706179	  
Rv2039c	  	   -­‐	  	   0.000484628	   194.3968051	   0.002074669	   0.003936373	   15.0968211	   0.019891938	  
Rv2040c	  	   -­‐	  	   0.000615561	   18.94415269	   0.002503155	   0.002811632	   11.23199306	   0.015172133	  
Rv2043c	  	   pncA	  	   0.000668639	   89.07507208	   0.002702416	   0.083635464	   4.17052283	   0.214040051	  
Rv2047c	  	   -­‐	  	   1.84E-­‐16	   2.47E+00	   2.09E-­‐14	   1.54E-­‐12	   1.64E+01	   1.33E-­‐10	  
Rv2048c	  	   pks12	  	   8.86E-­‐30	   1.95E+00	   7.05E-­‐27	   1.56E-­‐33	   1.59E+01	   6.22E-­‐30	  
Rv2051c	  	   ppm1	  	   4.42E-­‐07	   4.57E+02	   5.50E-­‐06	   2.87E-­‐07	   1.29E+02	   6.45E-­‐06	  
Rv2069	  	   sigC	  	   0.001792967	   23.19853026	   0.006089351	   0.000700426	   4.834467417	   0.004836103	  
Rv2072c	  	   cobL	  	   0.000153988	   11.78700013	   0.000784134	   0.471092288	   0.450552649	   0.794543694	  
Rv2079	  	   -­‐	  	   7.02E-­‐05	   15.97554886	   0.000401215	   0.500126193	   0.778050664	   0.827171168	  
Rv2089c	  	   pepE	  	   0.000186777	   129.5060986	   0.000921216	   0.004839515	   25.10083592	   0.023414539	  
Rv2091c	  	   -­‐	  	   4.98E-­‐06	   9.46E-­‐01	   4.33E-­‐05	   3.96E-­‐16	   2.12E+02	   6.84E-­‐14	  
Rv2096c	  	   -­‐	  	   0.000133285	   68.27614707	   0.000695635	   0.132106175	   4.346675784	   0.308325269	  
Rv2097c	  	   -­‐	  	   0.110762482	   2.345667661	   2.02E-­‐01	   4.02E-­‐05	   66.97517656	   0.000440829	  
Rv2115c	  	   -­‐	  	   6.39E-­‐06	   1.69E+02	   5.36E-­‐05	   1.11E-­‐06	   2.54E+02	   2.07E-­‐05	  
Rv2119	  	   -­‐	  	   6.78E-­‐09	   2.36E+02	   1.50E-­‐07	   0.004578154	   0.864114527	   0.022478171	  
Rv2131c	  	   cysQ	  	   0.000731937	   69.33856786	   0.002911097	   0.000731937	   69.33856786	   0.00498444	  
Rv2138	  	   lppL	  	   3.91E-­‐06	   1.26E+02	   3.52E-­‐05	   3.91E-­‐06	   1.26E+02	   6.08E-­‐05	  
Rv2140c	  	   TB18.6	  	   0.000457509	   51.13642252	   0.001982042	   0.00018178	   59.64756297	   0.001610108	  
Rv2170	  	   -­‐	  	   0.000589246	   80.46060723	   2.42E-­‐03	   5.49E-­‐07	   1.63E+02	   1.10E-­‐05	  
Rv2192c	  	   trpD	  	   0.000434348	   61.13059981	   0.001896158	   0.000434348	   61.13059981	   0.00333475	  
Rv2198c	  	   mmpS3	  	   8.10E-­‐09	   2.99E+02	   1.75E-­‐07	   8.10E-­‐09	   2.99E+02	   2.42E-­‐07	  
Rv2206	  	   -­‐	  	   0.003470546	   30.34111481	   1.07E-­‐02	   1.95E-­‐05	   12.70227707	   0.000241925	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Rv2207	  	   cobT	  	   2.45E-­‐05	   122.5683263	   1.64E-­‐04	   1.98E-­‐06	   1.83E+02	   3.40E-­‐05	  
Rv2208	  	   cobS	  	   0.001069185	   52.62478273	   0.003973969	   0.051563969	   1.39112482	   0.145028222	  
Rv2222c	  	   glnA2	  	   1.29E-­‐10	   2.57E+02	   4.67E-­‐09	   2.29E-­‐08	   2.33E+02	   6.50E-­‐07	  
Rv2224c	  	   -­‐	  	   1.14E-­‐13	   1.16E+01	   7.43E-­‐12	   1.83E-­‐17	   1.06E+01	   5.24E-­‐15	  
Rv2230c	  	   -­‐	  	   1.88E-­‐05	   88.66073421	   0.000133323	   0.000551054	   10.41662387	   0.003999163	  
Rv2231c	  	   cobC	  	   4.54E-­‐06	   1.11E+00	   4.00E-­‐05	   2.55E-­‐10	   8.67E+01	   1.18E-­‐08	  
Rv2237	  	   -­‐	  	   3.30E-­‐06	   2.72E+02	   3.03E-­‐05	   0.053051461	   3.591214684	   0.148164087	  
Rv2241	  	   aceE	  	   7.15E-­‐17	   1.33E+00	   8.37E-­‐15	   2.21E-­‐16	   1.22E+01	   3.99E-­‐14	  
Rv2249c	  	   glpD1	  	   0.000819463	   58.93026435	   0.003207682	   0.073368503	   1.802336399	   0.192091202	  
Rv2250c	  	   -­‐	  	   0.000995221	   90.96801097	   0.003746252	   1	   0.74993255	   1	  
Rv2252	  	   -­‐	  	   0.002241411	   101.6328517	   0.007416049	   0.401778309	   1.017408349	   0.707336138	  
Rv2253	  	   -­‐	  	   2.09E-­‐11	   2.99E+02	   8.92E-­‐10	   1.21E-­‐09	   2.11E+01	   4.90E-­‐08	  
Rv2257c	  	   -­‐	  	   0.035030629	   54.63778174	   0.076547698	   0.000434348	   162.630375	   0.00333475	  
Rv2259	  	   adhE2	  	   4.62E-­‐07	   2.60E+00	   5.70E-­‐06	   1.73E-­‐09	   3.52E+01	   6.75E-­‐08	  
Rv2269c	  	   -­‐	  	   0.000359438	   137.4931591	   0.00162257	   0.211707454	   5.222696675	   0.441279111	  
Rv2274c	  	   -­‐	  	   2.40E-­‐05	   143.1038523	   0.000161231	   0.024004683	   10.34236828	   0.082440955	  
Rv2275	  	   -­‐	  	   0.000438823	   35.35557142	   0.0019115	   0.011914308	   5.106389203	   0.047007145	  
Rv2276	  	   cyp121	  	   2.44E-­‐06	   1.73E+02	   2.38E-­‐05	   0.002240606	   87.21036665	   0.012532898	  
Rv2305	  	   -­‐	  	   0.000213717	   99.35509301	   0.001030245	   0.128793902	   1.723729984	   0.302726566	  
Rv2307B	  	   -­‐	  	   0.00018518	   98.18974584	   0.000915998	   0.045601471	   8.786184171	   0.132667923	  
Rv2317	  	   uspB	  	   0.000505698	   110.1649546	   0.002148678	   0.0005303	   65.14092324	   0.003891147	  
Rv2322c	  	   rocD1	  	   0.000427507	   46.01814771	   0.001870404	   0.018753026	   2.567974576	   0.068048161	  
Rv2334	  	   cysK1	  	   0.000855225	   10.73994793	   0.00332476	   0.027361201	   5.284950801	   0.091058994	  
Rv2358	  	   -­‐	  	   0.002054127	   66.22072435	   0.006836204	   0.007496105	   45.53081346	   0.032510368	  
Rv2363	  	   amiA2	  	   7.56E-­‐05	   1.652506013	   4.28E-­‐04	   1.92E-­‐09	   4.38E+02	   7.29E-­‐08	  
Rv2374c	  	   hrcA	  	   0.000372337	   1.199430649	   1.67E-­‐03	   1.32E-­‐12	   2.78E+01	   1.19E-­‐10	  
Rv2379c	  	   mbtF	  	   2.10E-­‐10	   1.14E+02	   7.03E-­‐09	   9.24E-­‐12	   2.33E+02	   6.81E-­‐10	  
Rv2380c	  	   mbtE	  	   6.72E-­‐10	   1.22E+02	   1.98E-­‐08	   6.34E-­‐14	   1.32E+02	   7.41E-­‐12	  
Rv2381c	  	   mbtD	  	   4.94E-­‐07	   5.88E+01	   5.89E-­‐06	   1.98E-­‐06	   4.25E+01	   3.40E-­‐05	  
Rv2383c	  	   mbtB	  	   1.11E-­‐17	   2.08E+02	   1.64E-­‐15	   1.22E-­‐16	   4.35E+01	   2.32E-­‐14	  
Rv2384	  	   mbtA	  	   5.76E-­‐06	   4.66E+01	   4.95E-­‐05	   2.54E-­‐05	   33.6822168	   0.000304834	  
Rv2397c	  	   cysA1	  	   0.005883294	   36.75053885	   0.016736668	   0.001317277	   55.08676826	   0.008034986	  
Rv2400c	  	   subI	  	   3.32E-­‐05	   55.73715426	   0.000211809	   0.001423297	   9.066718522	   0.008589458	  
Rv2410c	  	   -­‐	  	   9.64E-­‐05	   107.3199401	   0.000525768	   0.006156897	   8.303452144	   0.027999719	  
Rv2416c	  	   eis	  	   0.00015512	   194.5424741	   0.000788892	   0.999998755	   0.700824719	   1	  
Rv2427c	  	   proA	  	   0.00013498	   4.211520244	   7.03E-­‐04	   8.46E-­‐06	   25.71639708	   0.000118062	  
Rv2430c	  	   PPE41	  	   0.000181656	   15.76025726	   0.000899683	   0.023110322	   6.417210879	   0.08020048	  
Rv2454c	  	   -­‐	  	   0.001407168	   44.08591967	   0.004974495	   0.001407168	   44.08591967	   0.008505025	  
Rv2455c	  	   -­‐	  	   1.95E-­‐06	   6.83E+01	   2.00E-­‐05	   3.74E-­‐07	   1.01E+02	   8.09E-­‐06	  
Rv2462c	  	   tig	  	   5.30E-­‐09	   1.24E+01	   1.20E-­‐07	   9.07E-­‐08	   1.21E+01	   2.30E-­‐06	  
Rv2467	  	   pepN	  	   9.06E-­‐07	   1.56E+00	   9.98E-­‐06	   1.13E-­‐16	   3.88E+01	   2.26E-­‐14	  
Rv2470	  	   glbO	  	   3.72E-­‐06	   1.25E+02	   3.37E-­‐05	   3.72E-­‐06	   1.25E+02	   5.83E-­‐05	  
Rv2476c	  	   gdh	  	   4.12E-­‐22	   3.63E+00	   1.26E-­‐19	   3.19E-­‐17	   1.35E+01	   7.40E-­‐15	  
Rv2492	  	   -­‐	  	   2.44E-­‐05	   116.2848964	   0.000163539	   0.483014738	   0.44463168	   0.809502577	  
Rv2495c	  	   pdhC	  	   0.002768167	   59.07618892	   0.00884968	   0.731088489	   0.56335605	   1	  
Rv2496c	  	   pdhB	  	   0.000166053	   125.0740165	   0.000833827	   0.013391795	   63.28213276	   0.051758181	  
Rv2500c	  	   fadE19	  	   0.000814146	   45.62356146	   0.003196309	   0.32642889	   3.236926477	   0.606072688	  
Rv2501c	  	   accA1	  	   2.25E-­‐08	   2.20E+00	   4.33E-­‐07	   2.58E-­‐09	   1.54E+01	   8.88E-­‐08	  
Rv2506	  	   -­‐	  	   0.38450528	   0.753916334	   0.567202336	   0.00012973	   116.2103828	   0.001197285	  
Rv2510c	  	   -­‐	  	   2.04E-­‐05	   96.77445435	   0.000142244	   0.071135768	   0.810189342	   0.188228177	  
Rv2518c	  	   lppS	  	   4.91E-­‐07	   3.97E+02	   5.87E-­‐06	   4.91E-­‐07	   3.97E+02	   1.00E-­‐05	  
Rv2522c	  	   -­‐	  	   0.002248932	   23.74400689	   0.007434749	   0.205284926	   1.08523725	   0.434264975	  
Rv2527	  	   -­‐	  	   0.00031439	   19.26448057	   0.001435508	   0.004343404	   10.14228403	   0.021511478	  
Rv2535c	  	   pepQ	  	   2.29E-­‐06	   5.93E+01	   2.25E-­‐05	   4.90E-­‐07	   7.74E+01	   1.00E-­‐05	  
Rv2536	  	   -­‐	  	   0.002994807	   89.6206161	   0.009513546	   0.009648862	   11.27273048	   0.039889319	  
Rv2543	  	   lppA	  	   3.81E-­‐05	   4.077832294	   0.000236738	   0.000392092	   16.89926476	   0.003093946	  
Rv2544	  	   lppB	  	   0.000100708	   4.324556664	   0.000545662	   0.001576003	   29.95406546	   0.009354874	  
Rv2553c	  	   -­‐	  	   1.88E-­‐10	   3.55E+02	   6.40E-­‐09	   1.88E-­‐10	   3.55E+02	   9.02E-­‐09	  
Rv2563	  	   -­‐	  	   0.000402631	   189.1887383	   0.001779181	   0.000635668	   32.13664039	   0.004474425	  
Rv2564	  	   glnQ	  	   6.89E-­‐06	   5.31E+01	   5.72E-­‐05	   5.86E-­‐09	   6.80E+01	   1.83E-­‐07	  
Rv2569c	  	   -­‐	  	   2.24E-­‐10	   1.10E+02	   7.37E-­‐09	   0.001670445	   2.242957137	   0.009842013	  
Rv2582	  	   ppiB	  	   0.00024831	   66.84216208	   0.001178437	   0.00024831	   66.84216208	   0.002110108	  
Rv2583c	  	   relA	  	   8.45E-­‐08	   1.06E+02	   1.38E-­‐06	   5.59E-­‐08	   1.15E+02	   1.47E-­‐06	  
Rv2605c	  	   tesB2	  	   0.000144106	   104.3855757	   0.000738165	   0.000192526	   11.45199159	   0.001690232	  
Rv2606c	  	   -­‐	  	   8.78E-­‐06	   1.81E+02	   7.03E-­‐05	   2.32E-­‐05	   128.9410833	   0.000282742	  
Rv2637	  	   dedA	  	   0.000849976	   136.5166026	   0.003307587	   0.938504818	   1.341691543	   1	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Rv2672	  	   -­‐	  	   5.78E-­‐05	   1.980345954	   3.40E-­‐04	   1.89E-­‐06	   2.46E+01	   3.28E-­‐05	  
Rv2680	  	   -­‐	  	   0.000948521	   10.9380681	   0.003620219	   0.000366669	   103.9038752	   0.002934092	  
Rv2681	  	   -­‐	  	   0.001053167	   1.455944396	   3.93E-­‐03	   1.49E-­‐05	   26.19811066	   0.000190699	  
Rv2683	  	   -­‐	  	   3.25E-­‐06	   2.58E+01	   2.99E-­‐05	   0.114266842	   4.353543544	   0.276254851	  
Rv2687c	  	   -­‐	  	   0.0010805	   15.96410799	   0.003997346	   0.101820749	   1.083256913	   0.251319586	  
Rv2690c	  	   -­‐	  	   7.19E-­‐05	   153.853478	   4.09E-­‐04	   7.19E-­‐05	   153.853478	   0.000733271	  
Rv2694c	  	   -­‐	  	   0.000836471	   53.1940147	   0.003264616	   0.078958808	   2.105291162	   0.20443957	  
Rv2702	  	   ppgK	  	   0.001908351	   29.05973879	   0.006442708	   0.110051674	   0.871381192	   0.267038137	  
Rv2710	  	   sigB	  	   1.53E-­‐09	   2.87E+02	   3.97E-­‐08	   1.64E-­‐10	   3.13E+02	   7.98E-­‐09	  
Rv2716	  	   -­‐	  	   0.000135223	   18.65005722	   0.000702983	   0.101867531	   2.214111322	   0.251319586	  
Rv2717c	  	   -­‐	  	   5.51E-­‐07	   1.66E+02	   6.47E-­‐06	   0.000687806	   17.48209287	   0.004765516	  
Rv2733c	  	   -­‐	  	   2.66E-­‐07	   3.46E+01	   3.71E-­‐06	   1.48E-­‐06	   2.23E+01	   2.65E-­‐05	  
Rv2734	  	   -­‐	  	   1.18E-­‐05	   1.98E+02	   8.93E-­‐05	   0.002052041	   21.05373826	   0.011637129	  
Rv2735c	  	   -­‐	  	   1.87E-­‐11	   1.05E+01	   8.25E-­‐10	   0.000340281	   1.350487288	   0.002761828	  
Rv2737c	  	   recA	  	   2.91E-­‐15	   1.86E+00	   2.57E-­‐13	   4.90E-­‐14	   1.33E+01	   6.10E-­‐12	  
Rv2744c	  	   35kd_ag	  	   0.001064552	   314.8165875	   0.003964162	   0.063088603	   8.156626091	   0.170450662	  
Rv2752c	  	   -­‐	  	   2.11E-­‐06	   1.80E+02	   2.11E-­‐05	   0.000103818	   20.22619622	   0.000992513	  
Rv2776c	  	   -­‐	  	   0.000992112	   0.914734764	   0.003746252	   0.000431552	   19.65840267	   0.00333475	  
Rv2795c	  	   -­‐	  	   5.24E-­‐06	   8.70E+01	   4.54E-­‐05	   0.0015204	   86.66781347	   0.009065413	  
Rv2807	  	   -­‐	  	   0.000367704	   2.089468763	   1.65E-­‐03	   7.35E-­‐05	   37.70196954	   0.000745833	  
Rv2809	  	   -­‐	  	   2.40E-­‐05	   365.4666194	   0.000161231	   0.022068194	   5.327160798	   0.077326175	  
Rv2816c	  	   -­‐	  	   3.92E-­‐05	   13.23259535	   0.000242061	   0.154045554	   1.013746889	   0.347892771	  
Rv2817c	  	   -­‐	  	   0.001046489	   78.60073198	   0.003915227	   0.107346214	   4.614164031	   0.261751008	  
Rv2819c	  	   -­‐	  	   1.88E-­‐06	   1.98E+02	   1.94E-­‐05	   0.000482539	   14.2117476	   0.003635004	  
Rv2821c	  	   -­‐	  	   4.63E-­‐05	   15.55839033	   0.000280679	   0.533874782	   1.4757823	   0.867302945	  
Rv2824c	  	   -­‐	  	   3.21E-­‐06	   1.68E+00	   2.96E-­‐05	   2.21E-­‐06	   1.55E+01	   3.77E-­‐05	  
Rv2833c	  	   ugpB	  	   2.74E-­‐05	   76.79957496	   0.000180917	   0.000550215	   45.14733304	   0.003999163	  
Rv2849c	  	   cobO	  	   0.002430807	   166.4082249	   0.007930532	   0.52254259	   3.295716105	   0.854854744	  
Rv2855	  	   mtr	  	   4.80E-­‐06	   6.94E+01	   4.20E-­‐05	   0.005598404	   35.08984071	   0.026218636	  
Rv2857c	  	   -­‐	  	   0.000995672	   236.0139052	   0.003746252	   0.164750958	   80.43791309	   0.368512126	  
Rv2869c	  	   -­‐	  	   1.50E-­‐09	   1.30E+02	   3.92E-­‐08	   2.99E-­‐10	   1.55E+02	   1.35E-­‐08	  
Rv2894c	  	   xerC	  	   0.001112296	   104.509711	   0.004084582	   0.01210163	   44.3128068	   0.047604534	  
Rv2913c	  	   -­‐	  	   2.07E-­‐05	   21.14189764	   0.000143944	   0.006663739	   2.306878179	   0.02964395	  
Rv2922c	  	   smc	  	   6.50E-­‐06	   6.94E+00	   5.45E-­‐05	   1.03E-­‐07	   4.11E+01	   2.56E-­‐06	  
Rv2928	  	   tesA	  	   1.21E-­‐08	   3.46E+02	   2.51E-­‐07	   0.011307615	   6.382131787	   0.045322308	  
Rv2930	  	   fadD26	  	   6.87E-­‐19	   1.25E+01	   1.24E-­‐16	   1.36E-­‐05	   11.22146053	   0.000175732	  
Rv2931	  	   ppsA	  	   1.38E-­‐36	   3.13E+01	   5.47E-­‐33	   6.04E-­‐12	   8.08E+00	   4.71E-­‐10	  
Rv2932	  	   ppsB	  	   6.68E-­‐28	   7.29E+00	   4.43E-­‐25	   5.81E-­‐07	   1.69E+01	   1.16E-­‐05	  
Rv2934	  	   ppsD	  	   2.64E-­‐26	   1.25E+01	   1.50E-­‐23	   2.12E-­‐07	   1.58E+01	   4.89E-­‐06	  
Rv2935	  	   ppsE	  	   2.06E-­‐35	   5.47E+00	   4.09E-­‐32	   7.02E-­‐10	   1.26E+01	   2.97E-­‐08	  
Rv2937	  	   drrB	  	   6.60E-­‐05	   1.325655943	   3.80E-­‐04	   4.77E-­‐07	   1.60E+01	   9.88E-­‐06	  
Rv2939	  	   papA5	  	   1.89E-­‐18	   1.37E+01	   3.01E-­‐16	   5.35E-­‐05	   5.677796332	   0.000568593	  
Rv2940c	  	   mas	  	   1.16E-­‐33	   1.03E+01	   1.15E-­‐30	   1.59E-­‐09	   7.40E+00	   6.26E-­‐08	  
Rv2945c	  	   lppX	  	   1.76E-­‐06	   4.12E+02	   1.83E-­‐05	   4.48E-­‐07	   1.82E+01	   9.38E-­‐06	  
Rv2952	  	   -­‐	  	   1.97E-­‐06	   4.96E+01	   2.02E-­‐05	   0.011327728	   3.351092984	   0.045322308	  
Rv2959c	  	   -­‐	  	   0.00016202	   1.094570225	   8.19E-­‐04	   3.62E-­‐05	   10.65495927	   0.000402073	  
Rv2960c	  	   -­‐	  	   0.00091943	   94.50984117	   0.003522711	   0.541687263	   1.016029283	   0.872897461	  
Rv2967c	  	   pca	  	   1.52E-­‐21	   3.38E+00	   4.31E-­‐19	   1.08E-­‐23	   4.98E+01	   7.15E-­‐21	  
Rv2985	  	   mutT1	  	   7.01E-­‐06	   2.23E+02	   5.81E-­‐05	   0.001083608	   3.600168485	   0.006829652	  
Rv2997	  	   -­‐	  	   0.001011731	   19.34704331	   0.003799483	   0.032415443	   1.319371908	   0.10426132	  
Rv3005c	  	   -­‐	  	   0.012393662	   1.045580341	   3.17E-­‐02	   3.32E-­‐09	   9.20E+01	   1.09E-­‐07	  
Rv3032	  	   -­‐	  	   0.000731937	   104.1026857	   0.002911097	   0.000731937	   104.1026857	   0.00498444	  
Rv3036c	  	   TB22.2	  	   2.21E-­‐07	   9.24E+01	   3.17E-­‐06	   2.26E-­‐09	   5.10E+01	   8.26E-­‐08	  
Rv3040c	  	   -­‐	  	   2.11E-­‐05	   95.91664279	   1.46E-­‐04	   4.17E-­‐05	   104.6111858	   0.000452697	  
Rv3041c	  	   -­‐	  	   5.59E-­‐05	   100.0427651	   0.000332162	   0.000487377	   20.3892083	   0.003650276	  
Rv3044	  	   fecB	  	   2.24E-­‐05	   105.5304474	   1.53E-­‐04	   2.24E-­‐05	   105.5304474	   0.000273525	  
Rv3045	  	   adhC	  	   0.010656316	   1.275776175	   0.027992184	   0.000926331	   35.28302194	   0.006031266	  
Rv3052c	  	   nrdI	  	   1.52E-­‐05	   466.7559545	   1.11E-­‐04	   1.52E-­‐05	   466.7559545	   0.000193754	  
Rv3057c	  	   -­‐	  	   0.000131357	   1.572678609	   6.87E-­‐04	   2.16E-­‐09	   1.67E+01	   8.02E-­‐08	  
Rv3058c	  	   -­‐	  	   0.004623356	   1.361538521	   0.013670695	   0.00019715	   13.03000512	   0.001719442	  
Rv3066	  	   -­‐	  	   0.000413539	   22.26419293	   0.001823333	   0.005766116	   2.530182898	   0.026633966	  
Rv3071	  	   -­‐	  	   1.09E-­‐05	   1.35E+02	   8.43E-­‐05	   0.073096143	   2.71012443	   0.191756834	  
Rv3088	  	   -­‐	  	   5.39E-­‐05	   18.7782012	   0.000322328	   0.065857416	   1.215840582	   0.176850062	  
Rv3101c	  	   ftsX	  	   2.75E-­‐06	   2.90E+02	   2.63E-­‐05	   1.76E-­‐05	   130.4790612	   0.000221635	  
Rv3102c	  	   ftsE	  	   0.007474086	   53.63492472	   0.020542116	   0.000434348	   148.1989031	   0.00333475	  
Rv3106	  	   fprA	  	   0.000494913	   43.09500864	   0.002111876	   0.695984522	   1.06026645	   1	  
continued	  on	  next	  page 
	  142	  
Rv3127	  	   -­‐	  	   4.89E-­‐07	   1.17E+02	   5.87E-­‐06	   0.008455409	   1.727070353	   0.035659769	  
Rv3131	  	   -­‐	  	   0.001528081	   43.7335347	   0.00530758	   0.062304524	   1.396625252	   0.168676032	  
Rv3132c	  	   devS	  	   2.89E-­‐07	   4.33E+00	   3.97E-­‐06	   3.73E-­‐10	   3.72E+01	   1.65E-­‐08	  
Rv3139	  	   fadE24	  	   5.39E-­‐08	   1.05E+01	   9.16E-­‐07	   2.55E-­‐06	   2.01E+02	   4.21E-­‐05	  
Rv3147	  	   nuoC	  	   2.14E-­‐05	   58.89235247	   0.000147635	   0.022769482	   0.514167083	   0.079225048	  
Rv3148	  	   nuoD	  	   0.002274816	   55.61913112	   0.007501612	   0.058002069	   5.567300674	   0.159636146	  
Rv3150	  	   nuoF	  	   4.42E-­‐10	   1.14E+02	   1.38E-­‐08	   2.14E-­‐05	   1.077629699	   0.00026389	  
Rv3151	  	   nuoG	  	   4.41E-­‐07	   9.33E+01	   5.50E-­‐06	   0.00168258	   7.287247818	   0.009884228	  
Rv3159c	  	   PPE53	  	   2.16E-­‐05	   9.13463569	   0.000148274	   0.000358015	   11.64500829	   0.002876414	  
Rv3164c	  	   moxR3	  	   0.003112272	   114.3291152	   0.009807849	   0.01172412	   20.57470475	   0.046667732	  
Rv3166c	  	   -­‐	  	   0.000378705	   94.58008328	   0.001692256	   0.009609552	   5.339999304	   0.039768146	  
Rv3168	  	   -­‐	  	   4.52E-­‐06	   2.90E+02	   4.00E-­‐05	   0.106809292	   10.84224961	   0.260761542	  
Rv3169	  	   -­‐	  	   0.000982425	   139.9665086	   0.003723145	   0.256733917	   0.762961559	   0.503510598	  
Rv3171c	  	   hpx	  	   0.000118377	   61.70242576	   0.000626877	   0.105432411	   1.029722219	   0.258351631	  
Rv3176c	  	   mesT	  	   0.001618831	   1.430524988	   5.57E-­‐03	   3.96E-­‐06	   3.67E+01	   6.13E-­‐05	  
Rv3193c	  	   -­‐	  	   1.20E-­‐10	   3.92E+01	   4.42E-­‐09	   2.63E-­‐09	   4.33E+01	   8.95E-­‐08	  
Rv3194c	  	   -­‐	  	   7.40E-­‐07	   2.80E+01	   8.31E-­‐06	   1.20E-­‐06	   1.42E+01	   2.23E-­‐05	  
Rv3200c	  	   -­‐	  	   0.000518034	   35.52087646	   2.18E-­‐03	   2.35E-­‐07	   5.56E+01	   5.37E-­‐06	  
Rv3205c	  	   -­‐	  	   2.95E-­‐05	   40.90933953	   1.92E-­‐04	   4.43E-­‐05	   39.23207714	   0.000479056	  
Rv3207c	  	   -­‐	  	   1.33E-­‐05	   3.85E+01	   9.85E-­‐05	   0.033717464	   8.686853745	   0.107533564	  
Rv3209	  	   -­‐	  	   0.003000168	   14.42475364	   0.009522481	   0.083399049	   3.533385449	   0.213847853	  
Rv3211	  	   rhlE	  	   0.001915786	   126.6007432	   0.006454583	   0.006465074	   88.24784331	   0.029052655	  
Rv3214	  	   gpm2	  	   0.000119167	   53.57784143	   0.000630222	   0.002963123	   10.15363494	   0.015754466	  
Rv3223c	  	   sigH	  	   4.63E-­‐07	   3.24E+01	   5.70E-­‐06	   3.22E-­‐09	   1.80E+01	   1.07E-­‐07	  
Rv3245c	  	   mtrB	  	   0.000265302	   26.32329421	   0.0012401	   0.000265302	   26.32329421	   0.002216611	  
Rv3249c	  	   -­‐	  	   0.003160479	   10.77502262	   0.009936147	   0.000517166	   18.983036	   0.0038159	  
Rv3261	  	   fbiA	  	   0.000964567	   89.25065377	   0.003667381	   0.0003954	   101.5755439	   0.003113871	  
Rv3262	  	   fbiB	  	   0.001219254	   109.5847384	   0.004420211	   0.003050233	   79.16047518	   0.016152831	  
Rv3267	  	   -­‐	  	   8.66E-­‐14	   3.41E+02	   5.74E-­‐12	   6.80E-­‐12	   1.41E+02	   5.20E-­‐10	  
Rv3268	  	   -­‐	  	   0.00019118	   9.377689682	   9.40E-­‐04	   7.60E-­‐07	   4.81E+01	   1.47E-­‐05	  
Rv3270	  	   ctpC	  	   0.000164216	   13.50376523	   8.26E-­‐04	   1.59E-­‐06	   3.05E+01	   2.83E-­‐05	  
Rv3274c	  	   fadE25	  	   5.57E-­‐05	   125.4309305	   3.31E-­‐04	   8.65E-­‐06	   232.3153528	   0.00011904	  
Rv3282	  	   maf	  	   0.000266721	   43.05470517	   0.001245012	   0.005644003	   37.76013209	   0.026252864	  
Rv3283	  	   sseA	  	   2.53E-­‐09	   2.58E+01	   6.21E-­‐08	   7.61E-­‐13	   4.63E+02	   7.39E-­‐11	  
Rv3286c	  	   sigF	  	   0.002446153	   95.7398064	   0.007974059	   0.516724164	   1.766843251	   0.846729295	  
Rv3291c	  	   -­‐	  	   0.002380725	   258.6871318	   0.00779271	   0.024261571	   24.295559	   0.083107896	  
Rv3300c	  	   -­‐	  	   0.000163084	   56.08841457	   0.000822032	   0.145208502	   1.686069653	   0.333041645	  
Rv3303c	  	   lpdA	  	   7.93E-­‐06	   6.64E+01	   6.46E-­‐05	   1.14E-­‐05	   23.39987451	   0.000151192	  
Rv3305c	  	   amiA1	  	   3.52E-­‐08	   1.37E+02	   6.39E-­‐07	   0.000462518	   8.694042842	   0.003510371	  
Rv3311	  	   -­‐	  	   1.25E-­‐08	   3.44E+02	   2.57E-­‐07	   5.78E-­‐09	   3.03E+02	   1.83E-­‐07	  
Rv3316	  	   sdhC	  	   0.001948772	   50.76858661	   0.006545832	   0.255919556	   5.605128353	   0.503405959	  
Rv3323c	  	   moaX	  	   2.12E-­‐06	   4.67E+02	   2.12E-­‐05	   0.000342174	   3.433947654	   0.002771542	  
Rv3340	  	   metC	  	   4.20E-­‐07	   1.93E+01	   5.31E-­‐06	   4.13E-­‐09	   2.22E+01	   1.35E-­‐07	  
Rv3342	  	   -­‐	  	   0.000466327	   91.50998659	   0.00201585	   0.022288906	   10.75716185	   0.077812434	  
Rv3371	  	   -­‐	  	   0.001222395	   11.68742276	   0.004427562	   0.563360461	   2.734849526	   0.900516299	  
Rv3378c	  	   -­‐	  	   4.34E-­‐06	   7.72E+01	   3.84E-­‐05	   0.003411779	   7.985855222	   0.017713633	  
Rv3383c	  	   idsB	  	   1.33E-­‐07	   1.97E+01	   2.02E-­‐06	   2.23E-­‐05	   4.741222584	   0.000273525	  
Rv3389c	  	   -­‐	  	   0.000394054	   143.8777636	   0.001751009	   0.043120775	   11.038092	   0.127625076	  
Rv3394c	  	   -­‐	  	   0.047344306	   1.844784901	   0.097306617	   0.000492259	   11.46210777	   0.003673006	  
Rv3395A	  	   -­‐	  	   0.001190255	   96.87619585	   0.004327356	   0.198050872	   9.77961002	   0.426216622	  
Rv3399	  	   -­‐	  	   1.85E-­‐07	   3.98E+01	   2.71E-­‐06	   4.08E-­‐06	   1.61E+02	   6.21E-­‐05	  
Rv3400	  	   -­‐	  	   0.00034615	   5.255245488	   1.57E-­‐03	   5.81E-­‐06	   7.58E+01	   8.46E-­‐05	  
Rv3412	  	   -­‐	  	   0.000675872	   154.1777543	   0.002728875	   0.179941582	   3.465949569	   0.397129673	  
Rv3414c	  	   sigD	  	   0.003097682	   43.93870291	   0.009769614	   1	   0.259960432	   1	  
Rv3417c	  	   groEL	  	   0.000476466	   35.75800251	   0.002051482	   0.004746461	   15.83805486	   0.023133181	  
Rv3420c	  	   rimI	  	   1.43E-­‐08	   1.14E+02	   2.93E-­‐07	   0.00051391	   10.49677006	   0.003798924	  
Rv3421c	  	   -­‐	  	   0.000221157	   42.71015893	   0.001062249	   0.441949456	   1.717767803	   0.756947883	  
Rv3424c	  	   -­‐	  	   0.002340083	   113.1647006	   0.007690908	   0.251321859	   0.927175901	   0.49726718	  
Rv3427c	  	   -­‐	  	   0.276760765	   0.52217404	   0.431299985	   0.00096147	   159.5440345	   0.006207411	  
Rv3434c	  	   -­‐	  	   4.59E-­‐05	   46.11263872	   0.000279194	   0.01303127	   3.434387318	   0.050681471	  
Rv3448	  	   -­‐	  	   2.02E-­‐06	   1.41E+01	   2.04E-­‐05	   0.000193333	   8.161778236	   0.001693582	  
Rv3454	  	   -­‐	  	   4.11E-­‐07	   7.07E+01	   5.23E-­‐06	   0.008389954	   1.55829782	   0.035439433	  
Rv3484	  	   cpsA	  	   1.52E-­‐06	   1.64E+00	   1.59E-­‐05	   4.90E-­‐17	   2.56E+01	   1.02E-­‐14	  
Rv3491	  	   -­‐	  	   6.21E-­‐05	   182.2869975	   0.000359964	   0.272601346	   4.885116493	   0.527547907	  
Rv3493c	  	   -­‐	  	   9.64E-­‐05	   129.5365156	   0.000525768	   0.006866313	   9.64870487	   0.030307797	  
Rv3494c	  	   mce4F	  	   1.02E-­‐09	   4.70E+00	   2.91E-­‐08	   1.80E-­‐09	   1.25E+01	   6.93E-­‐08	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Rv3496c	  	   mce4D	  	   0.000800149	   1.329488087	   3.14E-­‐03	   2.51E-­‐08	   1.01E+01	   7.04E-­‐07	  
Rv3497c	  	   mce4C	  	   0.000499899	   17.62665716	   0.002127061	   0.002819488	   10.84683026	   0.015193908	  
Rv3498c	  	   mce4B	  	   0.001537049	   15.43114231	   0.005334069	   0.000919112	   16.90615985	   0.006021927	  
Rv3502c	  	   fabG	  	   4.79E-­‐07	   1.62E+02	   5.82E-­‐06	   4.41E-­‐06	   1.12E+01	   6.62E-­‐05	  
Rv3527	  	   -­‐	  	   0.038958209	   5.821724167	   0.08361403	   0.00088387	   55.77183385	   0.005810169	  
Rv3528c	  	   -­‐	  	   0.000208641	   23.70869819	   0.001009449	   0.196452925	   5.545586729	   0.424385271	  
Rv3533c	  	   PPE62	  	   3.72E-­‐07	   1.45E+02	   4.87E-­‐06	   0.003475865	   8.24275282	   0.017975963	  
Rv3536c	  	   -­‐	  	   0.000640259	   18.01378143	   2.59E-­‐03	   2.42E-­‐05	   93.49752079	   0.000292022	  
Rv3537	  	   -­‐	  	   3.50E-­‐14	   1.82E+01	   2.53E-­‐12	   2.55E-­‐09	   1.38E+01	   8.88E-­‐08	  
Rv3540c	  	   ltp2	  	   0.001407168	   71.11777411	   0.004974495	   0.059857294	   9.768580122	   0.163609938	  
Rv3542c	  	   -­‐	  	   0.001772217	   17.42590792	   0.006029178	   0.001009201	   16.15102191	   0.006452723	  
Rv3543c	  	   fadE29	  	   8.42E-­‐07	   4.26E+01	   9.30E-­‐06	   5.85E-­‐07	   4.47E+01	   1.16E-­‐05	  
Rv3544c	  	   fadE28	  	   0.000260002	   3.672925821	   1.23E-­‐03	   3.60E-­‐05	   14.79066979	   0.000401194	  
Rv3548c	  	   -­‐	  	   0.002394611	   127.8964093	   0.007831718	   0.005282557	   126.5363078	   0.025070084	  
Rv3552	  	   -­‐	  	   0.000731937	   38.88020387	   0.002911097	   0.015834689	   16.94083926	   0.059242294	  
Rv3553	  	   -­‐	  	   0.003097682	   130.111872	   0.009769614	   0.296907295	   10.86284154	   0.562553746	  
Rv3555c	  	   -­‐	  	   1.17E-­‐05	   1.00E+02	   8.93E-­‐05	   0.00020805	   9.950857572	   0.001790941	  
Rv3556c	  	   fadA6	  	   8.07E-­‐06	   5.30E+01	   6.56E-­‐05	   2.30E-­‐06	   5.77E+01	   3.88E-­‐05	  
Rv3559c	  	   -­‐	  	   0.008249301	   53.76854354	   0.022335877	   0.00045494	   58.40007005	   0.003459461	  
Rv3560c	  	   fadE30	  	   5.46E-­‐05	   3.046621132	   3.26E-­‐04	   8.52E-­‐06	   12.12240323	   0.000118265	  
Rv3561	  	   fadD3	  	   3.71E-­‐05	   110.2355065	   0.000232508	   0.429457315	   1.089687388	   0.740334521	  
Rv3567c	  	   -­‐	  	   0.000585995	   150.4029208	   0.002410032	   0.120791407	   4.975667159	   0.288174819	  
Rv3568c	  	   bphC	  	   0.001871028	   70.0843516	   0.006332832	   0.011304803	   14.83751415	   0.045322308	  
Rv3569c	  	   bphD	  	   0.003966989	   24.72380187	   0.012034107	   0.000649374	   49.17512635	   0.004554778	  
Rv3571	  	   hmp	  	   8.97E-­‐05	   85.80885459	   0.000496666	   0.07203618	   7.169061242	   0.189629793	  
Rv3574	  	   -­‐	  	   0.000330613	   68.16275892	   0.001504403	   0.006723167	   22.29530554	   0.029834706	  
Rv3577	  	   -­‐	  	   4.60E-­‐05	   121.7176386	   0.000279349	   0.013950396	   23.08545034	   0.053516552	  
Rv3578	  	   arsB2	  	   0.002842032	   1.108979699	   0.009071236	   0.000454309	   45.31489212	   0.003459461	  
Rv3591c	  	   -­‐	  	   0.059233811	   1.615894174	   0.117025765	   0.001498086	   11.61795761	   0.00894578	  
Rv3610c	  	   ftsH	  	   1.97E-­‐05	   0.739189498	   1.38E-­‐04	   2.30E-­‐06	   1.48E+01	   3.88E-­‐05	  
Rv3615c	  	   -­‐	  	   0.000815471	   8.202016696	   3.20E-­‐03	   1.88E-­‐05	   12.7098927	   0.0002345	  
Rv3616c	  	   -­‐	  	   3.19E-­‐07	   6.01E+00	   4.31E-­‐06	   4.16E-­‐07	   2.23E+01	   8.90E-­‐06	  
Rv3626c	  	   -­‐	  	   0.000524315	   24.60450357	   0.002204231	   0.018733647	   6.337345032	   0.068039921	  
Rv3645	  	   -­‐	  	   1.12E-­‐10	   3.35E+02	   4.15E-­‐09	   1.12E-­‐10	   3.35E+02	   5.62E-­‐09	  
Rv3651	  	   -­‐	  	   0.001648612	   1.874877145	   5.66E-­‐03	   5.69E-­‐05	   16.66249563	   0.000599136	  
Rv3664c	  	   dppC	  	   9.85E-­‐05	   40.93903836	   0.000535684	   0.103016082	   3.47892679	   0.253681088	  
Rv3665c	  	   dppB	  	   3.36E-­‐08	   8.74E+00	   6.15E-­‐07	   1.81E-­‐09	   2.70E+02	   6.93E-­‐08	  
Rv3666c	  	   dppA	  	   4.21E-­‐07	   1.99E+02	   5.31E-­‐06	   2.04E-­‐05	   23.122938	   0.000251649	  
Rv3668c	  	   -­‐	  	   0.000113621	   40.58451058	   0.000604914	   0.000709067	   11.45713153	   0.004870395	  
Rv3670	  	   ephE	  	   0.000122158	   154.1461221	   6.44E-­‐04	   2.60E-­‐05	   228.5547665	   0.000310462	  
Rv3671c	  	   -­‐	  	   0.003781909	   84.75387835	   0.01151658	   0.001317277	   116.8024814	   0.008034986	  
Rv3679	  	   -­‐	  	   0.000910059	   5.11165741	   3.49E-­‐03	   1.27E-­‐06	   4.01E+02	   2.33E-­‐05	  
Rv3680	  	   -­‐	  	   3.07E-­‐07	   2.65E+00	   4.19E-­‐06	   2.68E-­‐12	   4.35E+02	   2.27E-­‐10	  
Rv3682	  	   ponA2	  	   6.36E-­‐19	   6.84E+01	   1.20E-­‐16	   1.20E-­‐25	   6.68E+02	   1.20E-­‐22	  
Rv3683	  	   -­‐	  	   0.000200165	   2.83888168	   9.72E-­‐04	   3.30E-­‐05	   17.68668158	   0.000374744	  
Rv3684	  	   -­‐	  	   8.92E-­‐08	   2.40E+02	   1.44E-­‐06	   0.000816976	   2.396663203	   0.005401166	  
Rv3699	  	   -­‐	  	   0.000546692	   16.1447759	   0.002283819	   0.008283798	   2.106388575	   0.035047517	  
Rv3710	  	   leuA	  	   0.001064465	   1.591731383	   3.96E-­‐03	   1.00E-­‐05	   57.75740299	   0.000135543	  
Rv3717	  	   -­‐	  	   0.001582957	   3.050370227	   5.47E-­‐03	   8.38E-­‐06	   152.1326452	   0.000117392	  
Rv3720	  	   -­‐	  	   3.00E-­‐08	   1.19E+00	   5.66E-­‐07	   8.98E-­‐08	   1.20E+01	   2.29E-­‐06	  
Rv3757c	  	   proW	  	   0.001190377	   16.53315409	   0.004327356	   0.296314784	   0.894875141	   0.562047964	  
Rv3759c	  	   proX	  	   0.000384675	   79.36188359	   0.00171316	   0.130038969	   1.677462031	   0.304752492	  
Rv3777	  	   -­‐	  	   0.00041681	   1.271752856	   0.001829641	   0.000490821	   118.8285309	   0.00366916	  
Rv3802c	  	   -­‐	  	   6.05E-­‐11	   3.72E+02	   2.38E-­‐09	   6.05E-­‐11	   3.72E+02	   3.44E-­‐09	  
Rv3804c	  	   fbpA	  	   3.56E-­‐06	   9.04E+01	   3.23E-­‐05	   0.001174391	   3.580144032	   0.007288415	  
Rv3810	  	   pirG	  	   0.000114168	   1.606948628	   6.07E-­‐04	   3.80E-­‐08	   1.96E+02	   1.03E-­‐06	  
Rv3813c	  	   -­‐	  	   0.001172567	   84.22665859	   0.004274333	   0.035998736	   80.20532277	   0.112552653	  
Rv3823c	  	   mmpL8	  	   5.43E-­‐24	   3.14E+00	   1.80E-­‐21	   4.38E-­‐27	   3.10E+01	   8.71E-­‐24	  
Rv3838c	  	   pheA	  	   0.004999953	   17.13323881	   0.014556964	   0.000995672	   25.55697785	   0.006406283	  
Rv3860	  	   -­‐	  	   0.00025343	   2.280031044	   1.20E-­‐03	   8.28E-­‐06	   11.35856831	   0.00011677	  
Rv3864	  	   -­‐	  	   2.36E-­‐07	   1.82E+02	   3.36E-­‐06	   2.69E-­‐08	   2.73E+02	   7.49E-­‐07	  
Rv3868	  	   -­‐	  	   2.63E-­‐15	   3.69E+01	   2.44E-­‐13	   5.81E-­‐14	   1.77E+01	   7.00E-­‐12	  
Rv3870	  	   -­‐	  	   2.23E-­‐12	   4.61E+00	   1.20E-­‐10	   1.45E-­‐12	   1.46E+01	   1.28E-­‐10	  
Rv3876	  	   -­‐	  	   4.70E-­‐08	   1.45E+01	   8.23E-­‐07	   4.11E-­‐06	   1.74E+00	   6.21E-­‐05	  
Rv3916c	  	   -­‐	  	   3.07E-­‐05	   51.37038448	   1.98E-­‐04	   3.72E-­‐06	   7.48E+01	   5.83E-­‐05	  
Rv3919c	  	   gidB	  	   0.001230753	   2.316777795	   4.45E-­‐03	   4.09E-­‐05	   32.20429099	   0.000446352	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Table 3.2. Genes required for surviving CD4-mediated stress 
Rv	  Number	   Gene	   MWU	  P-­‐value	   wt:MHC	  ratio	  
Rv0019c	   -­‐	   0.036291718	   0.021305927	  
Rv0050	   ponA1	   0.039678686	   0.112297814	  
Rv0163	   -­‐	   0.008756427	   0.210237414	  
Rv0176	   -­‐	   0.007152225	   0.103444727	  
Rv0200	   -­‐	   0.00535539	   0.056981315	  
Rv0211	   pckA	   0.008215453	   0.25	  
Rv0241c	   -­‐	   0.007548983	   0.25	  
Rv0242c	   fabG	   0.001066115	   0.25	  
Rv0634A	   -­‐	   0.003395271	   0	  
Rv0665	   -­‐	   0.044644399	   0	  
Rv0784	   -­‐	   0.011561192	   0	  
Rv0893c	   -­‐	   0.036165907	   0.25	  
Rv0926c	   -­‐	   0.046163388	   0.108115878	  
Rv0937c	   -­‐	   0.014453174	   0.199901486	  
Rv1062	   -­‐	   0.025530204	   0.062573889	  
Rv1096	   -­‐	   0.012651451	   0.100469202	  
Rv1121	   zwf1	   0.035478742	   0.109182797	  
Rv1170	   mshB	   0.006312207	   0	  
Rv1193	   fadD36	   0.026756502	   0.054452155	  
Rv1237	   sugB	   0.011038856	   0	  
Rv1432	   -­‐	   0.045176818	   0.171597184	  
Rv1448c	   tal	   0.012186994	   0.012872952	  
Rv1512	   epiA	   0.003548422	   0	  
Rv1519	   -­‐	   0.015260332	   0	  
Rv1568	   bioA	   0.007400462	   0.190061243	  
Rv1604	   impA	   0.021724434	   0.25	  
Rv1609	   trpE	   0.001375862	   0.207867048	  
Rv1622c	   cydB	   5.53E-­‐06	   0.200941859	  
Rv1755c	   plcD	   0.003334523	   0	  
Rv1829	   -­‐	   0.004701583	   0.146164946	  
Rv1913	   -­‐	   0.012296325	   0.080949093	  
Rv1954c	   -­‐	   0.01299173	   0.244898291	  
Rv1962c	   -­‐	   0.010629303	   0.208252337	  
Rv2135c	   -­‐	   0.027861141	   0	  
Rv2192c	   trpD	   0.037669967	   0.25	  
Rv2222c	   glnA2	   0.00430293	   0.023746514	  
Rv2269c	   -­‐	   0.016223977	   0.009559459	  
Rv2274c	   -­‐	   0.001735063	   0	  
Rv2383c	   mbtB	   0.001084174	   0.059279337	  
Rv2384	   mbtA	   0.017657347	   0	  
Rv2496c	   pdhB	   0.018302614	   0.023560933	  
Rv2553c	   -­‐	   0.001520846	   0.25	  
Rv2606c	   -­‐	   0.019274815	   0	  
Rv2745c	   -­‐	   0.032393036	   0.185798859	  
Rv2809	   -­‐	   0.003259852	   0	  
Rv2857c	   -­‐	   0.011038856	   0	  
Rv2879c	   -­‐	   0.01002359	   0	  
Rv2931	   ppsA	   0.003091397	   0.199297953	  
Rv2966c	   -­‐	   0.040451605	   0.111901222	  
Rv3101c	   ftsX	   0.000202429	   0	  
Rv3168	   -­‐	   0.01784547	   0	  
Rv3267	   -­‐	   0.000888031	   0.25	  
Rv3271c	   -­‐	   0.022389724	   0	  
Rv3320c	   -­‐	   0.011004546	   0.20725692	  
Rv3502c	   fabG	   0.011930481	   0.17299943	  
Rv3636	   -­‐	   0.005596797	   0.061449799	  
Rv3684	   -­‐	   0.004093713	   0.209292629	  
Rv3868	   -­‐	   0.002439503	   0.241047928	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Table 3.3A. Genes required for surviving acid stress (Tyloxapol pH 6.5 v 
Tyloxapol pH 4.5) 
 
Rv	  Number	   Gene	   MWU	  P-­‐value	   Ty6.5:Ty4.5	  ratio	  
Rv1621c	   cydD	   0.011403588	   21.83314743	  
Rv1623c	   cydA	   0.015494229	   20.62578152	  
Rv1622c	   cydB	   0.018733271	   16.53171566	  
Rv1620c	   cydC	   0.000275637	   15.46023648	  
 
Table 3.3B. Genes required for surviving acid stress in phosphate-citrate 
buffer (Tyloxapol pH 6.5 v pcit pH 4.5) 
 
Rv	   gene	   MWU	  P-­‐value	   Ty6.5:pcit4.5	  ratio	  
Rv0536	   galE3	   2.01E-­‐06	   21.10052984	  
Rv2282c	   -­‐	   5.42E-­‐05	   20.93847196	  
Rv1339	   -­‐	   0.028430726	   20.57718069	  
Rv2665	   -­‐	   0.016300213	   19.37981555	  
Rv2943A	   -­‐	   0.007903478	   17.49904946	  
Rv1717	   -­‐	   0.002628449	   17.47602033	  
Rv1620c	   cydC	   0.000121797	   17.31160396	  
Rv0326	   -­‐	   0.047650855	   17.15444784	  
Rv1621c	   cydD	   0.025758844	   16.77289417	  
Rv1623c	   cydA	   0.011462012	   15.69509581	  
Rv2630	   -­‐	   0.017523493	   14.87833358	  
Rv0612	   -­‐	   0.001483126	   14.55994587	  
Rv1287	   -­‐	   0.000127653	   13.96261956	  
Rv2758c	   -­‐	   0.022042404	   13.00406216	  
Rv3229c	   -­‐	   0.000104834	   12.90834055	  
Rv3203	   lipV	   0.017364817	   11.79062897	  
Rv2089c	   pepE	   0.01883695	   11.69807278	  
Rv3013	   -­‐	   0.001211151	   11.62492734	  
Rv1622c	   cydB	   0.002570576	   11.20090151	  
Rv1284	   -­‐	   0.034114539	   10.73117748	  
Rv0324	   -­‐	   0.001112296	   10.08128541	  
 
Table 3.3C. Genes required for surviving nitrosative stress 
 
Rv	  Number	   Gene	   MWU	  P-­‐value	   pH7:DETANO	  ratio	  
Rv0757	   phoP	   2.91E-­‐05	   23.03266802	  
Rv3283	   sseA	   2.95E-­‐05	   13.57730202	  
Rv3270	   ctpC	   1.24E-­‐06	   12.85968522	  
Rv1620c	   cydC	   0.000126385	   12.17374061	  
Rv1622c	   cydB	   8.38E-­‐05	   9.333274474	  
Rv2563	   -­‐	   0.000142698	   8.034889817	  
Rv0467	   icl	   3.31E-­‐05	   7.78349238	  
Rv3855	   ethR	   7.49E-­‐05	   7.339175141	  
Rv0561c	   -­‐	   9.97E-­‐05	   6.851134457	  
Rv3200c	   -­‐	   1.19E-­‐05	   6.747794845	  
Rv2476c	   gdh	   1.69E-­‐18	   6.335121997	  
Rv2047c	   -­‐	   3.95E-­‐06	   6.046666345	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Table 3.3D. Genes required for surviving tryptophan starvation 
 
Rv	  Number	   gene	   MWU	  P-­‐value	   trp:Rv	  ratio	  
Rv2192c	   trpD	   0.01536	   258	  
Rv2246	   kasB	   0.04024	   193	  
Rv1612	   trpB	   0.04017	   142	  
Rv3160c	   -­‐	   0.01624	   101	  
Rv1609	   trpE	   0.00435	   64.167	  
Rv1053c	   -­‐	   0.04468	   23.227	  
Rv3374	   echA18.1	   0.03826	   23.111	  
Rv2661c	   -­‐	   0.04043	   18.444	  
Rv1559	   ilvA	   0.01168	   18.148	  
Rv1013	   pks16	   0.00002	   17.809	  
Rv2283	   -­‐	   0.04043	   15.889	  
Rv0346c	   ansP2	   0.00096	   11.155	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Chapter 4. 
Host Mechanisms of Tryptophan Starvation and 
Inhibition of Bacterial Tryptophan Biosynthesis to treat 
TB. 
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Section 4.1: Overview and Attributions 
Overview. The results in Chapter 3 suggested that CD4 T cells attempted to kill 
Mtb by starving the pathogen of tryptophan, and that Mtb survival in the face of 
CD4 T cells was dependent on tryptophan biosynthesis. Thus, we sought 1.) to 
understand the mechanism by which CD4 T cells starve Mtb of tryptophan and 
2.) to chemically inhibit bacterial tryptophan biosynthesis in order to help the 
immune system kill Mtb. We found that IFN-γ, a cytokine secreted by CD4 T cells 
during infection, was able to induce killing of tryptophan auxotrophs to a greater 
extent than wildtype Mtb. The auxotroph’s hypersusceptibility to IFN-γ was 
dependent on IFN-γ stimulation of indoleamine-2,3-dioxygenase (IDO), which 
catabolizes intracellular tryptophan. CD4 T cells, through IDO induction by IFN-γ, 
starve Mtb of exogenous tryptophan, and we predicted that inhibiting 
endogenous tryptophan biosynthesis in this environment would be bactericidal. 
We found two halogenated anthranilates that could inhibit tryptophan 
biosynthesis, and showed that these compounds are potent inhibitors of bacterial 
growth, especially in synergy with immune activation. 
 
Attributions. The following Chapter is an expanded version a manuscript, which 
also includes most of Chapter 3. I wrote the manuscript and we aim to submit in 
the next month. The work in this Chapter could not have been done without the 
generous help of Sam Behar and his graduate student Alissa Rothchild. Sam 
invited me into his lab, and Alissa and I did all of the mouse macrophage 
experiments together. We “discovered” the anthranilate compounds in a paper 
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from Laurie Rahme’s group at the Massachusetts General Hospital, and she was 
kind enough to share her thoughts and valuable input. Joseph Mire, a graduate 
student in Jim Sacchettini’s lab, and I were collaborating on another tryptophan-
related project, and his expertise was tremendously helpful. Finally, Deeann 
Wallis in Jim Sacchettini’s lab and Veronique Dartois at the Public Health 
Research Institute did the pharmacokinetic profiling in mice, and their help in 
designing the mouse efficacy study was invaluable. Brian Schuster, a technician 
in our lab, helped with delivering the compounds during the mouse efficacy study, 
and Andrej Trauner, a post-doc in the lab, tested compounds in M. smegmatis. 
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Section 4.2: Bacterial tryptophan biosynthesis 
determines Mtb survival upon IFN-γ  induction of IDO  
 
Introduction  
The transposon screen and follow-up studies demonstrated that tryptophan 
biosynthesis is required for surviving CD4-mediated stress. This suggests that 
CD4 T cells are able to starve Mtb of tryptophan. Some pathogens, such as 
Toxoplasma gondii and certain strains of Chlamydia, are natural tryptophan 
auxotrophs, and we realized that tryptophan starvation during infection with these 
pathogens could be the same mechanisms that fail to kill the non-tryptophan 
auxotrophic Mtb1-8. In a cell culture model of Chlamydia infection, bacterial 
growth is inhibited by the addition of IFN-γ, and this growth inhibition can be 
almost entirely reversed by the addition of tryptophan1. Furthermore, chemical 
inhibition or genetic perturbation of IDO could also reverse this growth inhibition2-
4, 7. IDO is one of the most highly transcriptionally induced genes with IFN-γ 
stimulation, and is required for the tryptophan starvation seen in IFN-γ-activated 
macrophages5, 7. We were interested in whether or not this same pathway was 
induced by CD4 T cells, and if IDO-mediated tryptophan starvation was 
responsible for the specific requirement for bacterial tryptophan biosynthesis in 
the face of CD4 immunity.  
Results 
Tryptophan auxotrophy is bactericidal 
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To study the effects of tryptophan auxotrophy and starvation during Mtb infection, 
we deleted the trpE gene in Mtb and replaced it with the hygromycin resistance 
gene (Fig 4.1A). TrpE, or Anthranilate synthase, converts chorismate to 
anthranilate in the first committed step of tryptophan biosynthesis. The next 
enzyme in the pathway, TrpD, converts anthranilate to N-(5’-phosphoribosyl)-
anthranilate, and a knockout of trpD has been shown to be a tryptophan 
auxotroph as well (Fig 4.1B)9, 10. The trpE knockout grew normally in liquid media 
only when supplemented with 1 mM tryptophan (Fig 4.2A). Interestingly, lower 
amounts of tryptophan delayed entry into the logarithmic phase of growth, but the 
growth dynamics from that point onwards was similar to wildtype. Genetic 
complementation with the trpE gene restored normal growth in media lacking 
tryptophan. To confirm our screen results (Fig 3.2A), we infected wt and MHCII-/- 
mice with a mixture of wt Mtb, the trpE knockout and the complemented strain. 
Growth of these strains in mice are pending, with results expected in the coming 
weeks.  
 
Auxotrophy in Mtb is not always bactericidal9.  Our results suggested that CD4 
cells help starve Mtb of exogenous tryptophan, so we sought to test the 
bactericidal potential of blocking endogenous tryptophan biosynthesis in the face 
of this exogenous starvation. To do so, we grew the auxotroph in tryptophan to 
both mid-log and stationary phase, and then continued the culture either in the 
presence or absence of tryptophan and plated to measure survival. The 
auxotroph was rapidly killed when starved of tryptophan, suggesting that 
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tryptophan biosynthesis would be a good bactericidal drug target (Fig 4.2B and 
C). Interestingly, the rate of death of this auxotroph was much more rapid 
compared to the trpD knockout in previous studies. In one paper, no loss of 
viable bacteria was measured at 10 days after tryptophan starvation of the trpD 
knockout, and a 100-fold effect was seen 30 days after starvation9. The trpE 
knockout, on the other hand, has about a 100,000-fold loss of viability at two 
weeks, a level which is not even reached at 13 weeks of trpD knockout starvation. 
The key difference between the two mutants is the ability of the trpD knockout to 
make anthranilate, and it is possible that there is an alternative pathway for 
tryptophan biosynthesis from anthranilate. Regardless, it appears that blocking 
tryptophan biosynthesis is much more bactericidal than previously appreciated. 
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Figure 4.1. A.) The hygromycin resistance gene, flanked by 500 bp regions 
surrounding (and partially including) trpE, transformed into dsDNA recombinase-
expressing Mtb, resulting in the construction of a trpE knockout strain. 
Transformants were plated on 1 mM tryptophan. B.) TrpE conversion of 
chorismate to anthranilate forms the first dedicated synthetic step for making 
tryptophan.
trpE Rv1610 trpC trpB trpA 
hygR Rv1610 trpC trpB trpA 
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B 
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Figure 4.2. A.) Growth of the auxotroph (trpE KO), H37Rv wildtype (wt) and 
complemented strain (comp) in 7H9 media in the presence or absence of 
tryptophan was measured by OD600. To measure CFU/ml for trpE KO, wt, and 
comp strains grown to mid-log phase (B) or stationary phase (C), washed, and 
suspended in 7H9 media with or without tryptophan.  
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Tryptophan auxotrophs are hypersusceptible to IFN-γ  mediated killing in 
macrophages 
During a typical lung infection, Mtb first enters alveolar macrophages, which then 
form an inflammatory structure known as the granuloma11. Upon adaptive 
immune activation, CD4 T cells enter the granuloma and stimulate the infected 
macrophages12. Our screen results suggested that one of these stimulatory 
mechanisms demands the need for bacterial tryptophan biosynthesis, and we 
sought to delineate the mechanism by which CD4 cells exert this need. To do so, 
we infected cultured mouse peritoneal macrophages with wt Mtb, the trpE 
knockout and the complemented strain. Over a five-day infection, the wt and 
complemented increased in colony forming units (CFU) by about 5-fold, while the 
trpE knockout had no measureable growth, demonstrating that tryptophan 
biosynthesis is required for growth even in unstimulated macrophages (Fig 4.3A). 
 
In addition to the growth defect in macrophages, we also expected that the trpE 
knockout would be especially sensitive to CD4-mediated stress. Indeed, the trpE 
knockout was significantly hypersusceptible to IFN-γ and TNF-α, cytokines 
whose secretion is increased upon the arrival of CD4 T cells to an Mtb lesion. 
Compared to unstimulated macrophages, stimulated macrophages decrease 
growth of wt Mtb by about 40%, where as IFN-γ and TNF-α stimulation 
decreased viable trpE knockout bacteria by about 90% (Fig 4.3B). We also 
simulated the effect of CD4 cells by co-culturing infected macrophages with CD4 
cells from spleens of Mtb-infected mice. The trpE knockout was also 
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hypersusceptible to the growth-inhibition of CD4 T cells in co-culture (Fig 4.4B). 
Since human macrophages differ from mouse macrophages in their 
mycobacterial killing strategies, we tested the growth of our Mtb strains in 
monocyte-derived macrophages from human donors. As with previous reports, 
we observed that IFN-γ stimulation alone does not measurably inhibit wt Mtb 
growth. However, while the trpE knockout grows slightly over the 5-day infection, 
its growth is inhibited by IFN-γ stimulation of macrophages (Fig 4.5). 
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Figure 4.3. A.) Wildtype and trpE KO Mtb strains were infected into mouse 
peritoneal macrophages with and without IFN-γ and TNF-α. The approximate 
infectious dose was assessed by lysing the macrophages and plating for CFU at 
day 1 post-infection. Mycobacterial growth was assessed plating for CFU at day 
5 post-infection. B.) The inhibitory effect of IFN-γ was measured by dividing the 
day 5 CFU from untreated macrophages by the CFU from IFN-γ treated 
macrophages. 
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IFN-γ  induction of IDO necessitates mycobacterial tryptophan biosynthesis 
To show that the auxotroph’s hypersusceptibiliy to IFN-γ was tryptophan 
dependent, we added tryptophan to the media in IFN-γ-treated macrophages, 
and showed that the addition of tryptophan reversed the IFN-γ hypersuscpetbility 
(Fig 4.4A). As expected, tryptophan did not change the bacterial growth inhibitory 
effect of IFN-γ in wildtype Mtb, showing that tryptophan supplementation does not 
have a general growth effect on Mtb. Interestingly, tryptophan supplementation 
could not restore growth of the auxotroph in unstimulated macrophages to 
wildtype Mtb levels. It is possible that the levels of tryptophan needed to restore 
wildtype growth (1 mM in liquid broth) cannot be reached intracellularly, while the 
amount of tryptophan required to protect from IFN-γ-mediated killing could.  
 
Many intracellular pathogens are natural tryptophan auxotrophs whose 
intracellular growth is also inhibited by IFN-γ stimulation, and we next attempted 
to determine if similar processes affected tryptophan availability in Mtb infection. 
One of the most highly transcriptionally induced genes in response to IFN-γ is a 
tryptophan-catabolizing enzyme, indoleamine-2,3-dioxygenase (IDO). IDO 
utilizes tryptophan as a synthetic precursor for kynurenines, immune signaling 
molecules that help control inflammation. In this synthetic process, it also greatly 
decreases the intracellular tryptophan pool. IDO is thus required for IFN-γ-
mediated growth inhibition in Chlamydia and other tryptophan auxotrophic 
intracellular pathogens.  
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We tested the role of IDO in the trpE knockout’s hypersusceptibility to CD4 T cell 
and IFN-γ by either a.) inhibiting IDO in both human and mouse macrophages 
with a specific chemical inhibitor, 1-methyl tryptophan (1-MT) (Fig 4.4B, Fig 4.5) 
or b.) using mouse macrophages derived from IDO knockout mice (Fig 4.4C)13, 14. 
In both cases, the hypersusceptibility was reversed. To demonstrate that 1-MT 
did not affect auxotroph growth, the trpE knockout was grown in 7H9 media with 
1-MT. No growth was observed. This evidence demonstrates that CD4 T cells, 
likely through IFN-γ, depletes intracellular tryptophan, which forces Mtb to 
synthesize its own tryptophan. 
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Figure 4.4. A.) trpE KO Mtb strains were infected into mouse peritoneal 
macrophages with and without IFN-γ and TNF-α. To determine if the cytokine 
effect was tryptophan dependent, 100 µM tryptophan was supplemented in the 
media. B.) Either IFN-γ and TNF-α or CD4 T cells from Mtb-infected mouse 
spleens were added on day 1 post-infection. The IDO inhibitor 1-MT was added 
to test the role of IDO in cytokine or CD4-mediated growth inhibition. C.) 
Macrophages were harvested from IDO knockout (IDO-/-) mice, and infected with 
Mtb strains with and without IFN-γ and TNF-α. 	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Figure 4.5. Human monocytes were isolated from buffy coats using magnetic 
CD14 antibodies. Cells were allowed to differentiate in the presence of GM-CSF 
for 5 days, and then infected with Mtb strains. Macrophages were further 
stimulated on day 1 post-infection with IFN-γ and treated with either 1-MT or 
supplemented with tryptophan.  
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Section 4.3: Anthranilate analogs kill Mtb in synergy 
with the immune system  
 
Halogenated anthranilate analogs disrupt tryptophan biosynthesis to kill 
Mtb in vitro 
The need for tryptophan biosynthesis in the face of CD4 immunity suggested that 
the pathway would be a good drug target in vivo. In other bacteria, anthranilate 
analogs have been used to poison anthranilate-utilizing synthetic pathways. 
Pseudomonas aeruginosa synthesizes quorum-sensing molecules called 4-
Hydroxyl-2-alkylquinolones (HAQs) that are required for virulence15. Anthranilate 
is the synthetic precursor of HAQs, and three compounds in a series of 
halogenated anthranilates were able to block HAQ synthesis and decrease 
pathology of a Pseudomonas infection15. In the first committed step of tryptophan 
biosynthesis, TrpE converts chorismate to anthranilate, which is then converted 
to N-(5’-phosphoribosyl)-anthranilate by TrpD. Thus, we reasoned that 
anthranilate analogs might poison tryptophan biosynthesis as well, and we tested 
a panel of anthranilate analogs for Mtb growth inhibition in the presence and 
absence of tryptophan. Two fluorinated anthranilates, 2-amino-5-fluorobenzoic 
acid (5-FABA) and 2-amino-6-fluorobenzoic acid (6-FABA) had an MIC of 5 µM in 
liquid broth (Table 4.1 and Fig 4.6).  
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Table 4.1. MICs in 7H9 of Anthranilate analogs tested 
 
 
Figure 4.6. Alamar blue assay in 7H9 with and without tryptophan 
supplementation. 
Compound! MIC in 7H9! MIC in 7H9 with 1 mM trp!
4-CABA! > 500 µM! > 500 µM!
6-CABA! > 500 µM! > 500 µM!
4-FABA! > 500 µM! > 500 µM!
5-FABA! 5-10 µM! > 500 µM!
6-FABA! 5-10 µM! > 500 µM!
4,6-dFABA! > 500 µM! > 500 µM!
5-MeABA! > 500 µM! > 500 µM!
6-MeABA! > 500 µM! > 500 µM!
5-MeOABA! > 500 µM! > 500 µM!
6-MeOABA! > 500 µM! > 500 µM!
!"#$%$&
!"#$%$'()**(+,(-./&
!"#$%$'()(0,(-./&
1**(+,((&*2)(+,((&
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Neither compound had any measurable activity when the media was 
supplemented with 1 mM tryptophan, showing that the compounds affect 
tryptophan biosynthesis (Fig 4.7A). We also tested 5-FABA and 6-FABA activity 
in Mycobacterium smegmatis (M. smeg). 5-FABA had an MIC of 10 µM in M. 
smeg, and 6-FABA had an MIC of 65 µM in M. smeg (Fig 4.8). Both molecules 
were rescued for growth in the presence of tryptophan, suggesting that the 
mechanism of action in M. smeg is similar to the mechanism in Mtb. Consistent 
with the auxotroph killing seen in tryptophan starvation, 6-FABA was also 
bactericidal in liquid broth (Fig 4.7B). Cultures were started in 7H9 broth with 
various amounts of 6-FABA, and bacteria were plated for CFU at days 0, 2, 3, 
and 6. At 20 µM 6-FABA, we saw a 100-fold decrease in CFU compared to the 
starting inoculum at day 6, and about a 10,000-fold decrease in CFU compared 
to the untreated control at the same time point.  
 
To determine the exact mechanism of action of these compounds, we plated a 
total of 109 Mtb bacteria on 7H10 plates with 100 µM 6-FABA. About 300 
colonies were retrieved, and 10 were picked and grown up in 100 µM 6-FABA in 
7H9 broth. These colonies are currently being sequenced. Furthermore, strains 
overexpressing TrpE and TrpD were generated in Mtb and M. smeg. If either of 
those two enzymes are the targets of 6-FABA or its toxic metabolites, we would 
expect that overexpressors would be less susceptible to 6-FABA. These 
hypotheses are currently being tested. 
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Figure 4.7. A.) Mtb was treated with 6-FABA and growth was assessed by 
measuring OD600.  B.) Mtb was treated with 6-FABA and cultures were sampled 
and plated for CFU to test viability. 
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Figure 4.8. A.) Alamar blue testing for M. smeg MICs for 5-FABA and 6-FABA  
B.) M. smeg was grown in various amounts of 5-FABA and growth rates were 
measured (C.) to confirm the MIC in vitro. 
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6-FABA synergizes with IFN-γto kill Mtb in macrophages  
We next tested 6-FABA in macrophages infected with Mtb. One day after 
infection, we added 6-FABA and measured bacterial growth by plating for CFU 
on day 5. At concentrations as low as 10 µM, 6-FABA significantly limited growth 
by over 10-fold (Fig 4.9A). The number of CFU at d5 was lower than at d1, 
suggesting that 6-FABA had bactericidal activity in macrophages. Chemical 
inhibitors that affect macrophage survival can also decrease bacterial growth, so 
we performed viability tests to exclude that as a possibility. LDH release did not 
increase with 6-FABA treatment of macrophages, demonstrating that 6-FABA is 
not cytotoxic (Fig 4.9B).  
 
Since the tryptophan auxotroph was hypersusceptible to the effects of IFN-γ 
stimulation, we hypothesized that 6-FABA’s block of tryptophan biosynthesis 
would work in synergy with IFN-γ to kill Mtb in macrophages. To test this, we 
dosed both IFN-γ (10U/ml) and 6-FABA (0.2 µM) to a level where each 
individually had about a 2-fold inhibitory effect on bacterial growth (Fig 4.10A and 
C). Without synergy, we predicted that the combined effect of 6-FABA and IFN-γ 
would be about 4-fold. Instead, the effect was 41.7-fold in mouse and 8.7-fold in 
human macrophages, demonstrating clear synergy (Fig 4.10B and D). 
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Figure 4.9. A.) Mouse peritoneal macrophages were infected with Mtb. On day 1 
post-infection, macrophages were treated with 6-FABA. Cells were lysed and 
plated for CFU on day 5. B.) Mouse peritoneal macrophages were treated with 
increasing doses of 6-FABA or staurosporine, and viability was calculated using 
an assay for LDH release.  
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Figure 4.10. A.) Human monocyte-derive and C.) mouse peritoneal 
macrophages were infected with Mtb and treated with IFN-γ (with vitamin D in 
human macrophages and with TNF-α in mouse macrophages) and/or 6-FABA on 
day 1. Doses were titrated such that the effect of a single treatment would 
decrease CFU compared to the untreated macrophage control. CFU ratios of the 
experimental conditions to the untreated controls were calculated for both human 
(B.) and mouse (D.) experiments. Using these ratios, the predicted non-
synergistic value was determined and compared to the actual combined effect of 
IFN-γ and 6-FABA. 
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6-FABA is bioavailable when orally dosed in mice.   
Synergy with IFN-γ in macrophages suggested that 6-FABA could kill Mtb in vivo 
in conjunction with CD4 T cells. Since acids are often poorly tolerated and 
absorbed in oral formulations, we synthesized an ester derivative in hopes of 
improving pharmacokinetic and tolerability profiles in mice. Since the ester had 
no anti-mycobacterial activity in vitro, we relied on esterase activity in vivo to 
generate the active-form acid. Using both 6-FABA and the ester derivative, we 
first determined that both compounds were bioavailable in with both oral and 
intraperitoneal delivery (Fig 4.11A and B), and that oral doses of up to 250 
mg/kg/day did not result in clinical illness or weight loss. 5-FABA was not as 
bioavailable as 6-FABA in mice (Fig 4.11A and B). While the ester was not 
detectable in plasma of treated mice, the acid form was detectable at almost 
identical amounts to the 6-FABA-dosed mice, suggesting that the ester was 
rapidly converted to 6-FABA in vivo.  
 
We infected mice with 102 aerosolized Mtb bacilli, and allowed infection to 
establish in the lungs for 8 days. We treated mice six times a week with either 
INH (25 mg/kg/day), 6-FABA (200 mg/kg/day) or the ester derivative (200 
mg/kg/day), and will measure bacterial growth 2 weeks and 4 weeks after 
treatment initiation.  This experiment is currently ongoing. The pharmacokinetic 
properties measured predict that the plasma levels of 6-FABA in both 6-FABA 
and ester derivative dosed mice will stay above the in vitro MIC for most of the 
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treatment duration. This is an encouraging fact, and we look forward to 
measuring the efficacy of these compounds in vivo.  
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Figure 4.11. A.) 5-FABA and 6-FABA (25 mg/kg) were given at a single dose by 
intraperitoneal injection or oral gavage. At 15 minutes, 1 hour, 4 hours, 8 hours 
and 24 hours, blood was drawn and levels of 5-FABA and 6-FABA were 
measured in the plasma. B.) For 5-fluoro and 6-fluoro derivatives of anthranilate, 
both ester and acid forms were delivered by oral gavage and acid levels were 
measured in the plasma. Ester levels were not detectable.  
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Discussion 
 
In this study, the high-throughput profiling in Chapter 3 helped us narrow our 
search for candidate virulence factor drug targets.  Targeting virulence factors 
has been touted recently for many reasons, including i.) expansion of the 
potential target list beyond in vitro essential genes, ii.) protection for the host 
against virulence factor toxicity, and iii.) reduction of resistance development for 
drugs whose targets do not affect viability16-18. By searching for mycobacterial 
processes that protect Mtb from CD4 T cell-mediated killing, we hoped to identify 
drug targets whose inhibition made Mtb more susceptible to antimycobacterial 
immunity. Since tryptophan auxotrophs, which could not survive in wt mice, were 
rescued in the absence of CD4 T cells, we determined that blocking tryptophan 
biosynthesis would allow CD4 T cells to kill Mtb.  
 
Small molecule inhibitors of tryptophan and other aromatic amino acid 
biosynthesis exist for other organisms, suggesting that certain enzymes in these 
pathways might be “druggable,” or suitable for chemical inhibition19. Furthermore, 
tryptophan is an essential amino acid for humans20, 21. Since hosts get all of their 
needed tryptophan from their diets, any cross-species activity of anti-tryptophan 
synthesis drugs should be non-toxic. This was experimentally validated by the 
lack of toxicity of 6-FABA in both cultured macrophages and treated mice.  
Halogenated anthranilates were first described as inhibitors of a Pseudomonas 
aureginosa quorum-sensing pathway15. The same group also noted that 6-FABA 
inhibited in vitro P. aureginosa growth in the absence of tryptophan. After testing 
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a series of anthranilate analogs, we found that both 6-FABA and 5-FABA had 
bactericidal activity against Mtb at low concentrations, though only in the 
absence of tryptophan.  
 
Rescue of growth with tryptophan strongly suggests that 6-FABA affects the 
tryptophan biosynthesis pathway, but it does not prove that 6-FABA inhibits 
tryptophan production. Because TrpD utilizes anthranilate as a substrate, we 
speculated that 6-FABA might be a competitive inhibitor of TrpD. However, it is 
also possible that 6-FABA could be a substrate of TrpD, resulting in the 
production of fluorinated intermediates that inhibit tryptophan biosynthesis or 
even fluorinated tryptophan that incorporates into and poisons proteins. In both 
these cases, the addition of exogenous tryptophan could conceivably rescue the 
toxic effect.  
 
Until now, the most promising work in TB drug development has produced small 
molecule inhibitors of a limited number of cell division and growth mechanisms22-
26. In order to expand our medical arsenal against TB, both new drugs and new 
targets are needed. Mtb has specifically evolved to survive in an infectious niche, 
a complex in vivo environment created by the interplay between host immunity 
and pathogen virulence. Here, we demonstrate that these virulence determinants, 
the mycobacterial products that allow Mtb survive host defenses, can be effective 
drug targets. In immunocompetent individuals, Mtb infection results in a complex 
interplay between host and pathogen that can result in disease. By targeting 
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tryptophan biosynthesis in this study, and hopefully other virulence factors in the 
future, we make Mtb more susceptible to immunity and tip the balance in favor of 
host. 
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Section 4.4: Materials and Methods 
 
Construction of trpE knockout and complement strains 
The hygromycin resistance gene was amplified with flanks containing 500 bp 
regions upstream and downstream (and slightly overlapping with) of trpE (See 
Table 4.2 for primers). This construct was electroporated into a strain of Mtb 
containing the plasmid pNIT(kan)::RecET-SacB, which contains the machinery 
for mycobacterial recombineering. Recombineering-competence was achieved 
by induction of the RecET complex by the addition of 1 mM isovaleronitrile (IVN, 
Sigma Aldrich) to a culture at OD600 0.8. IVN addition induced expression of the 
recombineering machinery on pNit(kan)::RecET-SacB. After 8h, 10 mL of 2M 
glycine was added, and the culture was grown overnight to yield recombineering-
competent Mtb. Transformations were plated on 7H10 agar with 1 mM 
tryptophan. Positive clones were plated on 7H10 agar containing 10% sucrose to 
counterselect against the recombinase plasmid, and scored for growth on 
kanamycin-containing agar to confirm the loss of pNit::RecET. Deletion of the 
endogenous locus was confirmed by PCR and by phenotypic tests for 
auxotrophy. Finally, to complement, the trpE-rv1610 two-gene operon was 
amplified and cloned, along with an artificial promoter, using multisite gateway 
into pDE43-MCK, which integrates into the L5 site (see Table 4.2 for primers).   
Macrophage infections 
Peritoneal macrophages were stimulated with Thioglycollate Medium (3%) by 
intraperitoneal infection. Three – five days after injecting, the peritoneum was 
exposed and macrophages were harvested by adding 10 mL of RPMI media with 
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penicillin and streptomycin into the peritoneal cavity and retrieving the fluid. Cells 
were washed and incubated with CD11b microbeads (Miltenyi) for 15 minutes on 
ice. Magnetic separation of CD11b+ cells was completed, and cells were plated 
for 2 days before use. Human monocyte-derived macrophages were made from 
donated buffy coats. Buffy coats were diluted and layered on Ficoll for gradient 
centrifugation. The middle cellular layer was harvested and washed multiple 
times, and then incubated with CD14 microbeads (Miltenyi) on ice for 15 minutes 
for magnetic isolation. Cells were then grown in GM-CSF (10 ng/ml) for 5 days 
before use. Cells were infected with Mtb at an MOI of 10:1 for 2 hours at 37° C. 
They were then washed 4 times with RPMI media and grown overnight. On day 1 
post-infection, most conditions were added. To lyse cells, Triton-X 100 (0.1%) in 
PBS was added to each well. Serial dilutions of the lysis were made and plated.  
Alamar Blue Assays 
In a 96-well plate, bacterial cultures were started at an OD600 of 0.003. After five 
days, resazurin reagent was added and cells were kept in a shaking 37° C 
incubator for another 1-2 days. Plates were read and the MIC was determined as 
the first concentration at which the color changes.  
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Table 4.2. Primers 
Primer Name Primer Sequence Notes 
JZ.140 trpE F 
upstream GCG AAT TTG GCC TGC TTT C 
Primer used to amplify the 5’ 
end of the 5’ flank for trpE 
knockout 
JZ.160 trpE 
R UP-ST 
XTRA 
ctaCTTGTCGTCGTCGTCCTTCTG TCG 
GCC AAG ACC TTG 
Primer used to amplify the 3’ 
end of the 5’ flank for trpE 
knockout 
JZ.161 trpE F 
DN-ST XTRA 
GTTTTTTTGGGCCTAGGGAAGGACA ACG 
GAT CCT ACG AAT ACA AC 
Primer used to amplify the 5’ 
end of the 3’ flank for trpE 
knockout 
JZ.143 trpE 
R 
downstream 
CGT CAC CAC TGG GAC ATG 
Primer used to amplify the 3’ 
end of the 3’ flank for trpE 
knockout 
JZ.156 HygF 
lox XTRA 
AAGGACGACGACGACAAGtagCGCTCTAG
AACTAGTGGATCC 
Primer used to amplify the 
hyrgromycin cassette with 
stitch PCR sequences. 
JZ.157 HygR 
lox XTRA 
TCCTTCCCTAGGCCCAAAAAAACTCT 
AGA CTC GAG GTA CCG G 
Primer used to amplify the 
hyrgromycin cassette with 
stitch PCR sequences. 
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Section 5.1: Summary of Findings 
Introduction 
Defining essential genes has traditionally been thought of as an important first 
step in drug design. The argument states that essential genes can serve as a 
high-pass filter for selecting protein targets of future therapeutics. Further 
considerations, both biolgical (vulnerability of a target as defined by the amount 
of inhibition that results in bacterial death, propensity of resistance development) 
and chemical (size and polarity of potential binding pocket, structural similarity to 
previously targeted proteins) help to determine the promise of the protein as a 
therapeutic target1-5. Essential genes are traditionally determined as the genes 
required for growth in laboratory culture conditions6-8. However, Mtb replicates 
primarily in the human lung, which is a very different environment9. Effective 
drugs need to inhibit Mtb replication in vivo. Many genes that are required for 
replciation in vivo are not required for growth in vitro, and it is possible that 
certain genes required for growth in laboratory cultures and dispensible for 
bacterial growth during infection. Thus the search for in vitro essential genes is a 
good start, but it is both limited in scope and potentially misleading as a method 
of defining good in vivo drug targets. Furthermore, the immune system imposes a 
diverse set of pressures on the bacterium, and bacterial survival is dependent on 
multiple factors to survive these pressures10. By understanding these particular 
determinants of survival, we can leverage immune-imposed stresses to kill Mtb 
more effectively. Thus understanding the environment under which Mtb 
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replicates and the adaptive tools Mtb possesses allows us to define new and 
previously underexplored drug targets.  
 
To that end, the narrative in this dissertation is told in three parts. In Chapter 2, I 
present an improved methodology to define essential genomic regions in Mtb. 
The method—which involves the direct sequencing of transposon junctions in a 
transposon library—gives us a new picture of genetic requirement with much 
higher resolution and accuracy. In Chapter 3, I present our search for genetic 
requirement in many models relevant towards human disease. These include in 
vitro conditions that mimic immune-mediated stresses, including amino acid 
starvation, nitrosative stress, acid stress and iron depletion. Most importantly, I 
present the genetic requirements for survival during a mouse infection, and the 
specific determinants for surviving the CD4 T cell response. The latter 
determinants were particularly interesting to us. We reasoned that many of these 
genes could help us identify attempted (but failed) methods of CD4-mediated 
killing. By inhibiting the survival determinants, however, we predicted that we 
could turn these attempted killing strategies into effective mechanisms of immune 
control. To that end, Chapter 4 focuses on one of these attempted killing-survival 
strategy pairs. We show that CD4 T cells attempt to kill Mtb by starving the 
bacteria of tryptophan, and delineate the pathway by which this occurs. We also 
present a new inhibitor of bacterial tryptophan biosynthesis and show that the 
inhibitor is able to kill Mtb in synergy with adaptive immunity.  
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Defining Essential Genes in Mtb 
To define genes required for optimal growth in vitro, we introduced transposons 
to a pool of bacteria, creating a library of mutants in which each bacterium had a 
single transposon insertion. Coupled with the assumption that essential genes 
will not sustain insertions, this strategy has been used in Mtb and other bacteria 
for over a decade to define essential genes8, 11-13. When we started this work, 
deep sequencing was becoming increasingly accessible and inexpensive14. 
Along with Chris Sassetti’s lab, we helepd develop a platform in Mtb that 
specifically sequenced transposon-junctions6, 7, 15. While sequencing transposon 
junctions in other bacterial organisms was being developed concurrently, we 
realized that by mapping the exact location of transposon insertions, we had the 
resolution to determine genetic requirement beyond the level of the gene16-19. We 
took two approaches to leverage this resolution. First, we used unbiased sliding 
windows to define required regions irrespective of annotated features7. Second, 
we used an extreme value distribution to define essential stretches of insetion 
deserts, irrespective of the overall insertional landscape in the rest of the gene6. 
These methods allowed us to independently call essential genes during in vitro 
growth.  	  
Defining Genes Required for Growth in Infection Models 
Normal laboratory media does a poor job of modeling the in vivo environment of 
Mtb, so we sought to expand our genetic requirement analysis to models that 
mimic the more stressful milieu of the infected and inflammed human lung. We 
did this in vitro by passing our library through a number of conditions that 
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estimate certain in vivo stresses. We also modeled disease environment by 
infecting our library into mice. While the screen for genes required for growth in 
vivo yielded the most hits, as well as the hits with the largest effects, it was 
impossible to predict what elements of mouse host defenses each gene was 
responsible for combating. We reasoned we could start to tease apart the 
components of host immunity and their “cognate” bacterial in vivo survival 
determinants by doing the same screen in immune deficient mice. If genes were 
specifically required for combating a certain aspect of mouse immunity, these 
genes would be necessary for growth in wildtype mice but dispensible in mice 
lacking these immune components. There were many to choose from, including 
mice lacking the most critical components for mycobacterial immunity such as 
IFN-γ, TNF-α and iNOS20-22.  
 
We chose to focus on the CD4 T cell response because of two main factors. First, 
it is clearly relevant in both mouse and human immunity against Mtb, as CD4-
depleted mice and HIV-infected humans do much worse with TB compared to 
their immunocompetent counterparts23-28. Second, while we knew that CD4 T 
cells were crucial, the nature of the stress they imposed was, and still is, largely 
uncharacterized. We hoped that by defining the genes required for combating 
CD4 T cells, we would not only identify interesting bacterial survival determinants 
with future drug-target potential, but also use bacterial requirement profiles as a 
bioprobe to describe the nature of CD4 stress. The results of the screen had 
multiple facets, and the rest of the dissertation follows one particular result that 
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suggested a mechanism of CD4-mediated tryptophan starvation and bacterial 
adaptation through tryptophan biosynthesis. I followed one other pathway, 
gluconeogenesis, but the mechanism was difficult to determine. I will discuss 
some other hits below in the discussion of perspectives.  
 
Determining the mechanism of tryptophan starvation 
Tryptophan starvation through IDO is a well-described phenomenon in cell 
culture models of intracellular pathogens. IFN-γ induces IDO, which catabolizes 
tryptophan in macrophages and kills natural tryptophan auxotrophs29-31. We 
showed that the same pathway is in play during Mtb infection, and that in this 
case it involves CD4 T cells. The tryptophan auxotroph Mtb strain was 
hypersusceptible to the effects of CD4 T cells, and this hypersusceptibility was 
IDO-dependent and reversible by the addition of tryptophan. Unlike Chlamydia, 
though, Mtb is able to survive this host defense by synthesizing its own 
tryptophan. By elucidating the effect of this pathway on Mtb and Mtb’s response, 
we uncovered a vulnerable point in the Mtb lifecycle. CD4 T cells attempt to kill 
the bacteria by tryptophan starvation and as long as bacterial tryptophan 
biosynthesis is interrupted, this attempt works as a method of controlling Mtb 
growth. 
 
Discovering a chemical inhibitor of tryptophan biosynthesis 
By combining exogenous tryptophan starvation by CD4 T cells with endogenous 
tryptophan biosynthesis block by genetic manipulation, we created synergy that 
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induced profound bacterial killing in macrophages. This encouraged us to find a 
chemical inhibitor of tryptophan biosynthesis as a potential drug that worked in 
synergy with CD4 T cells. The fluorinated anthranilates constituted a small series 
of compounds that we could easily test for tryptophan biosynthesis blockade. 
Two of these molecules, 6-FABA and 5-FABA, had low MICs in Mtb, with 
bactericidal effects in vitro that were reversible with tryptophan. The molecules 
killed Mtb in synergy with IFN-γ in macrophages, and have good pharmacokinetic 
properties in mice. We are eagerly awaiting the results from an ongoing mouse 
efficacy study.  
 
This work demonstrates that there might yet be some promise in rationale drug 
design. We saw the life cycle of Mtb in the mouse model as a series of stress-
inducing components, each presenting a vulnerable checkpoint for the bacteria. 
Mtb survives because it possesses the tools to pass these checkpoints. For 
nitrosative stress, it has the proteasome to tidy up damaged proteins and 
nucleotide excision repair to fix damaged DNA32, 33. For changes in carbon 
sources it adapts by switching metabolic activity to fatty acid catabolism and 
gluconeogenesis15, 34-37. While Mtb successfully overcomes these checkpoints, 
they still represent a point of potential vulnerability, since inhibition of these 
checkpoint survival determinants restores the efficacy of the checkpoints. Host-
pathogen interactions are characterized by this give and take between the 
immune system and the pathogen. These battles have been fought for many 
evolutionary generations, and our immune system possesses many ancient 
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antimicrobial pathways that work against certain bacteria but not Mtb. By 
deciphering how Mtb survives these pathways, we can revive these ineffective 
pathways and turn them back into bacteria-killing host defenses.  
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Section 5.2: Perspectives 
The data mouse transposon screen remains a largely unmined bed of useful 
information. As a matter of volume, there are hundreds of uncharacterized genes 
that have been newly predicated as essential for growth in vivo. Traditional 
bacterial genetics can help define the activity of many of these hits and the 
reason for their in vivo requirement. Interesting pathways that were uncovered as 
virulence factors include a series of four thiosulfate transferases, a membrane 
transporter and ATPase (ftsEX) known in other bacteria to regulate cell division 
in specific circumstances (sporulation, low-osmotic culture conditions), the 
synthetic pathway (fbiABC) for the F420 coenzyme, and the alternative, or bc, 
cytochrome (cydABCD).  
 
The result of this screen lends itself well to candidate approaches for 
understanding bacterial physiology during infection, especially for pathways that 
are hit multiple times or hit in their entirety in the screen. However, a majority of 
our hits do not fall into this category. Not only are they not predicted to be in 
known pathways, but they do not have predicted functions at all. To start probing 
the function of these genes, we can start to employ more hypothesis-generating 
bioinformatic tools. One is the gene set overlap analysis done in Chapter 3 of this 
thesis. By overlapping the gene sets required for different conditions, we not only 
predict the nature of certain stresses, but we also create signatures of 
requirement for genes of unknown function. Requirement signatures can also be 
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overlapped with transcriptional signatures. In particular, transcriptional signatures 
can be used to create networks of coregulated genes, and searching for 
networks that are enriched in requirement gene sets can also help probe both the 
biological function of genes of unknown function and the environmental milieu of 
uncharacterized niches.  
 
The method applied to searching for CD4-survival genes can also be applied to 
many other immune deficient mice. A previous graduate student characterized 
mutants that were rescued as well as mutants that were hypersusceptible in 
iNOS deficient mice38. With higher resolution and higher confidence tools, it is 
worth trying this experiment again. Another particularly interesting model could 
be diabetic mice. It is unclear why diabetes increases TB risk, and assessing the 
genetic requirements for survival in a diabetic mouse could help shed light on the 
key determinants of growth-permissiveness in diabetes. Mice are not the best 
model of human disease, since they do not form human-like granulomas, do not 
seem to be able to ever decrease bacterial populations, and invariably die of TB 
infection. Macaques are also imperfect, but they do a much better job of 
modeling both the granuloma structure and the differential clinical outcomes of 
human infection and disease. A tranpsoson library screen seems increasingly 
possible in macaques; when done, it will certainly be informative. Comparisons 
between genetic requirements of bacterial survival in a macaque versus a mouse 
will be fascinating, and perhaps describe in more detail the differences between 
the two models.  
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The key motivation for our work is the breadth and depth of human suffering 
caused by TB around the world. The numbers of infected individuals are 
staggering: 2 billion infected, 2 million deaths per year, 10 million new cases 
each year, 500,000 MDR cases each year39. But the toll of TB is more clearly 
understood at the community level. Of the other major killers worldwide, many 
affect primarily older individuals (cancer, cardiovascular diseases) or young 
children (diarrheal diseases). TB, especially in the world of growing HIV 
prevalence, affects primarily working-age adults. From a socioeconomic 
perspective, this is catastrophic. Poor communities, those most affected by the 
HIV and TB epidemics, are losing the most productive parts of their societies. 
From a human perspective, the loss is much more difficult to calculate.  
 
TB also has a habit of targeting the most vulnerable. In rich-world nations like 
ours, it was New York prison inmates in the 1990s, and homeless populations 
and poor immigrant families today40. In Russia, the overburdened and corrupt 
criminal justice system that retains people in their overrun prison system longer 
than they should, or than they mean to, is the epicenter of TB transmission41. In 
China, TB is a reemerging epidemic amongst migrant worker populations 
flooding the cities for work as rural development takes a back seat to the 
government’s urban growth aspirations42. TB is both poverty-creator and poverty-
consequence. Either way, it is inextricably linked to those in our world who are 
underserved, underresourced, and whose lives too often fly under the radar. Our 
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efforts at understanding the biology of TB necessarily falls within this global 
context. In the last data chapter of this thesis, we make a small attempt to 
leverage our biological understanding to develop a potential new therapy against 
TB. It is a drop in the bucket, and thankfully so. There are many promising 
potential therapeutics in clinical trials already, and the TB drug development 
pipeline must not go dry, since drug resistance will be a constant battle for all 
new drugs. Public health interventions continue to roll out, and the extension of 
DOTS into new communities will make huge inroads in limiting the epidemic. 
Efforts need to be made on all levels to translate what knowledge we have to 
create effective treatments, preventions, and programs for TB. With the right 
allocation of resources to the most vulnerable populations, we have the tools now 
to stamp out the TB epidemic43; and with the development of better tools—more 
effective vaccines, quicker-acting drugs—the goal of TB eradication will inch ever 
closer.  
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